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identify non-synonymous single base changes (the most common cause of monogenic 
disease) that have deleterious effects on protein function in vivo.  The stability model 
analyzes the effect of the resulting amino acid change on protein stability by utilizing 
structural information such as reduction in hydrophobic area and loss of electrostatic 
interactions. The profile model makes use of the conservation and type of residues 
observed at a base change position within a protein family. In each model, a machine 
learning technique, the support vector machine (SVM) was trained on a set of 
mutations causative of disease, and a control set of non-disease causing mutations. In 
jack-knifed testing, the stability model identifies 74% of disease mutations, with a 
false positive rate of 15%; the profile model identifies 80% of disease mutations, with 
a false positive rate of 10%.  Evaluation of a set of in vitro mutagenesis data with the 
stability model established that the majority of disease mutations affect protein 
stability by 1 to 3 Kcal/mol.  The stability model’s effective distinction between 
disease and non-disease variants strongly supports the hypothesis that loss of protein 
stability is a major factor contributing to monogenic disease. 
Both models are used to identify deleterious SNPs in the human population. 
After carefully controlling of errors, we find that approximately one-fourth of the 
known non-synonymous SNPs are deleterious, thus providing a set of possible SNPs 
contributing to human complex disease traits.  
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1Chapter 1: Introduction 
SNP in Populations and Human Disease
A single nucleotide polymorphism (SNP) is a single nucleotide variation in 
DNA.  In the human population, SNPs are the most abundant genetic variations.  It is 
estimated that human population has approximately 10 million common SNPs with 
minor allele frequency (MAF) of  more than 1% (Kruglyak and Nickerson 2001).  
50,000 – 100,000 of these common SNPs are non-synonymous SNPs (i.e., resulting 
in an amino acid change) (Botstein and Risch 2003; Cargill et al. 1999; Halushka et 
al. 1999). In the current central SNP repository of dbSNP (Sherry et al. 2001), over 
10 million SNPs have been deposited, of which five million have been validated.     
In theory, a SNP may affect gene function through a number of mechanisms 
including changes in transcription, RNA processing, protein translation, folding of the 
polypeptide chain, stability of the folded state, post-translational modification, 
interactions with binding partners, and alterations to catalysis. An analysis of the 
Human Gene Mutation Database (HGMD) (Stenson et al. 2003) has shown that the 
vast majority of known monogenic disease cases act through changes to the coding 
sequence, with mis-sense mutations (a single base change resulting in change of a 
single amino acid) accounting for greater than 60% of all monogenic disease 
mutations.  Mis-sense SNPs may also be the major mutation type underlying human 
complex diseases.  The following reasons support this view: first, this type of 
mutation is prevalent in monogenic disease, and second, in the human genome, 
coding regions are larger than other functional regions, such as those for transcription 
regulation and splicing regulation. However, it has been suggested that complex 
2diseases may be predominantly affected by SNPs within gene regulation regions 
(Hirschhorn and Daly 2005). 
Two Types of Human Disease
Over the past 20 years, more than 1000 disease genes have been identified by 
genetic mapping, especially linkage analysis.  Most of these are genes for rare 
monogenic (one gene/one trait) disease which follow a simple Mendelian inheritance 
pattern.  Common human disease, such as hypertension, diabetes, Alzheimer, stroke, 
and heart disease, on the other hand, follow a more complicated inheritance pattern.  
As a consequence, common diseases prove to be much harder to analyze (Botstein 
and Risch 2003; Carlson et al. 2004; Emahazion et al. 2001).  The difficulty in 
analyzing common diseases may be caused by incomplete penetrance (a person 
carrying a predisposing allele may not exhibit the disease phenotype), genetic 
heterogeneity (mutations on one of several genes may result in identical phenotypes), 
and polygenic inheritance (a trait is controlled by multiple gene interactions so that 
each individual predisposing allele has a low risk factor and shows weak correlation 
with the disease trait).  In addition, environmental factors may also play an important 
role in shaping disease phenotypes.  Many phenotypic traits, such as behavioral 
characteristics and different drug response are also believed to follow such a complex 
inheritance pattern and are thus generally called complex traits.   
3The Allelic Structure of Human Disease
Owning to the extensive data on human monogenic diseases, their allelic 
structure is relatively clear.  Monogenic diseases are usually very rare in the human 
population and the frequency of disease alleles is also very low, usually << 1%.  The 
level of allelic heterogeneity is very high in monogenic diseases.  According to the 
human gene mutation database (HGMD) (Stenson et al. 2003), there are on average 
over 10 disease alleles per disease gene.    
However, little is known about the allelic structure of human complex 
diseases, since very few complex disease genes have been unambiguously identified.  
One popular view is the common disease/common variant (CD/CV) model (Reich 
and Lander 2001), which assumes that human common diseases are caused by one or 
a few predominating alleles at a small number of loci. Those alleles are generally old 
and common across different geographical populations.  Known complex disease 
alleles seem to support this hypothesis, such as the APOE O4 allele in Alzhemer’s 
disease (Corder et al. 1993) and the PPARP P12A in type II diabetes (Altshuler et al. 
2000).   However, such a small sample is not sufficient to exclude other possible 
models. For example, complex diseases may be affected by rare susceptibility alleles 
at a large number of loci.   The CD/CV model represents the best case scenario that 
we could possibly have for identifying disease genes. On this basis, association 
studies are proposed as a feasible way to identify disease genes, as discussed in detail 
later. 
4Genetic Mapping of Human Disease
Linkage Analysis 
Linkage analysis is performed on family pedigrees.  The extent to which a 
genetic marker and a disease trait are co-inherited allows one to estimate the 
recombination rate between them, and hence to also estimate the physical distance 
separating them.  Use of multiple genetic markers allows refinement of the position of 
the disease locus. Since its early success in the 1980s, linkage analysis has been used 
to identify many monogenic disease genes.  However, it meets a lot of difficulties 
when applied to complex diseases.  There are two major problems.  The first problem 
is related to the identification of a disease phenotype.  Unlike monogenic diseases that 
are relatively easy to be diagnosed because of their high severity, the precise 
description of a complex disease is no easy task and thus a clear diagnostic standard 
is needed (Botstein and Risch 2003).  The other major challenge arises from a 
consequence of a susceptibility being determined by multiple loci.  As a consequence, 
each disease-susceptible allele may only possess modest relative risk.  Risch and 
Merikangas have estimated that in order to achieve statistically significant results for 
a complex disease, the number of family pedigrees needed is impractically large 
(Risch and Merikangas 1996).   
Association Studies  
The choice for complex disease 
Association studies, also referred to as case-control studies, measure the 
association of a genetic marker, usually a SNP, with a disease trait in a population.  A 
5marker is assumed to be associated with a disease if it has a significantly higher 
frequency in the patient population than the control population.  Currently, it is 
believed that association studies offer a more practical approach for common human 
disease than linkage analysis.  A large population sample is easier to get than a large 
number of suitable families for linkage analysis, which would be needed to obtain 
sufficient statistical power. A population can be regarded as a multigenerational 
family descended from a single or a few founders.  Inside such a big family, all but a 
few most recent generations are missing.  Numerous historical recombination events 
are included, so that only markers very close to a disease mutation will be in LD 
(Linkage disequilibrium) with the disease mutation. While this feature allows high 
precision mapping of disease genes, it does require a large number of markers unless 
the location is already approximately known.  Association studies can be conducted 
within a list of disease candidate genes or on the whole genome (Botstein and Risch 
2003).   
Linkage Disequilibrium 
Linkage disequilibrium (LD) is the non-random association between genetic 
markers in a population.  On average, there is a reverse correlation between the level 
of LD and distance between SNPs because the likelihood of recombination between 
two SNPs increases with the distance between them.  However, it has been found that 
the extent of LD varies in the human genome (Pritchard and Przeworski 2001).  The 
human genome contains “hotspot” regions with relatively high recombination rates.  
Hotspots are separated by relatively large haplotype blocks in which there are low 
recombination rates.  A Haplotype is defined as a set of strongly associated alleles, 
6usually SNPs, inside such a block.  There are typically a small number of common 
haplotypes at each genomic region in a population.  Usually presence and absence of 
a few SNPs can be used to determine which haplotype is present.  These are called 
haplotype tag SNPs.  Using tag SNPs rather than all the SNPs will decrease the 
number of markers required for association studies (Gabriel et al. 2002).   
Haplotype blocks are heterogeneous among different populations (Gabriel et 
al. 2002).  European and Asian populations are relatively more homogenous, with 
larger blocks.  African populations are more heterogeneous, and contain relatively 
small haplotype blocks.  Tishkoff et al. (Tishkoff and Verrelli 2003) argued that this 
difference may be due to several possible factors: African populations are older,  
African populations have a larger effective population size and non-African 
populations experienced a bottleneck event.  It has been proposed that European and 
Asian populations first be used to map a disease trait to a certain chromosomal 
region, and then African populations with smaller haplotype blocks can be used for 
fine-scale mapping (Tishkoff and Verrelli 2003).  
Bioinformatics 
So far, association studies have not delivered many successes in mapping 
complex disease, because of many challenges, including the possibility that complex 
diseases are caused by many rare variants and other statistical problems.  On the other 
hand, the knowledge of the human genome sequence (Lander et al. 2001; Venter et al. 
2001) and a large number of SNPs opens the way for the development of a detailed 
understanding of the mechanisms by which genetic variation results in phenotype 
variation.  In particular, it should now be possible to identify the contribution of SNPs 
7to human disease and thus provide a set of prioritized SNPs for association studies.  
Computational analysis of SNPs can be used as complementary data to confirm 
positive association study results and to identify causative mutations, which should be 
especially helpful when a disease gene is inside a large LD block.  Informatics also 
has a significant role to play in relating the effect of an individual SNP in a protein to 
the gene-gene network environment and hence to the phenotypic impact, as discussed 
later.  
Computational Modeling of SNPs: Overview 
Mis-sense variants are the most frequent known monogenetic disease 
mutation.   As a consequence, many computational methods have been developed to 
model the impact of mis-sense variants on protein function in vivo. All of these 
methods require some formal training and testing to assess their ability to distinguish 
between disease and non-disease data.  A variety of approaches have been used to 
collect deleterious mis-sense variants and non-deleterious mis-sense variants for 
training and testing purposes.  Wang and Moult (Wang and Moult 2001) used a set of 
known human monogenic disease mis-sense variants in the Human Gene Mutation 
Database as the deleterious data set.  Sunyaev et al. (Ramensky et al. 2002; Sunyaev 
et al. 2001) used disease variants annotated in the Swiss-Prot database (Boeckmann et 
al. 2003) as the deleterious data set.  Others (Chasman and Adams 2001; Krishnan 
and Westhead 2003; Ng and Henikoff 2003) used mis-sense mutants that affect the 
phenotype in mutagenesis experiments on Lac repressor and T4 lysozyme as the 
deleterious data set.  Two different methods have been used to collect non-deleterious 
variants.  Sunyaev et al. (Ramensky et al. 2002; Sunyaev et al. 2001) used non-
8synonymous base differences between human proteins and closely related proteins in 
other mammals.  Other groups (Chasman and Adams 2001; Krishnan and Westhead 
2003; Ng and Henikoff 2003)  used the mis-sense mutants that do not show 
phenotype effects in mutagenesis data for Lac repressor and T4 lysozyme as the non-
deleterious data set. 
Two principal strategies have been developed for identifying which mis-sense 
base changes are most likely to be causative of disease. The most common approach 
makes use of the fact that the more critical a position in a protein sequence is to 
viability, the more restricted are the residue types accepted there. A number of 
different methods for assessing the significance of amino acid conservation have been 
developed (Chasman and Adams 2001; Krishnan and Westhead 2003; Ng and 
Henikoff 2003; Ramensky et al. 2002; Sunyaev et al. 2001).  Methods that utilize 
sequence conservation have the advantage of including all kinds of impact on protein 
viability. Also, these methods can be used with any human protein for which a 
suitable set of sequence relatives is known, and so have wide applicability. The 
approach has the disadvantage that it provides no direct insight into the underlying 
mechanism.  The second strategy is to make use of knowledge of protein structure 
and function. For instance, recognizing that a change occurs in a key catalytic residue, 
or one involved in ligand binding, or a target for post-translational modification.  
Wang and Moult (Wang and Moult 2001) used a structure-based model to 
identify amino acid substitutions likely to significantly affect protein stability as well 
as other contributions to function.  Stability impact was assessed using a set of simple 
rules based on changes in hydrophobic burial, backbone strain, overpacking, and 
9electrostatic interactions. Other groups have combined sequence and structure 
strategies to varying degrees.  Sunyaev (Ramensky et al. 2002; Sunyaev et al. 2001) 
predicted the effect of mis-sense mutations using empirically derived rules which 
make use of a variety of data, such as functional information, hydrophobic 
propensity, side-chain volume change and transmembrane location (Ng et al. 2000), 
together with sequence information.  In Chasman’s (Chasman and Adams 2001) 
method, ANOVA (Analysis of variance) and principal component analysis were 
applied to a series of features that capture aspects of structural and sequence context. 
Features showing strong discrimination between mutations affecting or not affecting 
the phenotype, such as the relative residue temperature factor, relative surface 
accessibility, relative phylogenetic entropy (sequence conservation in the protein 
family) and burial of charge, were selected.  A probability model was then 
constructed based on the selected features, and used to estimate the likelihood that a 
given mutation will affect function. A similar probability approach has also been used 
to include function effects (Lau and Chasman 2004). Krishnan and Westhead 
(Krishnan and Westhead 2003) used two machine learning methods, a decision tree 
and a support vector machine, to predict the impact of single amino acid changes 
based on a set of structural (secondary structure and surface accessibility) and 
sequence attributes, such as sequence conservation score calculated using ScoreCons 
(Valdar and Thornton 2001). Secondary structure and surface accessibility data were 
taken from the HSSP database (Dodge et al. 1998) or predicted using PHD 
(Przybylski and Rost 2002). 
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Computational Modeling of SNPs: Hypotheses 
In this project, we have developed both a structure based model and a 
sequence based model.  The central hypothesis of the structure-based model is that 
moderate loss of stability of the folded state of a protein molecule is frequently 
associated with monogenic disease. In principle, the stability could be assessed with 
numerical free energy calculations.  However, at present, such calculations are not 
reliable enough to provide useful answers (Mark and van Gunsteren 1994). 
Knowledge-based methods, dividing stability into a set of factors such as electrostatic 
interaction and hydrophobic burial, provide an alternative approach.  In the present 
work, a knowledge based method has been used to estimate whether or not an amino 
acid substitution reduces protein structure stability significantly.  15 factors that are 
related to the free energy of the folded state of protein are used.  They are described 
more fully later. A machine learning technique (a support vector machine, SVM 
(Vapnik 1995), see the following section ) is used to distinguish deleterious mis-sense 
variants and non-deleterious variants using these 15 factors. 
The underlying hypothesis for the sequence based model is that deleterious 
mutations would be removed during evolution and thus critical amino acids tend to be 
conserved across species.  Five features that capture the relative sequence 
conservation at each position in a multiple-species sequence alignment are used as 
basis for SVM to identify deleterious mis-sense variants.  Those mutations at a 
conserved position tend to be the most deleterious. 
11 
 
SNPs3D: a resource for analysis of SNP, identification of candidate genes 
and construction of gene relationship networks 
Some SNP analysis methods form the basis of tools that are available through 
web servers.  Facilities range from tools to visualize SNPs in their three dimensional 
context, such as MutDB (http://www.mutdb.org) (Dantzer et al. 2005; Mooney and 
Altman 2003), TopoSNP (http://gila-fw.bioengr.uic.edu/snp/toposnp) (Stitziel et al. 
2004; Stitziel et al. 2003), SAAP (http://www.bioinf.org.uk/saap/) (Cavallo and 
Martin 2005), to detailed analysis of the molecular effects of mis-sense SNPs.  For 
example, SNPeffect (http://snpeffect.vib.be/)  provides a comprehensive analysis of 
mis-sense SNPs at the protein level (Reumers et al. 2005) including stability analysis 
using FOLD-X (Guerois et al. 2002), and other functional analysis;  PolyPhen 
(http://www.bork.embl-heidelberg.de/PolyPhen) models SNP effects with both 
structure and sequence information (Ramensky et al. 2002); SIFT 
(http://blocks.fhcrc.org/sift/SIFT.html) provides sequence analysis of mis-sense SNPs 
(Ng and Henikoff 2003). 
In the present work, we have used the structure and sequence based models to 
identify deleterious SNPs in the current version of dbSNP (Build 124), and a publicly 
available website, SNPs3D, has been developed to provide easy access to our analysis 
for the scientific community.   
To maximize use of data, it is necessary to put SNP analysis into the pathway 
context.  A number of projects, including the Ingenuity Pathway database 
(http://www.ingenuity.com) and the Protein Reference Database (Peri et al. 2004), 
(http://www.hprd.org), are developing mammalian pathway descriptions by means of 
12 
 
manual curation of the literature.  Although these databases provide rather precise 
data, the human-curation process makes development slow.  This problem is 
becoming more serious as the size of the relevant literature increases. Protein 
interaction networks have also been built automatically (Giot et al. 2003; Lee et al. 
2004) (Li et al. 2004; Tong et al. 2004), using probability models to integrate data 
from high throughput experiments such as yeast-2-hybrid (Fields and Song 1989; 
Phizicky et al. 2003) and TAP pull-downs (Jansen et al. 2003).    
In SNPs3D, a network of gene-gene interactions is derived from the literature. 
A variety of computational methods are being developed to automatically extract 
information from the literature.  These methods range from simple technologies 
which process at the word level and require only a limited linguistic context (Stapley 
and Benoit 2000)  to state of the art technologies such as natural language processing 
(NLP), that handle more complex relations across sentences (Daraselia et al. 2004). 
So far, these methods have not been used extensively in generally available gene-
disease interfaces.   
We make use of simple text mining techniques.  Each gene or disease is 
treated as a concept. Words and terms are extracted from relevant PubMed abstracts 
ordered by their relevance to the concept.   The overlap of the keyword profiles 
between a pair of genes is used to build a gene relationship network.  Profiles are also 
used to provide a list of candidate genes for diseases. A Java interface has been 
developed to display gene-gene relationship.  The Java interface also allows access to 
a range of relevant information including pathways (Kanehisa et al. 2004), mRNA 
expression profiles (Su et al. 2002), mouse knockout (http://www.bioscience.org 
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/knockout/knochome.htm), disease-gene relationship databases (Hamosh et al. 2005; 
Stenson et al. 2003) and the underlying literature.     
 
Technology overview
Classification 
The work described in this thesis makes use of a machine learning technique, 
the support vector machine (SVM), to classify mis-sense mutations as deleterious or 
non-deleterious to protein function in vivo. The support vector machine is a 
computational technique for data classification.   
SVMs are one of a large number of machine learning techniques, including 
Decision Trees (Markey et al. 2003; Sachs 2003), Neural Networks (Bidiwala and 
Pittman 2004; Gromiha et al. 2004), Bayesian Networks (Li and Chan 2004; Nariai et 
al. 2004).  These techniques have been used in solving many scientific and 
commercial classification problems.  SVMs were introduced in 1995 and have spread 
into many fields, because they are easy to handle and are usually among the top-
ranking algorithms (Rost and Eyrich 2001).  They have been used successfully to 
solve a number of biological questions (Bhasin et al. 2005; Hua and Sun 2001; 
Mitsumori et al. 2005; Tsirigos and Rigoutsos 2005; Zhao et al. 2005).  
In the present application, we wish to classify mis-sense mutations as 
deleterious or non-deleterious on the basis of a set of features.  The features used for 
the structure based model are 15 stability parameters, such as overpacking, 
electrostatic interactions and hydrophobic effects.  Five features related to sequence 
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conservation were used for the sequence model.  Figure 1-1 shows a simple example 
for a two feature system. 
A central issue in all data classification is over-fitting.  When a training set is 
presented to a learning algorithm, the algorithm usually tries to find a model which 
correctly classifies as many of the objects as possible. A very complicated model may 
perfectly classify the objects in the training set, but may poorly classify new 
observations because the model is too specific.  This phenomenon is known as over-
fitting.  Cross-validation is used to objectively test the usefulness of a model, by 
training on one dataset and testing on a different one.  In this project, disease causing 
variations and non-deleterious variations are separated into two groups: one group 
functions as a training set, and the other is used to validate each model.  
Comparative modeling 
A protein structure is required in order to evaluate the stability effect of a mis-
sense variant.  Currently, experimentally-solved 3D structures are only available for a 
small fraction of human proteins.  The number of proteins for which structural 
information is available can be increased significantly by modeling.  Comparative 
modeling makes use the fact that when two proteins have similar sequences, 
indicating a common evolutionary origin, their 3D structures will also be similar.  As 
the sequence identity between two proteins decreases, their structural similarity also 
decreases, so that the most reliable models are based on a high level of sequence 
relationship.  A protein whose structure is to be built is called a target.  A protein with 
a sequence similar to that of a target and with a solved structure is called a template.  
A comparative model is constructed simply by coping structural coordinates of 
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Figure 1-1.   Illustration of a Support Vector Machine.   
There are two classes of data represented by squares and round points.  Each data 
point has two features, defining the X and Y coordinates. The support vector machine 
selects a partition in the space (in this case the curved line) that separates the two data 
sets as far as possible. Such a partition is seldom perfect and some points will be mis-
classified.  In general, the further from the partition surface a point lies, the higher the 
confidence.  In this thesis, the data are mis-sense mutations, which are classified as 
deleterious or non-deleterious to protein function in vivo.
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related regions of a template to create a target model and changing the side-chains 
types and coordinates as necessary.  According to the results of CASP (Critical 
Assessment of Structure Prediction), models based on a sequence identity around 
30% have approximately 1.5 Å root mean square (RMS) error for main chain atoms 
(Baker and Sali 2001).  As we shall see later, this is not quite good enough for our 
purpose, and a 40% threshold is used.  Figure 1-2 illustrates the comparative 
modeling process. 
 
17 
 
1ii4_F      PYWTNTEKME KKLHAVPAAN TVKFRCPAGG
FGFR3       PYWTRPERMD KKLLAVPAAN TVRFRCPAAG 
A
B
Step 1 copy main 
chains from 1ii4_F
Step 2 copy identical 
side chains from 1ii4_F
Step 3 model 
other side chains
Template: 1ii4_F Model: FGFR3
Model: FGFR3Final Model: FGFR3
 
Figure 1-2.   The process of comparative modeling. 
A.  Part of the sequence alignment between the protein of a gene FGFR3 and the 
closest available template structure, PDB (Deshpande et al. 2005) code 1ii4_F.  The 
boxed region is used to illustrate the detailed procedure of comparative modeling.  B. 
Comparative modeling, (the structure represented by the green area in Figure B 
corresponds to residues inside the rectangle in Figure A). Step 1. Main-chain 
coordinates are copied to the target from the template based on the sequence 
alignment, for example, the main-chain coordinates of Histidine on the template are 
copied to Leucine on the target.  Step 2. Side-chain coordinates are copied to the 
target from the corresponding identical template residues.  Step 3.  The remaining 
side-chains are modeled, for example the purple for Leucine. 
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Chapter 2: Loss of Protein Structure Stability as a Major 
Causative Factor in Monogenic Disease 
Introduction
The central hypothesis of the present work is that moderate loss of stability of 
the folded state of a protein molecule is frequently associated with monogenic 
disease. To investigate this, we must identify significant changes in the free energy 
difference between the folded and unfolded states of a protein molecule resulting 
from an amino acid substitution. A theoretically rigorous approach would be to use an 
appropriate integration of the energy change as one amino acid is morphed into 
another in the context of the protein structure. These free energy perturbation 
techniques (Beveridge and DiCapua 1989) have been incorporated in a number of the 
more widely used molecular dynamics software packages. Issues of conformational 
sampling, appropriate representation of the unfolded state and force field accuracy 
have generally resulted in poor accuracy (Mark and van Gunsteren 1994).  Recent 
results show encouraging improvement, but require care and method optimization in 
each case (Pan and Daggett 2001), restricting large scale application. Force field 
deficiencies may be reduced by parameterizing using free energy differences obtained 
from site directed mutagenesis experiments (Guerois et al. 2002). The resulting model 
is effective at predicting this type of stability change.  
We have developed a knowledge based method which estimates whether or 
not an amino acid substitution reduces protein structure stability sufficiently to be 
potentially causative of monogenic disease, As in the earlier work (Wang and Moult 
2001), we make use of the extensive literature on the effect of amino acid 
19 
 
substitutions on protein stability, as well as knowledge of the underlying factors 
affecting the free energy of the folded state. We identify a set of 15 such factors that 
may contribute to a free energy difference, through changes in interaction energy 
between amino acids, effects on the entropy of the system, and the local rigidity of 
the structure.  A machine learning technique (a support vector machine (Vapnik 
1995)) is used to partition the 15 dimensional space representing these factors into 
two volumes, in such a way that, as far as possible, disease causing mutations fall in 
one volume and non-disease causing ones in the other. Any new mutation may then 
be assigned a position in this space. Mutations falling in one volume are predicted to 
significantly decrease protein stability, and thus to be potentially disease causing. 
Those falling in the other volume are considered non-disease causing. Distance from 
the volume partitioning surface provides an approximate measure of confidence in the 
assignments, as illustrated in figure 1-1. 
The model is trained on a set of mis-sense mutations that cause monogenic 
disease, extracted from the Human Gene Mutation Database (HGMD (Stenson et al. 
2003)). A control set of residue substitutions not contributing to disease susceptibility 
was based on inter-species differences (Sunyaev et al. 2001). Stability effects are 
analyzed using available experimental structures of human proteins, or reliable 
comparative models. Jack-knifed testing shows that this model does differentiate 
between disease and non-disease mutations, validating the hypothesis that stability 
effects play a major and quite general role in monogenic disease. 
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Results
Selection of Data for Analysis 
As described in the methods, 10,263 disease causing mutations in 731 proteins 
were extracted from the HGMD (Stenson et al. 2003).  Appropriate structure 
information was available for 37% (3768 in 243 proteins) of these mutants, forming 
the disease set. 346 of the HGMD proteins had close orthologs in other species. The 
corresponding 16,682 inter-ortholog residue differences provided a set of non-disease 
variants. 14% (2309 in 153 proteins) of the inter-species variants had appropriate 
structure information, and formed the control set.  
Analysis of Factors Likely to Affect Protein Stability 
Eleven contributions to the energy and entropy of proteins stability are 
considered. There are four classes of electrostatic interaction: reduction of charge-
charge, charge-polar or polar-polar energy, or introduction of electrostatic repulsion; 
three solvation effects: burying of charge or polar groups, and reduction in non-polar 
area buried on folding; and two terms representing steric strain: backbone strain and 
overpacking. The other two contributions considered are cavity formation (affecting 
van der Waals energy), and loss of a disulfide bridge. Figure 2-1 shows examples of 
each of these, with the corresponding disease outcome. The crystallographic 
temperature factor and surface accessibility of mutated residues are also considered.  
Figure 2-2A shows the distribution of each of these effects in the disease and 
non-disease data sets.  (Criteria used are described in the Methods section). The red 
bar shows the fraction of all disease data points classified as disease, and the green
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Figure 2-1.   Examples of disease caused by structure destabilizing factors.  
For each case, bonds of wild type side chains are shown purple, and bonds of the 
mutant side chains are yellow. Atoms are colored by type. In a number of cases, more 
than one factor is involved. The selected one is judged to be the most significant. The 
full model considers all factors together. Disease associations are taken from the 
NCBI Refseq database. 
 
(a) Loss of polar-polar interactions. L226P in galactose-1-phosphate 
uridylyltransferase (GALT, PDB code 1HXP_B), causing galactosemia. This 
mutant introduces a proline into an alpha helix, resulting in the loss of a main 
chain hydrogen bond, as well as loss of hydrophobic interactions of the side 
chain. 
(b) Loss of hydrophobic interactions. F234S in GTP cyclohydrolase (GCH1, 
1IR8_I), causing dopamine-responsive dystonia. A large buried non-polar side 
chain is replaced by a small polar one, reducing the burial of non-polar area 
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on folding. A cavity is also created, and there is a small gain in polar-polar 
energy. 
(c) Loss of a salt bridge. R382L in isovaleryl Coenzyme A dehydrogenase (IVD, 
1IVH_C), causing isovaleric acidemia.  R382 forms a salt bridge (charge-
charge interaction) in the wild type protein, lost in this mutant. 
(d) Buried charge. G60D in aspartylglucosaminidase (AGA, 1APY_A), causing 
aspartylglycosaminuria. G60D introduces a charge group into the interior of 
the protein. It also causes over-packing.  
(e) Overpacking. C91Y acyl-Coenzyme A dehydrogenase (ACADM, 1EGE_C), 
causing ACADM hereditary deficiency. C91Y introduces a bulky side chain 
into the interior of the protein, resulting in substantial overpacking.  
(f) Cavity formation. F411I in glucocerebrosidase (GBA, 1OGS_A), causing 
Gaucher’s Disease. F411I replaces a large buried non-polar side chain with a 
smaller one, creating an internal cavity. There is also a loss of hydrophobic 
interaction. 
(g) Electrostatic repulsion. G38D in guanine nucleotide binding protein (GNAT1, 
1TAG), causing night blindness. Introduction of the aspartic acid side chain 
results in an unavoidable electrostatic repulsion with another aspartic acid. 
There is also limited overpacking.  
(h) Buried polar group. A543T in Hexosaminidase B (HEXB, 1O7A_D, causing 
Sandhoff Disease. Here a hydroxyl group is introduced in a buried non-polar 
environment. There is also minor overpacking. 
(i) Breaking of a disulfide bond. C163S in aspartylglucosaminidase (AGA, 
1APY_A), causing aspartylglycosaminuria. C163S replaces one component of 
a disulfide bond.  
(j) Backbone strain. G137V in arylsulfatase B (ARSB, 1FSU), causing 
Maroteaux-Lamy syndrome. G137V introduces a side chain onto a glycine 
residue with backbone dihedral angles unsuitable for other residue types.  
(k) Loss of charge-polar interaction. E167K in uroporphyrinogen decarboxylase 
(UROD, 1R3Q_A), causing familial porphyria cutanea tarda and 
hepatoerythropoetic porphyria. E167 forms charge – polar interactions with 
two main chain N-H groups, providing a helix cap. The mutation removes 
these interactions. 
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Figure 2-2A. Partitioning of each stability factor between the disease and non-disease 
data sets.   
The red bars show the fraction of disease variants covered by the corresponding 
factor, and the green bars show the fraction of non-disease variants covered. An ideal 
factor has high coverage of the disease set, and no examples in the non-disease set. 
Factors are ordered by the discriminatory power (ratio of disease to non-disease 
coverage), best discriminators to the left. The discriminatory power of each factor is 
included in the bar labels. The ratio ranges from infinite for breaking a disulfide 
bridge (no examples in the non-disease set) to 1 for polar-polar interactions (an 
approximately equal number of examples in the disease and non-disease sets).  
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bar is the fraction all non-disease points classified as disease. An ideal factor 
includes a large fraction of the disease points (red bars), and no non-disease points 
(green bar). The 11 energy and entropy factors are ordered by the ratio of the two bar 
heights, with the best discriminators on the left.  
Discrimination power ranges from perfect for disulfide bond breakage – (the 
only instances are in the disease set), to none (loss of polar-polar interactions is as 
common in the disease set as in the control set). Coverage also varies widely, from 
only 3% of disease cases involving disulphide bond loss to 24% of cases involving 
over-packing. The last two terms capture the ability of the structure to relax to partly 
compensate for unfavorable energy or entropic effects. As expected, regions of lower 
crystallographic temperature factor contain more disease mutations than non-disease 
ones. Similarly, buried residues, which generally have least space to adjust to change 
and more other energetic restrictions, have a two fold excess of disease mutations 
over non-disease ones.  
Greater discrimination can be achieved by taking advantage of the fact that 
most mutants affect more than one factor. Figure 2-2B shows some examples of 
discrimination using pairs of factors. For example, combining loss of a polar-polar 
interaction with a non-surface environment increases the ratio of disease to non-
disease cases from about one to approximately three. Highest discrimination will be 
obtained with a method that considers all the factors affected by a mutation. For this 
purpose, each mutant is represented as a point in a 15 dimensional factor space.  
Eleven of the dimensions are the energy and entropy factors shown in figure 2-2A. 
One dimension is the surface accessibility of the mutated residue, relative to
25 
 
Figure 2-2B. Improvement in discrimination when two stability factors are considered 
together.  
As in 2-2A, bars show the partitioning between disease and non-disease variants, now 
considering two factors at a time. Discriminatory power is considerably improved. 
For example, adding a non-surface requirement to loss of polar-polar interactions 
increase the discriminatory ratio from 1 to 3. Best discrimination is achieved when all 
relevant factors as considered, as in the full model. 
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the unfolded state. The other three are the CV temperature factor of the mutated 
residues, the Z value of the temperature factor, and the standard deviation of all CV
temperature factors. (Three dimensions rather than one are used to allow for variable 
scaling of the experimental values). As described in Methods, a support vector 
machine was used to determine a surface that optimally partitions the disease and 
non-disease points in this space.  
Accuracy of the SVM Model 
Figure 2-3 summarizes the results of the model. 74% of the 3768 mis-sense 
mutations in the disease dataset were assigned as disease causing, and 85% of the 
2309 mis-sense mutations in the non-disease dataset were classified as non-disease.  
For the 82% of data points more than a distance of 0.5 from the SVM partitioning 
surface, the prediction accuracy increases to 79% correctly identified disease data 
points, and 89% correctly assigned non-disease points. The 15% false positive rate 
arises from defects in the model. Since only stability factors are included in the 
model, all mutants that act through other mechanisms, such as effects on catalysis, 
binding and so on, are included in the 26% false negative rate. Some fraction of false 
negatives are mutants included in the HGMD database that do not appear to cause 
disease. For example, the mutant G15D in the alpha chain of Hemoglobin (HBA1) is 
in HGMD, but is predicted to be non-disease causing, with a confident SVM score of 
0.8.  The literature on this mutation (Molchanova et al. 1994) gives no indication of 
disease. Allowing for approximations in the model, a conservative conclusion is that 
substantially more than half of disease mutants operate at least partly through 
destabilization of the folded structure. 
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Figure 2-3.   Evaluation of the Support Vector Machine model.  
The left hand panel shows the fraction of disease variants correctly identified by the 
model in jack-knifed testing. The model is trained only to detect variants that cause 
disease by destabilization of the structure, so that the false negative rate of 26% 
includes all other causes, as well as deficiencies in the model. The bottom bar shows 
the result for the more confident subset of predictions (the 80% of the data with an 
SVM distance greater than 0.5), with a false negative rate of 21%. The right hand 
panel shows the same data for the non-disease data set. Here, the false positive rate 
(variants incorrectly assigned to disease) is 15% for the full set and 11% higher 
confidence classifications. 
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Model Evaluation using in vitro Mutagenesis Stability Data 
The SVM disease model is trained entirely on disease related mutant data, 
containing no explicit information about stability. Evaluation of the model’s 
performance against in vitro mutagenesis free energy data provides an independent 
test of the hypothesis that disease is strongly coupled with structure destabilization. 
We would expect that there should be a strong correlation between a potential disease 
outcome and the change in the free energy difference between the folded and 
unfolded states.  
As described in ‘Methods’, we have run the disease trained prediction model 
against a set of 581 of these in vitro stability data, from four proteins (Table 2-1). 
Figure 2-4 shows the relationship between the change in free energy and the fraction 
of mutations that would be predicted to have a disease outcome.  For mutants that 
stabilize or mildly destabilize the folded state (up to 1 Kcal/mole) the fraction of 
potential disease causing residues is close to the false positive rate of the model 
(16%).  As the change in free energy increases, so does the fraction of potential 
disease-causing mutations, reaching 90% in the 3 - 4 kcal/mol range, and 100% above 
4 kcal/mol.  These results confirm that the model is detecting destabilizing effects on 
structure.  The observation that most potential disease-classified mutations destabilize 
the folded state by about 2 to 3 Kcal/mol suggests that real disease causing mutations 
will be in this range.  That conclusion is supported by the fact that the distribution of 
SVM scores for mutants that destabilize by 
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Protein and PDB structure Structure 
class 
Number of Mutations 
(Total 581) 
Acyl-coenzyme A binding protein 
(2abd) 
All alpha 30 (Kragelund et al. 
1999) 
fk506 binding protein (1fkj) Alpha and 
beta  
34 (Fulton et al. 1999; 
Main et al. 1998) 
Barnase (1bni) Alpha and 
beta  
87 (Serrano et al. 
1992a; Serrano et al. 
1992b; Serrano et al. 
1992d) 
Staphylococcal nuclease (1stn) All beta 430 (Byrne et al. 1995; 
Green et al. 1992; 
Green and Shortle 
1993; Holder et al. 
2001; Meeker et al. 
1996; Schwehm et al. 
1998; Shortle et al. 
1990; Stites et al. 1994) 
Table 2-1.  In vitro mutagenesis data from four proteins, used to test the SVM model.   
Structure class is taken from SCOP (Andreeva et al. 2004) 
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Figure 2-4.   Application of the Disease/Stability model to in vitro site directed 
mutagenesis data.  
The plot shows the fraction of mutants classified as consistent with disease, as a 
function of the free energy difference between the folded and unfolded states. For 
stabilizing and weakly destabilizing mutants, the disease compatible fraction is 
similar to the false positive rate of the model. Above 3 Kcal/mol of destabilization, 
90% of mutants are classified as disease compatible. The results suggest that a typical 
disease causing mutant destabilizes the folded state by 2 – 3 Kcal/mol.  
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more than 2 Kcal/mol is similar to that of the disease causing mutants (means of -0.88 
and -1.00, medians of -0.68 and -0.60, respectively).  
It is informative to examine the outliers in this distribution. Five (L108I, 
L36V, L37V and A132G in staphylococcal nuclease and S92A in barnase) of the 53 
mutants that decrease stability by 3 to 4 Kcal/mol are predicted not to be consistent 
with disease.  The two L -> V mutants differ by one methyl group, and both result in 
a slight loss of hydrophobic burial. There are 24 L -> V mutants in the disease dataset 
and 37 cases in the non-disease dataset, suggesting that this class of mutant is finely 
balanced between disease and non-disease causing, and subtle effects tip the balance. 
Consistent with this, the SVM gives a low confidence score (0.14 and 0.13) for these 
two outliers. L108I creates no change of volume or overall hydrophobicity, so it is 
surprising that it is so destabilizing. There are 25 such mutations in the non-disease 
dataset, and only four in the disease set, suggesting this high level of destabilization is 
unusual. The SVM score is also in the less confident range (0.3). The authors of the 
experimental study (Holder et al. 2001) suggest loss of highly optimal van der Waals 
packing is primarily responsible for the large effect. The remaining two mutations,  
A132G and S92A, are both predicted to be non-disease causing with relatively high 
confidence (SVM scores 0.70 and 0.89).  For A132G, there is a minor loss of 
hydrophobic burial. There are 36 cases of A -> G mutations in the non-disease set and 
only 11 cases in the disease dataset. For S92A, the model identified the loss of a 
hydrogen bond and a slight gain of hydrophobic burial.  Serrano and colleagues 
(Serrano et al. 1992a; Serrano et al. 1992b) note that this residue is the first residue in 
a beta turn between two strands. The hydroxyl group is buried, and makes two 
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hydrogen bonds, suggesting it may be involved in unusually strong interactions.  
There are 77 cases of S -> A mutants in the non-disease set and only two in the 
disease set, indicating that such strong polar electrostatic interactions are unusual.  
Eight of the 52 mutants that increase protein stability are predicted to be 
consistent with disease. All but one are in Staphylococcal  Nuclease. All increase 
stability by less than 1 Kcal/mol. For three cases: N138G, S128A and H124F, the 
SVM returns a low confidence score. In none of the other cases is it clear why there is 
disagreement with experiment. For D21A and D21G, there is a predicted loss of 
charge-charge and charge-polar interactions.  For D21A and D21G, there is a 
predicted loss of charge-charge and charge-polar interactions. The distribution of 
these two mutations between the disease and non-disease datasets are 8/8 and 57/11 
respectively. T41I is predicted to result in a large gain of hydrophobic burial, offset 
by the loss of a charge-polar and polar-polar interactions in a buried environment.  
There are 41 cases of T -> I mutations in the disease dataset and 18 cases in non-
disease dataset, most with a predicted large gain hydrophobic burial and decreased 
electrostatic interactions. G50A is predicted to result in backbone strain. It is probable 
the structure is able to relax to accommodate the change in backbone angles. The 
temperature factor is moderately high, supporting this possibility. The eighth mutant, 
N58D, is in barnase. There is a predicted loss of polar-polar interaction and a slight 
gain of charge-polar interaction.  
Alternative Test Sets 
This work uses disease and non-disease related data for training and testing. 
Others (Chasman and Adams 2001; Ng and Henikoff 2003); (Krishnan and Westhead 
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2003) have used data on the phenotypic impact of single residue mutants in a 
bacterial and a phage protein. We have investigated the relationship between our 
assignment of disease potential and phenotypic impact in these mutagenesis sets. The 
data are a set of about 4000 mutants of the E.coli lac repressor  (Markiewicz et al. 
1994) and  a set of about 2000 mutants of  phage T4 lysozyme (Rennell et al. 1991).    
A total of 1,987 mutations in T4 lysozyme and 3,291 mutations in lac repressor can 
be modeled on the corresponding protein structures (PDB entries 1lbh and 7lzm 
respectively).  Each data set was partitioned into groups based on the phenotype 
annotations in the literature.  For lac repressor, these annotations are: “+” (wild-type 
phenotype, 200 fold repression of  beta-galactosidase activity, but in practice some 
times only 8 -10% of this); “+s” (wild-type phenotype under certain conditions, 
including temperature sensitive mutations);  “+-“ (20 -200 fold galactosidase 
glactosidase repression); “-+“ (4 – 20 fold);  and ”-“ (less than 4 fold repression). For 
T4 lysozyme, the groups are: “++” (wild-type phenotype – plaque size similar to 
control); “+” (signifcanlty smaller plaques); “+/-“ (Similar in size to “+’, but hazy 
morphology); and ”-“ (no plaques produced). 
 The HGMD trained SVM model was used to assign potential disease mutants 
in each of the phenotype categories. Figure 2-5 shows the results.  For both proteins, a 
high fraction of the mutants in the most severe class of phenotype impact are assigned 
as disease like (~90% for Lac repressor and ~100% for T4 lysozyme). However, for 
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Figure 2-5.   Application of the Disease/Stability model to mutants of Lac repressor 
and T4 lyzozyme.  
Symbols below the bars indicate the extent of phenotypic impact for that set of 
mutants, from ‘+’ for the most activity to ‘-‘ for none. Red regions of the bars show 
the fraction of mutants in each category found to be compatible with disease. As 
expected, a high fraction of the low activity mutants are assigned as compatible with 
disease, but a significant fraction of the maximum activity ones are also so classified. 
This result is consistent with the fact that a low % of activity is sufficient for a ‘+’ 
classification for both proteins. Numbers below each column show the number of 
mutants in that category.  
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both proteins, about 40% of ‘wild type’ mutants are also assigned as consistent with 
disease. The probable explanation is that a rather low level of enzyme activity is 
needed for a wild type classification: For T4 lyzozyme, as little of 4% residual 
enzyme activity may be classified as wild type (Rennell et al. 1991), and for Lac 
repressor, 10% activity is some times sufficient (Markiewicz et al. 1994). Such low 
levels of monogenic disease protein activity would likely usually result in disease.  
Functional Analysis of Single Residue Mutations 
An advantage of the structure/stability model is that it provides mechanistic 
insight into why a mutant has a deleterious effect on protein function. In principle, 
functional roles, such as ligand binding and catalysis, may also be assigned to 
particular residues, and so allow more general mechanism based analysis. As 
described in Methods, we have investigated this possibility using SwissProt 
functional annotation and experimentally observed ligand binding. Figure 2-6 shows 
the results. For the disease set, an additional 1.6 % of the mutants that were false 
negatives in the stability model are annotated as functionally important. Seven 
percent of the stability related mutants are also assigned a functional role. These low 
values probably reflect the incomplete assignment of function. Inclusion of these in 
the model would reduce the false negative rate by 1.6%. However, in the non-disease 
set, an additional 2.1% of mutants are assigned a functional role, leading to an 
increase in the fraction of false positives. Thus, we conclude that, at present, residue 
function annotation is too unreliable and incomplete to be useful.  
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Figure 2-6.   Distribution of direct functional effects of variants in the Disease and 
Non-disease data sets.   
Residue function was assigned from Swiss Prot annotation and on the basis of 
contacts with bound ligands. 7% of stability variants also have a known functional 
role, and only an additional 1.6% of false negatives are associated with function. 
2.1% of correctly classified non-disease variants are assigned a functional role. 
Overall, few variants are assigned function, and inclusion of those in a disease 
classification model would slightly increase the false positive rate. 
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Investigation of the Role of Protein Structure Accuracy 
Two-thirds of the mis-sense mutations are analyzed in the context of structure 
models rather than experimental structures.  The accuracy of these comparative 
models therefore plays a role in the accuracy of disease assignment. In general, 
accuracy of a structure model decreases with decreasing sequence identity between 
the structure of interest and the closest available template structure.  
To investigate the significance of this factor, disease assignment accuracy was 
examined as a function of structure/template sequence identity, in ranges between 
25% and 100% (‘100%’ are those cases for which an experimental structure of the 
human protein is available).  A separate SVM model was trained and tested within 
each sequence ID group.  
Results are shown in Table 2-2. Overall, disease assignment using protein 
models based on a structure template with more than 40% sequence identity is not 
significantly less accurate than that based on experimental structures.  For sequence 
identity of 30% or lower, errors in structure models begin to have a significant effect, 
with increases in both the false negative and false positive rates. Multiple factors 
contribute to the decline in accuracy, included less reliable side chain interactions 
arising from higher main chain position errors, an increased frequency of sequence 
alignment errors, and higher number of insertions and deletions (Tramontano and 
Morea 2003).  
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Disease Variants Non-Disease Variants 
%
Identity 
#
Mutants 
% of
Total 
#
Proteins FN 
#
Mutants 
% of
Total 
#
Proteins FP 
100% 1710 35% 85 25.5% 672 23% 50 16.7% 
90-99% 981 20% 67 23.2% 932 33% 61 13.2% 
40-99% 1077 22% 93 24.3% 705 25% 62 16.7% 
25-39% 1181 24% 142 27.5% 551 19% 91 28.2% 
Table 2-2.   Disease Assignment Accuracy as a Function of Structure Model Quality.   
Each row shows data using structure models based on a given range of sequence 
identity to an experimental structure. Accuracy is measured by the false positive rate, 
FP (fraction of non-disease variants classified as disease causing), and the false 
negative rate, FN (fraction of disease variants classified as non-disease causing) The 
‘100%’ row gives data for cases based on an experimental structure, rather than a 
model. Accuracy is unaffected by the use of a structure model for sequence identities 
down to about 40%.  
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Discussion and Conclusion
Role of Protein Destabilization in Monogenic Disease 
This work tested the hypothesis that destabilization of protein structure is a 
major factor in human monogenic disease. A simple factor based model of the 
stability impact of single residue mutants and an objective machine learning 
technique are used. In properly jack-knifed testing, the model is able to distinguish 
between mutants likely to lead to disease and those that do not, with reasonably low 
false negative (26%) and false positive (15%) rates. The false negative rate (those 
non-synonymous base changes that lead to disease not so categorized) partly reflects 
deficiencies in the model, but also includes the fraction of mutants that act through 
mechanisms other than destabilization. We conclude from these results that 
substantially more than half of monogenic disease mutants act through a process 
consistent with destabilization of the folded state.  
Use of the model to classify in vitro mutagenesis data strongly supports the 
role of stability in disease, and implies that a disease causing mutant typically 
destabilizes a protein by 2 – 3 Kcal/mol. For most globular proteins, the free energy 
difference between the folded and unfolded state is between 5 and 15 Kcal/mol 
(Privalov 1979), corresponding to an equilibrium constant between the unfolded and 
folded states of between 10-4 and 10-13. A mutant that destabilized by 2 Kcal/mol 
would increase the concentration of the unfolded state by about two orders of 
magnitude, but the fraction of unfolded molecules is still so small that there would be 
no expected effect on function in an in vitro assay. In vivo, though, chaperone 
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scavenging of unfolded proteins (Hohfeld et al. 2001) may cause such a 100 fold 
increase in the fraction of unfolded molecules to result in a much lower steady state 
protein concentration. 
Although loss of stability is clearly highly related to a disease outcome, it may 
sometimes be an effect on folding which is the actual mechanism. In vitro folding 
studies of simple proteins, such as barnase (Serrano et al. 1992c), show that about 
40% of mutants that affect stability also affect the folding rate. For disease mutants, 
folding may be slowed so much that most molecules are targeted for recycling by the 
quality control machinery in the ER and elsewhere (Plemper and Wolf 1999). Since 
not all mutants that affect stability also affect folding rate, if folding were the primary 
factor, a stability model should generate a high level of false negatives. The 
reasonably high accuracy of the stability model thus suggests that it is the most 
relevant factor. Nevertheless, without extensive experimental studies, it is not 
possible to know for what fraction of cases stability or folding is most relevant.  
Direct experimental evidence for the role of stability is scarce, since there are 
very few studies of the properties of disease-causing mutants in human proteins. One 
exception is for mutants in phenylalanine hydroxylase. Excess phenylalanine is toxic, 
and defects in this enzyme lead to phenylketonuria (PKU). Over 100 single residue 
disease causing mutants are known, and a subset of these have been studied in COS 
cells (Scriver et al. 2003). There is a clear correlation between the set assigned as 
affecting stability by our model and the in vivo total activity and concentration, as 
measured by immuno-precipitation.   
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Why does Protein Stability play a Prominent Role in Monogenic Disease? 
There are many mechanisms by which a single base change may affect the 
function of a protein in vivo: Changes in gene regulatory regions may lead to altered 
transcription rates; changes in the transcribed message may lead to altered processing, 
particularly splicing; message changes may affect translation through, for example, 
altering the secondary structure properties (Pelletier and Sonenberg 1987; Shen et al. 
1999). Surprisingly, data for monogenic disease in HGMD suggest that all these pre-
protein factors account for less than 10% of cases (Stenson et al. 2003). This number 
may be an underestimate of the true value, because of bias in detection methodology. 
Nevertheless, it is clear that protein level effects are by far the more common.  
Once a polypeptide chain has been produced, non-synonymous changes (those 
base changes resulting in an amino acid substitution) may affect in vivo activity in 
two major ways: Aspects of the protein’s molecular function may be altered, 
particularly ligand binding, catalysis, post-translational modification, or an allosteric 
mechanism. The likelihood of this class of effect depends on the fraction of residues 
in critically involved in one or more of these functions.  
The second way in which non-synonymous base changes may affect in vivo 
activity is by reduction of the concentration of protein. This may come about through 
less successful folding, or an increase in the fraction of unfolded protein, caused by a 
reduction in stability. Tests with the stability model, sampling a large number of 
randomly chosen mutants, show that approximately half are consistent with a disease 
outcome. Thus, the high fraction of disease mutants associated with stability loss is 
42 
 
likely a consequence of the higher fraction of mutants that can affect stability, 
compared with the other possible causes.  
Distinguishing Properties of Monogenic Disease Proteins 
For the 1000 or so monogenic disease proteins in HGMD,  the average 
number of known single residue mutants leading to disease is just over 10 (Stenson et 
al. 2003). Yet no mutants directly causative of monogenic disease are known in the 
remaining approximately 22,000 human proteins.  What is the difference between 
these two sets of proteins? First, monogenic disease proteins may be abnormally 
unstable or have abnormally fragile folding behavior. There is very little data with 
which to address this possibility, but many are relatively simple metabolic enzymes, 
and compared with most human proteins, the least likely to exhibit this sort of 
fragility. A second possibility is that mutants in many of the other proteins lead to a 
non-viable fetus, and so never be classified as disease causing. Gene suppression in 
C.elegans (Kamath et al. 2003) and Saccharomyces (Cliften et al. 2003; Rubin et al. 
2000), as well as limited mouse knockout data  all suggest that only 10 - 20% of 
proteins are essential in this sense, and so that is unlikely explanation. Third, and 
most probably, monogenic disease proteins may be the subset to which the system is 
least robust to component failure. Analysis of non-synonymous single nucleotide 
polymorphisms in the human population shows a significant fraction that appear to be 
as deleterious to protein structure and function as those found in monogenic disease 
genes (Chasman and Adams 2001; Ng and Henikoff 2003; Ramensky et al. 2002; 
Yue 2005), but with no disease outcome. Limited knowledge of human protein 
networks makes it difficult to rigorously test this possibility. Nevertheless, inspection 
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of the pathway context of monogenic disease proteins supports this explanation. 
Many, such as phenylalanine hydroxylase, appear to perform unique roles, with no 
redundancy alternative pathways. In contrast, inspection of the pathway context of 
proteins that contains SNPs that destabilize protein structure significantly, such as the 
T cell receptors (Wang and Moult 2003), usually suggests a mechanism that makes 
the system robust to failure of a protein component. Many different T cell receptors 
are involved in an antigenic response, so that reduced effectiveness of some will not 
have obvious disease consequences, although it may influence resistance to particular 
infections in subtle but significant ways. 
Advantages and Disadvantages of a Protein Structure Based Approach 
An advantage of the structure based approach is that it provides a detailed 
atomic level model of the precise mechanism by which an amino acid change results 
in a change in protein properties. A disadvantage is that it is limited to stability 
effects.  Use of comparative modeling allowed us to extend the number of mutants 
that can be analyzed. Tests showed that disease prediction accuracy is unaffected by 
the use of a model, down to 40% sequence identity to a known structure. This is in 
keeping with studies of the accuracy of structure modeling methods (Cozzetto and 
Tramontano 2005), and also partly reflects the fact that the method does not depend 
on very accurate structures.  Even so, only about 10% of human protein domains can 
currently be analyzed. The rapid advance of structural genomics (Service 2005) may 
quickly reduce this limitation. 
 
44 
 
Methods
Identification of Single Residue Variants related to Monogenic Disease  
Genes associated with monogenic disease were identified by checking all 
16,220 human gene names in the NCBI Locuslink (Wheeler et al. 2004) database (as 
of 04/26/2002) against the Human Gene Mutation Database(Stenson et al. 2003), 
(HGMD) (as of 02/09/2002).  HGMD contains the most comprehensive collection of 
mutations related to monogenic disease. Most are causative of monogenic disease, 
although a few may be associated with disease as a result of linkage disequilibrium 
rather than directly causative, or contribute to complex trait disease. Later versions of 
HGMD include more of the latter class, and so the earlier version was preferred. 731 
genes containing 10,263 single residue variations were identified.  
Identification of a Set of Single Residue Variants not related to Disease 
We also required a control set of mutants, not causative of disease. It is not 
known which base variants in the human population contribute to complex trait 
disease, and so it is not possible to use these. Following others (Sunyaev et al. 2001), 
we used non-synonymous base differences between human proteins and closely 
related proteins in other mammals. The justification here is that almost all variants 
that are fixed between species are essentially neutral and non-deleterious. To maintain 
compatibility between the disease and control sets, the same 731 monogenic disease 
proteins were used.  The protein sequences of these genes were compared to all other 
mammalian protein sequences in Swiss-Prot (Boeckmann et al. 2003), using BLAST 
(Altschul et al. 1997). Proteins with at least 90% sequence identity over at least 80% 
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of the full length were selected. Single residue differences in these alignments were 
used as a set of pseudo ‘mutations’, providing the non-disease set.  A total of 348 
proteins containing 16,682 such single-residue differences to the human disease set 
were obtained.   
Selection of Sets of Mutants with Protein Structure 
Each of the 731 human proteins was checked for entries in the Protein Data 
Bank (as of 7/26/2004)(Deshpande et al. 2005). Templates for models of human 
proteins were taken from the PDB for cases where there was no human structure 
available, and there was a PDB entry for an X-ray structure at least 3.0 Å resolution 
and with 40% or higher sequence identity to the human protein over at least 100 
residues.  
For the non-disease set, variants that might be partially compensated by other 
species differences in the same protein were eliminated as follows. All clusters of 
variants where there are interatomic contacts of 5Å or less between residues were 
discarded. For example, A2S in the myosin light chain is a variant between human 
and mouse, and between human and rat.  G20T, a variant between human and mouse, 
makes contact with the G20 position, and so both variants were excluded. The rat 
protein has no change at G20, so rat A2S was retained in the non-disease set.  
Support Vector Machine 
The Support Vector Machine software package SVMlight 
(http://svmlight.joachims.org/) was used to determine the partitioning surface 
between the disease and non-disease data in the 15 dimensional parameter space. 
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Continuous variables were normalized in the form of a Z score  [Z=(value-
mean)/standard-deviation]. A radial basis kernel was used, allowing for complex 
surface topology. For this kernel, the higher the parameter P, the more complex the 
effective surface, allowing better accommodation of the data. Too higher a gamma 
leads to over-fitting, and less accurate prediction on new data. A P value of  0.2 was 
selected, based on a series of trials. Weights were assigned to the disease and control 
data sets to compensate for their different sizes, such that they contributed equally to 
determining the partitioning surface. The distance of a data point from the 
partitioning surface provides an approximate measure of confidence in a prediction.  
SVM Model Training and Testing 
A subset of 90% of the disease and non-deleterious variations were selected 
randomly to form a training set. The resulting SVM model was used to predict which 
of the 10% of data not included in training are disease causing. The training and 
testing procedure was repeated 30 times, randomly selecting the test data on each run. 
For each trial, the false negative rate (the fraction of disease variations mis-classified 
as non-disease) and false positive rate (the fraction of non-disease variants mis-
classified as disease causing) in the test dataset were calculated.  The average false 
positive and false negative rates provide the measure of the prediction accuracy.  
In-vitro Mutagenesis Data 
Free energy difference data from site directed mutagenesis experiments was 
used to test the ability of the SVM model to identify known destabilizing mutations.  
Four proteins with a large number of associated site directed mutagenesis 
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experiments(Byrne et al. 1995; Fulton et al. 1999; Green et al. 1992; Green and 
Shortle 1993; Holder et al. 2001; Kragelund et al. 1999; Main et al. 1998; Meeker et 
al. 1996; Schwehm et al. 1998; Serrano et al. 1992a; Serrano et al. 1992b; Serrano et 
al. 1992d; Shortle et al. 1990; Stites et al. 1994) were selected. They cover three 
classes of protein folds (SCOP (Andreeva et al. 2004) classification): all alpha, all 
beta and alpha & beta. Table 2-1 lists the proteins, and the number of mutants in each.  
More data are available in the PROTHERM database (Bava et al. 2004)   but 
inconsistencies in format, particularly the sign convention for free energy, prevent the 
large scale use of these.  
Comparative Modeling of Protein Structure 
Comparative models were built using the in-house APSE (Automatic Protein 
Structure Emulator) pipeline. Modeling protocols in APSE are based on experience 
with building comparative models in the CASP experiments (Samudrala and Moult 
1997) and a variety of projects. The procedure can be run in automatic or semi-
automatic mode. A core backbone model is first constructed by copying regions of 
the chosen template structure. Alignments are obtained using CLUSTALW. Co-
ordinates of side chains conserved between the human protein and the PDB template 
are copied. Remaining side chains are added using SCWRL (Canutescu et al. 2003).  
Where necessary, quaternary structure was taken from the PQS (Protein 
Quaternary Structure) database of biological units (Henrick and Thornton 1998).  
Additional subunits are modeled in the same manner as the chain of interest. Side 
chains are modeled in the multimer context.  
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Modeling the Structure of Single Residue Mutants 
All SCWRL library back-bone dependent conformations (Canutescu et al. 
2003) for the new side chains were built.  The conformation least damaging to 
stability was selected, based on the following rules. First, the conformation with the 
least worst overpacking was selected. I.e. if there is one conformation with an 
interatomic contact of 2.6Å and another with 2.7Å, the latter was accepted. No 
distinction was made between conformations with contacts 3.0Å or longer. If more 
than one conformation remained, the one with the least loss of hydrophobic area was 
selected. In cases where there is no loss of hydrophobic area, conformations with loss 
of a salt bridge were next eliminated, then those with electrostatic repulsion, 
hydrogen bond loss, cavity formation, backbone strain, introduction of a buried 
charge, and finally, introduction of a buried polar group. 
Modeling the Stability Impact of a Single Residue Mutant 
Table 2-3 lists the stability factors that provide the 15 dimensions used in 
assessing the impact of each mutant on protein stability. These are divided into those 
factors treated as continuous variables, and those treated as two state variables 
(significantly destabilizing or not).     
Continuous factors 
1. Electrostatic interactions: The difference in electrostatic energy between a 
wild type protein and its corresponding mutant was calculated using a simple 
Coulomb’s law treatment, with no solvent model.  The partial electrostatic interaction 
energy between a pair of polar or charged groups ‘i’ and ‘j’ is calculated in the usual 
manner as: 
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Type Factors 
Electrostatic interaction: polar-polar, polar-charge, charge-
charge. 
Over-packing 
Hydrophobic burial 
Surface accessibility 
Continuous 
factors 
Structural rigidity: Crystallographic B-factor, Z score and 
standard deviation 
Cavity 
Electrostatic repulsion 
Backbone Strain 
Buried charge 
Buried Polar 
Binary factors 
Breakage of a disulfide bond 
Table 2-3.  The 15 factors included in the stability model.  
The effect of each single residue mutant on stability is expressed in terms the value of 
one or more of these contributions to the energy and entropy. ‘Continuous factors’ are 
represented by a continuous variable, ‘binary factors’ are two states, either 
significantly or not significantly affecting stability  
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Eij = K ^k^lqkql/rlk 
where the sums are over all atoms 'k' of group ‘i’  and atoms 'l' of group ‘j’, 
the 'q's are the partial atomic charges in electrons, and rlk is the distance between 
atoms 'l' and 'k', in Å. 'K' is the scaling constant (332) nominally converting energies 
to Kcal/mol. (Absolute scale is not significant here, because of the Z score 
normalization). Interactions between a pair of groups are included if the centers of 
charge are less than a cutoff distance dc apart. The center of charge of a group rc is 
defined as: 
 rc = ^k|qk|rk/^k|q k|
Where the sum is over all atoms in the group. Electrostatic group definitions 
and partial atomic charges are as in (Pedersen and Moult 1997). The threshold for 
group-group interactions, dc, is 5Å. This protocol for electrostatic calculations has 
been to be effective at identifying incorrect structural features in experimental 
structures(Oliva and Moult 1999). 
2. Overpacking: For each mutant, the closest inter-atomic distance between 
the mutant residue and any neighboring residue was used.  
3. Relative surface accessibility: Solvent accessible surface (Lee and Richards 
1971) was calculated with in-house software. The relative surface accessibility of a 
residue is defined as the surface area of the side chain in the folded state divided by 
an estimate of the average surface area in the unfolded state (Shrake and Rupley 
1973).  
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4. Hydrophobic burial Change: The change in buried non-polar area aANP 
resulting from a single residue mutation is defined as: 
 aANP = ^iaai - ^jaaj
where the first sum ‘i’ is the change in non-polar area on folding for all non-
polar atoms in the mutant structure and the second sum ‘j’ is over all non-polar atoms 
in the wild type structure. The change in atomic non-polar area in folding is given by: 
 aa = au - af
where au is the estimate of the average atomic surface area in the unfolded 
state (Shrake and Rupley 1973) for that atom, and af is the calculated atomic area in 
the folded structure. Non-polar atoms are those assigned zero charge.  
5. Crystallographic Temperature factors: For each experimental structure used 
directly or as a model, the average temperature factor <B>, and standard deviation 
b(B) over all CV atoms was calculated, and used to obtain a temperature factor Z 
score for each CV: Zi = (Bi - <B>)/b(B). Bi, Zi, and b(B) were used as parameters in 
the SVM.  
Binary factors 
6. A Cavity is assigned to any mutation resulting in the loss of volume of an 
aliphatic carbon group or greater at a zero solvent accessibility position. For example, 
Ala mutated to Gly, where the wild type Cc atom has zero solvent accessibility.  
7. Electrostatic repulsion is assigned to any mutation which results in two like 
charged groups with an unavoidable atomic contact of less than 4.5 Å. 
8. Backbone Strain is assigned to any mutation if one of the following 
conditions is met:  
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A. Replacement of a glycine residue with d/e angles in a non-allowed region 
for other residue types. Allowed regions were those covering 90% of observed d/e
values, as provided in PROCHECK (Laskowski RA 1993), 
B. Replacement of a cis-proline (f = 0+/-60o) with another residue. 
C. Replacement of another residue by proline, where the d value is 
inappropriate (Permitted d for Pro = -60+/-15o).  
9. Buried charge is assigned to any mutation which results in a zero solvent 
accessibility, electrostatically isolated, charge group. 
10. Buried Polar is assigned to any mutation which results in a zero solvent 
accessibility polar group with no hydrogen-bond. A hydrogen bond is defined as a 
donor to acceptor distance   <= 2.5Å, and an angle at the acceptor >= 90.0º.  
11. Breakage of a disulfide bond is assigned to any mutation which replaces a 
cysteine residue in an S-S bond with a non-cysteine residue. 
Evaluation of Discrimination power of each Stability Factor 
The frequencies of each stability factor in the disease and non-disease datasets 
were calculated.  The ratio of the two frequencies defines a discrimination power. For 
this purpose, a threshold was chosen for each of the continuous factors. Any mutation 
with a value higher than the threshold was considered to destabilize protein structure. 
Thresholds were chosen by inspection of the distribution of values for the disease and 
non-disease sets, selecting levels that provide a high fraction of true positives and true 
negatives, while minimizing false negatives and false positives. The following values 
were used: 
53 
 
1. Overpacking: At least one unavoidable atomic contact of 2.5Å or less of 
the mutated residue to a neighboring one. 
2. Hydrophobic burial: Loss of hydrophobic burial of more than 50 Å2. 
3. Electrostatic interaction: Any reduction in electrostatic interaction energy, 
for polar-polar, charge-charge and charge-polar interactions. 
4. Buried residue: Relative residue accessibility of less than 20%(i.e. the wild 
type side chain accessibility is less than 20% of the estimated average unfolded state 
accessibility). 
5. Moderate crystallographic Temperature Factor:  The CV temperature factor 
of the mutated residue has a Z score of less than  +1 (i.e. the temperature factor is less 
than one standard deviation above the mean for the protein). 
Identification of Residues with a Role in Molecular Function 
Each mutated residue, and all residues with one or more atomic contacts of 6Å 
or less to it, was checked against the SWISS-PROT feature annotation table for 
possible functional effects.  Additionally, a check was made for atomic contacts of 
the mutated residue of 6Å or less to any ligand atom in PDB entries for that protein 
and other X-ray structures with at least 40% sequence identity over at least 100 amino 
acids, and at 3.0Å or better resolution. 
 
54 
 
Chapter 3: Identification and Analysis of Deleterious 
Human SNPs 
Introduction
In this chapter, we analyze non-synonymous or missense SNPs in the human 
population.  We use two methods to identify which missense SNPs are deleterious to 
protein function. Both methods have been developed and tested on amino acid 
changes causative of monogenic disease, and a control set of single residue changes 
fixed between closely related mammalian species (Sunyaev et al. 2001). One method 
analyzes the impact of amino acid changes on protein stability, making use of the 
three dimensional structural environment (Yue et al. 2005) as described in the chapter 
2. We find the majority of single base changes that cause monogenic disease 
significantly destabilize the folded state of the protein concerned. The second method, 
reported in this chapter, makes use of the tendency of critical amino acids to be 
conserved within a protein family. The more conserved and restricted the type of 
amino acid at a position, the more likely that a substitution not consistent with that 
pattern will have a deleterious impact on protein function. This method is more 
general than the stability model, including all types of protein level effect. It is also 
more widely applicable, since it does not require knowledge of three dimensional 
structure. On the other hand, it provides less direct insight into the mechanism by 
which a missense SNP affects protein function. The principles of sequence 
conservation methods have also been explored by others (Chasman and Adams 2001; 
Krishnan and Westhead 2003; Ng and Henikoff 2003; Ramensky et al. 2002; 
Sunyaev et al. 2001).  We have used a machine learning method, the support vector 
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machine, trained on five simple features that capture the relative sequence 
conservation at each position in a multiple sequence alignment. The support vector 
machine allows the identification of a subset of high confidence predictions. The use 
of two separate methods provides an additional means of assessing the reliability of 
the conclusions. 
The two methods have been used to analyze sets of non-synonymous SNPs 
found in the human population, extracted from the dbSNP database (Sherry et al. 
2001), and a subset of those for which population frequency data are available. The 
subset are data from Perlegen (Hinds et al. 2005) and the Hapmap consortium (2003). 
Using stringent criteria, we find that about ¼ of these SNPs are classified as 
deleterious at the same level as those causing monogeneic disease in other genes. 
These are very likely to have a significant impact on protein function, and so 
probably contribute to complex disease traits, and provide a basis for prioritization in 
association studies.  
We have also examined a number of aspects of the relationship between 
monogenic disease genes and the rest. First, we have compared the occurrence of 
deleterious SNPs in monogenic versus non-monogenic disease genes. We find that, 
whereas in monogenic disease genes nearly all deleterious SNPs occur at low 
frequency in the population, in other genes, a larger proportion are found at high 
frequencies, consistent with the idea that the effect of deleterious SNPs in other genes 
is buffered. Second, we have looked at the rate of sequence divergence of monogenic 
versus other genes. An interesting variation with conservation level is found. Third, 
we have found that there is a correlation between the phenotypic impact of mouse 
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knockouts and whether or not the orthologous human gene is implicated in 
monogenic disease. Finally, we have checked to see if monogenic disease genes are 
less likely to have paralogs than the others, exploring the idea that paralogs some 
times can provide substitute function. No such effect is found.  
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Results
Training and Testing Data used for the Classification Methods 
Table 3-1 summarizes the monogenic disease and control datasets used for 
training and benchmarking the sequence profile and structure stability methods. There 
were a total of 10263 deleterious mutants in 731 proteins and 16682 control 
substitutions in 348 proteins available. The profile model includes 92% and 71% of 
these respectively, since profiles can be built for most proteins. In testing, high 
confidence (‘HC’, SVM score > |0.5|) classifications were obtained for over 80% of 
these. Significantly fewer data (37% and 14% respectively) are included in the 
stability model, because of low structural coverage of human proteins. High 
confidence classifications are again obtained for about 80% of cases. The last two 
rows show the data for cases where both methods could be applied. The fraction of 
high confidence predictions is similar.  
Accuracy of the Classification Methods 
Figure 3-1 shows the false positive (blue bars) and false negative rate (red 
bars) for both methods separately, on all data and for just the high confidence 
classifications (an SVM score of greater than 0.5 for non-deleterious classifications 
and less than -0.5 for deleterious ones), as well as the corresponding data for the cases 
where the two methods agree. As expected, the false positive and false negative rates 
are highest for the individual classification methods, lower when only high 
confidence classifications are considered, and lowest of all when only high 
confidence classifications shared by both methods are included (3% false positive, 
58 
 
Deleterious Mutants Control substitutions 
# % Proteins #  %  Proteins 
All Data 10263 100% 731 16682 100% 348
Profile 9468 92% 693 11778 71% 336
Profile HC 7986 78% 673 10171 61% 336
Stability 3768 37% 243 2309 14% 153
Stability HC 3046 30% 229 1904 11% 152
Profile+Stability 3641 35% 235 2141 13% 148
Profile+Stability                   
HC 
2501 24% 216 1498 9% 146
Table 3-1.   Training and Testing Data for the Profile and Stability methods.  
‘Deleterious mutants’ are amino acid changes that cause monogenic disease (Stenson 
et al. 2003). ‘Control substitutions’ are amino differences between human proteins 
and closely related orthologs. ‘HC’ are high confidence classifications from the 
Support Vector Machine. The ‘#’ and ‘%’ columns give the number and percent of 
data in each row. ‘Proteins’ are the number of proteins from which data are included.  
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Figure 3-1.   Evaluation of the profile and Stability Methods. 
False positive and false negative rates are shown for the two methods alone, and for 
cases where both can be applied and the classifications agree. Results are shown for 
all classifications, and for the high confidence subsets (‘HC’, SVN score > |0.5|). 
Higher false negative rates for the stability model reflect the fact that only stability 
and folding effects are included, where as the profile model includes all effects on 
protein function in vivo.
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9% false negative). The false negative rate of the profile method is slightly lower than 
that of the stability method (20% versus 26% for all classifications, 15% versus 21% 
for high confidence ones). This difference is expected, since the profile method 
includes all effects on protein function at the amino acid level, including ligand 
binding, catalysis, allosteric mechanisms, and post-translational modifications, as 
well stability and folding effects, whereas the stability model includes only stability 
and folding contributions. Less expected is the lower false positive rate for the profile 
method (10% versus 15%, 6% versus 11% for high confidence classifications). The 
balance between false positive and false negative rates is determined by the relative 
weights given to the deleterious and control datasets in training the SVM. Equal 
weights, taking into account the differences in data set sizes, were used. Different 
weighting would adjust the false positive rates to be more similar. 
For both methods, the finite error rates reflect both the effects of 
approximations in the methods and the nature of the data sets.  The stability method 
incorporates a number of approximations in modeling the structure of mutants, and 
uses a scenario based analysis of effects on stability (Yue et al. 2005). As discussed 
later, for the profile method, the effect of a limited number of sequences in a profile is 
the main approximation.  The HGMD data (Stenson et al. 2003) used as a disease set 
contains some entries that are not strictly causative of monogenic disease. For 
example, the mutant G15D in the alpha chain of Hemoglobin (HBA1) is in HGMD, 
but is predicted to be non-disease causing, with a confident SVM score of 2.9.  The 
literature on this mutation (Molchanova et al. 1994) gives no indication of disease.  
Since 1999, HGMD have added some mutants that disease ‘associated’ or ‘risk’ 
61 
 
polymorphisms. This work uses the HGMD version of 04/26/2002, which includes 
152 mutants identified as not necessarily causative of disease. The false negative rate 
for these is very high: 62% for the profile method and 73% for the stability method. 
The assumption of no deleterious effects fixed between species might contribute to a 
finite false positive rate. There are 41 HGMD mutants where the altered amino acid is 
the wild type in another species. Of these 37 are classified by the profile model, but 
only four are found to be deleterious. Thus, these appear to be largely inappropriate 
entries in HGMD, rather than deleterious mutants fixed in other species. In spite of 
the limitations in the models and data, the errors are sufficiently small that firm 
conclusions about the level of deleterious SNPs in the human population can be 
reached, provided the false positive and false negative rates are taken into account.   
Sensitivity to the Number of Sequences in a Profile 
To classify deleterious nsSNPs, the profile method makes use of five features 
related to the relative sequence conservation, including the probability of accepting an 
amino acid substitution (based on PSSM, position specific scoring matrix) and four 
entropy factors.  The reliability of the PSSM and entropy values depends on the size 
of the sequence alignment. We examined the accuracy of the method as a function of 
the number of sequences available, after filtering out redundant and less reliably 
aligned sequences, as described in Methods. Profiles were divided into sets with 
different numbers of sequences, and the accuracy evaluated for each set. Table 3-2 
shows the results. All sets have similar accuracy, except the set with the smallest 
number of sequences (2 – 9). This group has a similar false negative rate but a higher 
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Deleterious Control No. of 
sequences FN Proteins # FP Proteins #
[2-9] 0.18 60 500 0.31 16 787
[10-19] 0.17 82 1073 0.14 24 1296
[20-39] 0.18 167 1957 0.11 85 2785
[40-59] 0.22 121 1871 0.13 66 2263
[60-79] 0.19 94 804 0.10 48 1578
>=80 0.18 169 3263 0.10 97 3069
Table 3-2.   Accuracy of the Profile method as a function of the number of sequences 
in the alignment.  
Accuracy is measured in terms of the false negative rate (FN) and the false Positive 
rate (FP). The ‘#’ columns show the number of variants analyzed in each alignment 
size range, and ‘proteins’ are the number of human proteins included. Accuracy is 
approximately equal in all but the smallest alignment range, where there is a sharp 
rise in the false positive rate. 
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false positive rate (31%) than the other groups.  The high false positive rate is 
probably a consequence of the low maximum entropy for a small number of 
sequences: the maximum for two sequences is approximately 1 bit, while for 20 
sequences, it is 4.3 bits. Additionally, for small profiles, the PSSM is dominated by 
the BLOSUM scores rather than the pattern of residue use.  
Comparison between BLOSUM, PSSM, and Profile Models  
The full profile method includes the PSSM for the aligned sequences, and 
entropy factors. We compared the performance of a PSSM (Altschul et al. 1997) 
alone, which takes into account which residues are observed at each position in a 
sequence alignment, with performance using an average substitution matrix 
(BLOSUM (Henikoff and Henikoff 1993)), which considers only the likelihood of the 
substitution in all proteins at all positions. It has been suggested that the BLOSUM 
matrix is suitable for use in  identifying damaging nsSNPs (Cargill et al. 1999; Ferrer-
Costa et al. 2002).  Since a PSSM contains information unique to each sequence 
family and sequence position, we would expect it to produce more accurate 
classifications. 
BLOSUM 45 and BLOSUM 62, representing average substitution preferences 
between proteins with different levels of sequence identity, were tested. PSSM and 
BLOSUM method accuracy as a function of a score threshold were examined, and the 
threshold returning the lowest sum of false positives and false negatives chosen in 
each case. The results are shown in table 3-3, with the full profile method included 
for comparison. The BLOSUM matrices both yield similar false positive and negative 
rates, of about 27% and 36% respectively, whereas the PSSM has significantly lower 
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False Positive Rate False Negative 
Rate 
BSOSUM 45 27% 38%
BLOSUM 62 28% 36%
PSSM 22% 28%
Profile model 10% 20%
Table 3-3.   Comparison of Classification accuracy of BlOSUM matrices, a PSSM 
and the full Profile method. 
The PSSM method has substantially lower false positive and false negative rates than 
obtained with either BLOSUM matrix. The additional entropy information in the full 
profile model further improves accuracy.  
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values of 22% 28%. The profile model is substantially more accurate than the PSSM 
alone, with false positive and false negative rates of 10% and 20% respectively, 
establishing the entropy terms do provide significant additional information.  
Comparison of Expected and Observed Accuracy for the Combined 
Classification Methods 
Reliable false positive and false negative rates are essential for accurately 
estimating the fraction of deleterious SNPs in the population. In principle, the values 
obtained from the benchmarks are accurate. A further test is provided by examining 
the consistency of the individual method errors with those of the combined methods. 
Since the two methods are based on different principles and their primary causes of 
error are unrelated, the errors are approximately independent. Under these conditions, 
the expected specificity and sensitivity for the cases where the methods agree can be 
calculated (see Methods). Comparison of these values with the actual ones then 
provides the consistency test.   
Table 3-4 shows the observed and expected values for the combined methods. 
Results for two combined sets are shown. The first includes the subset of data to 
which both methods can be applied. Specificity is substantially higher for the 
combined methods, and sensitivity lower, as expected. The second set includes data 
to which both methods can be applied, and where high confidence classifications are 
returned in all case. For both data sets, the expected and observed values are 
reasonably close, supporting the reliability of the false positive and false negative 
rates returned by single method benchmarking. Observed sensitivities are a little 
higher than expected, suggesting the false negative rate may be slightly 
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Single Model Both Models  
Profile Stability Observed Expected 
SN 80% 74% 63% 59%All Results 
 SP 90% 85% 96% 98%
SN 85% 79% 73% 67%High  
Confidence  SP 94% 89% 97% 99%
Table 3-4.   Sensitivity (SN) and Specificity (SP) for the combined methods, 
compared with that Expected from the accuracy of the individual ones.  
The first pair of columns shows the sensitivity and specificity for each method alone. 
The third column shows the results for the cases where both models can be applied, 
and the fourth column shows the expected sensitivity and specificity of the combined 
models, given the results for the individual methods. The first two rows show the 
results for all classifications. The high confidence set includes only cases where a 
high confidence result is obtained. Agreement between observed and expected 
provides a test of the accuracy values (see Methods). 
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overestimated. Specificities are about 2% lower than an expected, but the values are 
so high (worst case 96%) that any small amount of noise may account for this. 
Analysis of Population SNPs: Approximately a Quarter of Non-Synonymous 
Population SNPs are Deleterious. 
We now use the profile and stability methods to identify deleterious non-
synonymous SNPs (nsSNPs) in the human population. As described in Methods, 
nsSNP data were obtained from three sources: the NCBI dbSNP database (Sherry et 
al. 2001), the Perlegen data (Hinds et al. 2005), and the Hapmap project results 
(2003). dbSNP contains a wide range of data, some of which is based on a single 
observation. Both Perlegen and the Hapmap project have genotyped sets of 
individuals from several different populations. Since these SNPs are all verified, and 
have associated population frequency information, we have analyzed them as a 
separate data set, referred to as the Frequency set. Table 3-5 shows the number of 
data available in the full dbSNP set and the Frequency set, and the number of data 
that can be classified by the stability and profile methods, the combined methods, and 
the number of high confidence classifications in each case.  
Figure 3-2 shows the fraction of population SNPs assigned as deleterious in 
dbSNP (blue bars) and the Perlegen/Hapmap data (purple bars).  Results are again 
shown for the two methods separately, and for the combined methods, for all 
classifications, and those of high confidence. Deleterious classifications in both SNP 
sets are lowest for the most stringent conditions (high confidence classifications for 
the combined methods), with 33% for all dbSNP data and 17% for the Frequency 
subset, The highest deleterious rates are for the stability model alone, with 40% for 
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All Frequency Set 
#
SNPs 
%
SNPs 
#
Genes
#
SNPs 
%
SNPs 
#
Genes
dbSNP Build 
124 
50772 100% 15710 10403 100% 6316
Profile 29081 57% 11129 6377 61% 4297
Profile HC 22067 43% 9782 4911 47% 3549
Stability 5166 10% 2019 885 9% 624
Stability HC 3960 8% 1776 681 7% 509
Profie+stability 3150 6% 1512 531 5% 415
Profile+stability 
HC 
2096 4% 1180 370 4% 304
Table 3-5.   Data used for identifying deleterious Human SNPs. 
The top line shows the number of missense SNPs available in the dbSNP database, 
and the subset of these with population frequency information, from Perlegen and the 
Hapman project. Classifications were made on the full set and the frequency set. The 
number of SNPs classified in each case, and the number of genes are given for the 
profile method, the stability method and the combined methods. In each case, values 
are given the full data and for the subset that are classified with high confidence 
(SVM score > |0.5|).  
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Figure 3-2.   Estimated fraction of Deleterious SNPs in the Human Population.  
Results are shown for all missense SNPs in dbSNP build 124 (blue bars), and a subset 
for which there are population frequency data (purple bars). Deleterious rates are 
calculated using the profile and stability methods, the two methods combined, and 
also, in each case, for high confidence (‘HC’, SVM score > |0.5|) classifications only. 
Consistently lower rates are found for the frequency subset than for all dbSNP data, 
partly reflecting the effect of incorrect entries in the latter. Variations in the rate for 
the different classification methods reflect the differing false positive and false 
negative levels. Lower rates for the high confidence predictions reflect the fact these 
are generally obtained only for more severe effects on protein structure and function. 
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the dbSNP data, and 31% for the Frequency subset. Deleterious SNP rates are 
consistently substantially lower for the Frequency subset than the full dbSNP set, 
presumably reflecting the effect of the unreliable single observation component in 
dbSNP. As a control, we also analyzed the 952 Hapmap SNPs which were found to 
have zero frequency, that is, are in dbSNP, but were not observed in the Hapmap 
population. The profile method classifies 50% of those SNPs as deleterious, a much 
higher value, and close to that obtained in tests introducing random mutations. 
The deleterious population SNP rates in figure 3-2 are distorted somewhat by 
the finite false positive and false negative rates of the classification methods. 
Distortions can occur in both directions: A high false positive rate contributes to over-
estimating the deleterious SNP level, but a high false negative rate contributes to an 
underestimate. We correct for these effects as follows: For a given true deleterious 
rate Dtrue, with a false positive rate fp and false negative rate fn, the expected apparent 
deleterious rate Dexp is given by: 
 
Dexp =  Dtrue - Dtrue * fn + [1- Dtrue ]* fp
Where the second term (Dtrue * fn ) is the underestimate effect of false 
negatives, the third ([1- Dtrue ]* fp ) is the over-estimate effect of false positives. The 
most probable value of Dtrue can then be obtained by examining the difference 
between the expected (Dexp) and observed (Dobs) deleterious rates, as a function of 
Dtrue.
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Figure 3-3 shows the residual |Dobs – Dexp| as a function of possible Dtrue 
values, for each of the method conditions, using the frequency subset. There are well 
defined minima in the residual curves, at values of Dtrue between 15 and 25%. Lower 
values are obtained with the high confidence subsets (~20%), and the lowest value 
(15%) is obtained with the high confidence assignments common to both methods. It 
is expected that high confidence scores are only obtained for the more severe effects 
on protein function and stability. Application of the stability method to site directed 
mutagenesis data where experimental folding free energies are available confirms that 
on average high confidence assignments have a more severe effect in protein stability 
(data not shown), Thus, the lower level (15 – 20%) of deleterious SNPs found for the 
high confidence score subsets are an estimate of the fraction of more severely 
deleterious SNPs in the population. The best estimate of the fraction of population 
missense SNPs that are as detrimental to protein function as those found for 
monogenic disease is provided by the full set of classifications for the profile and 
stability methods, separately and combined. In all three cases, that value is close to 
25%. Thus, the analysis leads to the conclusion that approximately one quarter of 
non-synonymous SNPs found in the population are as deleterious to protein function 
as single base changes known to cause monogenic disease. This value is little lower 
than reports by other groups (Chasman and Adams 2001; Ramensky et al. 2002), 
probably because of the effect of correcting for finite errors rates in the methods.  
Deleterious SNPs in Monogenic Disease Genes 
There are 4,458 nsSNPs in dbSNP located in monogenic disease genes, 
among which 1,656 are assigned as deleterious by the profile method. Only a small 
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Figure 3-3.   Difference between the expected and observed fraction of deleterious 
population SNPs as a function of the underlying true rate.  
Residuals are calculated as a function of possible true values (X axis), using the false 
positive and false negatives rates for each method. Minima give the estimated true 
deleterious rates. The Stability, Profile and combined methods all yield rates close to 
25%. The High confidence classifications yield lower values, reflecting the fact that 
generally only severe effects on protein structure and function have high confidence 
classifications. Data are for the frequency subset of dbNSP.  
 
73 
 
portion (152) is also present in HGMD as known monogenic disease mutants.  The 
reminder might be new monogenic disease causing variants, known variants not yet 
entered into HGMD, or false positives. Given a false positive rate of 10%, we only 
expect 446 in that category. If the additional SNPs really are disease causing, we 
would expect them to be predominantly at low frequencies in the population. Figure 
3-4 shows a comparison of the population frequency distribution of the 970 of these 
in the frequency subset with the corresponding distribution for all other genes. As 
expected, there are many more low frequency SNPs in both sets. Both sets also show 
a higher fraction of deleterious SNPs at low frequency, compared to non-deleterious, 
consistent with their being selected against. That bias is stronger for the monogenic 
disease gene set, and only about 10% are at frequencies higher than 20%, the 
expected fraction of false positives.   
To investigate the possibility that some of the additional deleterious missense 
SNPs in monogenic disease genes are in fact disease causing, we examined the subset 
of 18, in 15 different genes, which are assigned as deleterious with high confidence 
by both classification methods. Table 3-6 summarizes the data for these SNPs. Five 
are already in HGMD, but given the very low false positive rate for this subset (3%, 
as shown in figure 3-1), the others are candidate mutants for monogenic disease. Two 
of these have surprisingly high population frequencies for monogenic disease 
mutants: SEROINA7 L303F, at 20%; and AMACR G175D with a frequency 34%. 
SERPINA7 belongs to a family of serine protease inhibitors, but also functions as a 
thyroid binding–globulin (TBG). There are many mutations associated with TBG 
deficiency, and many of these also have a high population frequency 
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Figure 3-4.   Distribution of SNP Frequencies in the Human Population. 
Solid red bars show the fraction of all deleterious missense SNPs in each frequency 
range, for all non-monogenic disease genes. The hashed red bars show the same data 
for monogenic disease genes, Green bars show the corresponding data for Non-
deleterious SNPs. As expected, low frequency SNPs are the most common, for all 
categories. Deleterious SNPs are biased towards low frequencies in both sets, but the 
effect is considerably stronger for monogenic disease genes. 
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Gene SNP ID SVM 
Stability 
SVM 
Profile 
Substit-
ution 
Freq Source Population HGMD 
CFTR 766874 -0.88 -1.75 S605F 0.002 Hapmap afr,eur,chn,jap  
FCER1A 2298805 -0.73 -2.67 S101N 0.007 Perlegen afr,eur,chn  
NTRK1 6336 -1.06 -1.17 H604Y 0.011 Hapmap afr,eur,chn,jap CM990977 
DNASE1 1799891 -0.54 -0.77 P154A 0.011 Hapmap afr,chn,jap  
CFTR 1800100 -1.06 -2.12 R668C 0.014 Perlegen afr,eur,chn CM950247 
LYZ 1800973 -0.92 -0.72 T88N 0.015 Hapmap afr,eur,chn,jap  
CHAT 8178990 -0.82 -1.26 L125F 0.021 Hapmap afr,eur,chn,jap  
EPX 2302311 -1.32 -0.81 N572Y 0.027 Hapmap afr,eur,chn,jap  
HFE 1800562 -1.00 -1.77 C194Y 0.028 Perlegen afr,eur,chn CM960828   
TAP1 1057149 -0.80 -1.94 R708Q 0.029 Perlegen afr,eur,chn  
CYP2A6 17791931 -0.81 -1.99 L160H 0.035 Perlegen afr,eur,chn CM980517 
KLK3 17632542 -0.58 -1.67 I179T 0.036 Perlegen afr,eur,chn  
PTGS2 5272 -1.40 -1.42 E488G 0.056 Hapmap afr,eur,chn,jap  
HFE 1799945 -0.70 -0.66 H63D 0.085 Hapmap afr,eur,chn,jap CM960827 
CYP2A6 5031017 -1.57 -1.61 G479V 0.125 Hapmap afr  
OTOR 6135876 -0.91 -0.96 L31P 0.141 Perlegen afr,eur,chn  
SERPINA7 1804495 -1.28 -1.38 L303F 0.203 Perlegen afr,eur,chn  
AMACR 10941112 -1.51 -2.35 G175D 0.341 Hapmap afr,eur,chn,jap  
Table 3-6.   Very high confidence classifications of deleterious population SNPs in 
monogenic disease genes.  
‘SVM Stability’ and ‘SVM Profile’ are the scores assigned by the two classification 
methods. A score < -0.5 is high confidence.  The ‘Freq.’ column gives the mean 
frequency of each SNP over the populations. The ‘Population’ column lists the 
populations in which each SNP has been genotyped: afr: African, eur: European, chn: 
Chinese, jap: Japanese populations. Only five of these SNPs are in the HGMD 
database of disease causing mutations (IDs in the last column).  
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(Mori et al. 1990) (Waltz et al. 1990). These mutants alone are not sufficient to cause 
disease, since the resulting tendency for hyperthyroid is usually reversed by reduced 
thyroid hormone secretion. The high frequency is thus likely a consequence of a 
second factor being required for disease. There is no obvious explanation for the high 
frequency of the AMACR SNP. 
Divergence Rates of Monogenic Disease-Associated Proteins  
Figure 3-5 shows a comparison of divergence rates of monogenic disease 
proteins versus all others. A larger proportion of the most highly conserved proteins 
are non-disease, whereas at moderate to high conservation, a higher proportion is 
disease. At the lower conservation levels, non-disease proteins are slightly more 
common. This pattern can be rationalized as follows. Damage to the most conserved 
proteins is more likely to be lethal, and thus, not identified as disease causing. The 
lowest conserved proteins are likely buffered against deleterious changes in some 
way, and so are also not involved in monogenic disease. It is the more moderately to 
highly conserved genes where deleterious SNPs are likely to lead to disease, but not 
to be lethal. Other reports (Huang et al. 2004; Smith and Eyre-Walker 2003), using 
only average values, and separately analyzed Ks and Ka rates, come to contradictory 
conclusions. With more genomes becoming available, further study will be 
worthwhile.  
Comparison with Mouse Knockout Data 
The profile and stability models detect SNPs that reduce the level of protein 
function in vivo. The limit of reduced function is the absence of the gene. Thus, we 
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Figure 3-5:  Protein Sequence Divergence Rates for Human Monogenic Disease 
Proteins (Blue bars) and all others (Purple bars).    
Rates are expressed in terms of the sequence identity between each human protein 
and its mouse ortholog. Disease proteins have a larger proportion of high sequence 
identity mouse orthologs, showing that, on average, their sequences diverge more 
slowly than those of other proteins.   
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would expect a relationship between the response of the human phenotype to 
deleterious SNPs, and the response of mice to knockout of the corresponding 
orthologs. Mouse knockout data were obtained from 
http://www.bioscience.org/knockout/knochome.htm.  In this database, genes are 
clustered into four knockout phenotype groups. The first group is of genes where the 
knockout is compatible with viability. This group is further subdivided into cases 
where there is a detectable effect on the phenotype, and cases where the phenotype is 
apparently unaffected. The other three groups are of genes where knockout causes 
post-, peri- and prenatal mortality.   
Table 3-7 shows the fraction of monogenic disease genes found in each of the 
mouse knockout groups.  The lowest fraction of monogenic genes is for the ‘no 
effect’ group of knockouts (8%), consistent with fully buffered genes generally not 
contributed to monogenic disease. The next lowest fraction is for the prenatal 
mortality set (28%), consistent with defects in these human genes probably resulting 
in a non-viable fetus, and so not be classified as disease associated. Approximately 
half of the other knockout groups have equivalent monogenic disease genes, 
consistent with non-lethal but significant impact on the phenotype often being 
classified as monogenic disease. Overall though, the correlations are not as high as 
might be expected. There are several possible reasons for that. As more mouse 
knockout data becomes available, a fuller analysis will be possible.   
Frequency of Paralogs for Monogenic Disease and other Genes 
A possible distinguishing feature between monogenic disease genes and the 
rest is that the phenotype is robust to reduced function on the latter because of 
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Phenotype Total 
genes 
Disease 
genes 
Fraction  
DIsease 
NO APPARENT 
EFFECT 
 13      1    8% COMPATIBLE 
WITH 
VIABILITY With EFFECT  147     71   48% 
POSTNATAL OR PERINATAL 
MORTALITY 
 51     22   43% 
PRENATAL MORTALITY     29      8   28% 
Table 3-7.   Relationship between Mouse Knockout Phenotypes and Human 
Monogenic Disease Genes. 
 
‘Total genes’ are the number of mouse knockouts in each phenotype category, and 
‘Disease genes’ are the number for which the human ortholog is a monogenic disease 
gene. 
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redundancy of function – other genes can at least partly compensate for reduced 
activity. Full identification of possible substitute genes requires a detailed knowledge 
of human protein networks, not yet available. However, it might be expected that 
paralogs would often perform this role, and a number of such cases are known.  For 
example, E-selectin and P-selectin are paralogous, with 40% protein sequence 
identity.  Single gene knock-out mice show mild phenotypes, while the double knock-
out mice have a severe disease phenotype, consistent with overlapping function 
(Frenette et al. 1996). On the other hand, there are many cases where paralogous 
genes are involved in different biological processes, for example malate and lactate 
dehydrogenases.  
Paralogs were identified by searching each human protein sequence against all 
others, selecting relatives with a BLAST E-score of 10-3 or better.  Table 3-8 shows 
the fraction of monogenic and other genes with at least one paralog. There is no 
difference between the two types of gene – in both cases about 87% have paralogs. 
We conclude from this that buffering mechanisms are more varied than just the use of 
paralogs.  
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Monogenic Disease Genes Other Genes 
Count % Count %
No paralogs 227 13% 705 13%
Paralogs 1460 87% 4887 87%
Table 3-8.   Fraction of Monogenic and other genes that have paralogs. 
Monogenic disease data are from HGMD (Stenson et al. 2003). ‘Other Genes’ are 
other human genes containing at least one SNP classified as deleterious. There is no 
difference in the fraction with paralogs for the two sets, suggesting other mechanisms 
dominant in shielding the phenotype from the adverse effects of deleterious SNPs in 
the non-monogenic disease genes. 
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Discussion & Conclusion
The main conclusion of this study is that about one quarter of the known 
missense SNPs in the human population are significantly deleterious to protein 
function in vivo. Others have reported a figure of about 1/3 (Chasman and Adams 
2001; Ramensky et al. 2002). It has also been suggested that the fraction is much 
lower (Ng and Henikoff 2003), with false positives, errors in dbSNP, and known 
monogenic disease mutations inflating the apparent value. We have carefully 
controlled for false positives and false negatives in two ways. First, using two 
independent SNP classification methods has allowed us to check that the expected 
error levels are obtained for the combined methods, so validating the individual 
values. Second, we have calculated the apparent deleterious rate taking into account 
the error levels, and obtained a best fit for the underlying true deleterious rate. We 
have also examined the difference in apparent deleterious rate for all of dbSNP and a 
validated subset. There is indeed a higher value of about 1/3 for all dbSNP, but the 
value of a quarter is obtained on reliable data. Some of the deleterious SNPs are in 
known monogenic disease genes, but about 80% of the dbSNP ones, and 70% of the 
validated set, are not.  
Some of the new deleterious SNPs in monogenic disease genes are candidates 
for previously unrecognized disease causes. The deleterious SNPs in non-monogenic 
disease genes are candidates for contributing to complex disease traits. Presumably, 
the network environment of the proteins concerned buffers the effect on the 
phenotype. This view is supported by the analysis of the relationship between 
monogenic disease genes and mouse knockout phenotypes – knockouts with 
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intermediate impact on the phenotype are more likely to be orthologs of human 
monogenic disease genes. A simple form of buffering is overlapping function with 
paralogous proteins. For example, a T cell mediated immune response will involve 
many different T-cell receptors. We have found deleterious SNPs in some of these 
proteins (Wang and Moult 2003), but redundancy through paralogs will provide 
buffering. Surprisingly, we did not find that monogenic disease genes are less likely 
to have paralogs than others, so this mechanism is probably only one of a number. A 
proper understanding these buffering processes will require a detailed knowledge of 
the relationship protein function and network behavior.  
Many of the deleterious SNPs in non-monogenic disease genes are relatively 
rare. In one sense, this is expected, since overall, there are many more rare SNPs than 
common ones. The low frequency of deleterious SNPs may contribute to relatively 
rare complex traits, or they may contribute in many combinations to produce common 
traits (Smith and Lusis 2002) (Pritchard and Cox 2002).  
For complex diseases, variation in a single gene only marginally increases 
risk, and as a consequence, most association studies present weak and sometimes 
inconsistent results (Prince et al. 2001).  The deleterious SNPs found in this and other 
analyses provide additional information that can be used to select SNPs for inclusion 
in association studies, or, in larger scale studies, to provide prior probabilities that can 
be incorporated into the statistical model. 
The analysis of human SNPs was done using a structure based method (Yue et 
al. 2005), and a sequence profile based method. The sequence method has a larger 
coverage of missense SNPs because it does not require knowledge of three 
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dimensional structure.  Also, since sequence methods are based on evolutionary 
selection information extracted from multiple sequence alignments, they are not 
limited by current knowledge of protein function and structure, and so include a wider 
range of effects.   On the other hand, the sequence method assumes that deleterious 
SNPs will eventually be removed during evolution.  While this assumption may be 
true for those genes associated with monogenic disease or serving as major 
contributors to complex diseases, it may not be as true for those with only subtle 
effects on the  phenotype. For this reason, it is desirable to develop broadly based 
mechanistic models of SNP impact. 
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Methods
Construction of the Deleterious Variant Dataset and Non-deleterious Variant 
Dataset 
The same two datasets were also used for the stability model as described in 
Chapter 2.  Please refer to page 44 for the procedures of data construction. 
Source of Human Population Missense SNPS 
SNPs were obtained from NCBI dbSNP, build 124. Many of the dbSNP 
entries are not verified (are based on single observations, or population frequency 
data have not been deposited). A confirmed SNP set was built from data in Perlegen 
(as of May 2005) and the Haplotype genotyping projects (Phase I, as of May 2005).  
Files containing SNP and frequency information were downloaded from Perlegen and 
Hapmap project websites (http://genome.perlegen.com and http://www.hapmap.org/).  
These two datasets was processed as follows: 1) Both datasets were mapped to 
dbSNP RefSNP clusters. Hapmap provides a link from each record to a RefSNP ID; 
the Perlegen submission SNP ID and the mapping table, SNPSubSNPLink, between 
submission SNP IDs and RefSNP IDs in dbSNP build 124 were used to link each 
Perlegen record to the related RefSNP cluster; 2) For each RefSNP entry, mean 
frequencies were calculated from the three Perlegen populations, and from the 
available Hapmap populations; 3) In cases where data are available for both sources, 
the Hapmap information was discarded. dbSNP links were used to map each SNP to 
the corresponding amino acid substitution. 
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Construction of Sequence Profiles 
Each human protein sequence was searched against the NR (Non-redundant 
Protein Database) using PSIBLAST (Altschul et al. 1997) with an E-score cutoff of 
10-3 and three search rounds.  The PSIBLAST sequence alignment (profile) and the 
position specific scoring matrix (PSSM) were retained for further use. Profiles were 
filtered as follows: 
1.  Closely-related proteins were removed: If a pair of proteins has more than 
90% sequence identity in PSIBLAST, one was eliminated from the profile. 
2.  Less reliably aligned proteins were removed: Any protein with less than 
30% sequence identity to the query human sequence was removed.    
3. Regions of the alignment where more than 50% of the sequences have a 
gap were removed. 
 
Features for the Support Vector Machine 
The following five features were used for the SVM: 
1. The probability of substituting the variant residue type ‘a’ at position ‘j’ in 
the sequence alignment, P(a,j), taken from the corresponding matrix element in the 
PSSM.   
2. The Entropy at each position ‘j’ in the alignment is calculated using the 
Shannon entropy formula (Shannon, C.E. A Mathematical Theory of Communication. 
The Bell Systems Technical Journal, 27 (1948), 379-423):  
 Sj = k^Pilog2Pi
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Where the sum is over the twenty possible amino acids, and Pi is the 
probability of particular residue type ‘i’ at this position. Probabilities are calculated 
from the filtered alignment profile. 
3. The mean entropy <S> over the sequence is calculated by averaging over 
all sequence positions. 
4. The standard deviation of the entropy over all positions is calculated as: 
 b(S) = [(^i(Sik<S>)2)/(N-1)]1/2 
Where the sum is over all sequence positions, and Si is the entropy at a 
particular position, and N is number of sequence positions.   
5. The entropy at each position j is expressed as a Z score: 
 Zj = (Sj - <S>)/ b(S) 
Support Vector Machine (SVM) 
The five parameters described above: probability of accepting that amino acid 
substitution, entropy, mean entropy, standard deviation of the entropy and the entropy 
Z score, were used as features to train a SVM. The deleterious variant set consisted of 
these values for all the monogenic disease causing residue positions, and the control 
set were the values for the inter-species amino acid differences. SVMlight 
(http://svmlight.joachims.org/), an implementation of SVM in C, was used, with a 
linear kernel. Weights were assigned to the disease and control data sets to 
compensate for their different sizes, such that they contributed equally to determining 
the partitioning surface.  40% of each of the two sets was randomly selected to train 
the SVM.  The remaining 60% were used to evaluate accuracy.  The training and 
testing procedure was repeated 30 times. For each trial, the false negative rate (the 
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fraction of deleterious variations mis-classified as non-deleterious) and false positive 
rate (the fraction of non-deleterious variations mis-classified as deleterious) in the test 
dataset were calculated.  The average false positive and false negative rates provide 
the measure of the classification accuracy. The distance of a data point from the 
partitioning surface provides an approximate measure of confidence in a 
classification. 
Calculation of the Expected Sensitivity and Specificity of the Combined 
Stability and Profile Methods 
Assuming the two methods are independent: For sensitivity, if P1(T) 
represents the probability of identifying a true positive for model 1 and P2(T) 
represents the corresponding value for model 2, the probability that both models 
identify the same true positive is P12(T) = P1(T).P2(T). For specificity, if the 
probability of model 1 producing a false positive is P1(F)  and for model 2 is P2(F), 
the probability that both models identify the same false positive is P12(F) = P1(F). 
P2(F). The expected specificity is then 1 - P12(F). 
Estimate of Protein Divergence Rate from Human and Mouse Orthologous 
Genes 
Mouse orthologs were taken from the NCBI HomoloGene database (Wheeler 
et al. 2005). For each orthologous pair, the BLAST sequence identity was calculated 
between the all refseq mouse protein sequences and those of all the corresponding 
human refseq entries, and the highest value was used. (This procedure is necessary, 
since each gene may have multiple protein isoforms).  
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Matching of Mouse Knockouts with Human Genes 
The OMIM ID of each available mouse knockout gene was extracted and 
matched to the NCBI locuslink database, to identify the corresponding human gene 
name.  Human curation was used to match remaining mouse genes and verify each 
link. The matched human genes were compared to those in the HGMD database, to 
find the subset involved in monogenic disease. 
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Chapter 4: SNPs3D: Candidate Gene and SNP selection for 
Association Studies 
Introduction
Much of our present knowledge of the relationship between genotype and 
disease comes from statistical studies of the correlation between particular genetic 
variants and the likelihood of a specific disease. Linkage analysis, which tracks the 
transmission pattern of genetic markers within a pedigree family, has been successful 
in identifying over one thousand human monogenic disease genes (Stenson et al. 
2003).  On the other hand, there has so far been less success with common human 
diseases, such as hypertension, Alzheimer’s, asthma and cancer. Susceptibility to 
these is affected by multiple genes, as well as environmental factors. The risk from 
any single genetic variant is low, so that linkage analysis sample sizes are usually too 
small to provide statistically significant disease/genotype relationships. Association 
studies, based on analysis of genetic differences, particularly SNPs, between those 
with and without a disease in a broader population, are more powerful for detecting 
such low signals. Approximately 10 million human SNPs have so far been identified 
(Sherry et al. 2001). Currently, association studies depend on choosing a subset of 
these which includes those influencing the probability of disease, or that are in 
linkage disequilibrium with those that do so. A primary purpose of the SNPs3D 
resource is to provide a means of selecting candidate genes likely to influence disease 
susceptibility, and to further select the most relevant non-synonymous SNPs within 
those genes. 
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Rapid accumulation of new data on human SNPs, knowledge of the complete 
human genome sequence, and increasing information on biomarcomolecular 
interactions is opening the way to a more mechanism based understanding of the 
relationship between genotype and disease. At present, the relevant information is 
still very incomplete, and is scattered across many databases and thousands of 
articles. A second primary purpose of the resource is to collect and integrate as much 
as possible of the molecular level data relevant to the mechanisms that link genetic 
variation and disease.  
To achieve these goals, the resource is organized into three modules. One 
module generates lists of candidate genes for any specified disease, based on an 
analysis of the relationship between the disease and genes, as reflected in the 
literature. The second module provides a interactive graphical gene-gene network, 
built from literature associations, known protein-protein interactions (Bader et al. 
2003)(http://bind.ca/), and existing pathways (Kanehisa et al. 2004) 
(http://www.genome.jp/kegg/). The third module provides information on the 
relationship between non-synonymous SNPs and protein function. 
The identification of candidate genes and construction of gene networks both 
make use of simple text mining techniques. Concept profiles are constructed for each 
disease and for each gene.  Each concept (a disease or a gene) is represented by an 
ordered list of words and terms most closely associated with the concept. The set of 
words and terms is complied from the contents of the approximately 80,000 PubMed 
abstracts (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed) that have 
been manually associated with one or more human genes in the NCBI Gene database 
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(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene), using natural language 
processing (http://www.lsi.upc.es/~nlp/SVMTool).  Pairs of concepts, such as two 
genes or a disease and a gene, are linked by the overlap of their keyterm profiles. We 
call the resulting gene-gene network a KnowledgeNet, since it is derived directly 
from knowledge in the literature. Only two types of concept, gene and disease, are 
discussed in this chapter. However, the KnowledgeNet can also be used in others 
ways, for example investigating the relationship between a biological process (e.g. 
glycolysis) and genes.   
In SNPs3D, the likely functional impact of non-synonymous SNPs is assessed 
using two previously developed methods (Wang and Moult 2001; Yue et al. 2005; 
Yue 2005). One method makes use of protein structure to identify which amino acid 
substitutions significantly destabilize the folded state. The results show that up to 
three-quarters of monogenic disease single residue mutants act in that way (Yue et al. 
2005). The second method identifies deleterious substitutions through analysis of the 
extent and nature of amino acid conservation at the affected sequence position (Yue 
2005). Access to details of both analyzes is provided through the web interface. Links 
to another publicly available non-synonymous SNP analysis tool are also provided 
(Dantzer et al. 2005) (http://mutdb.org/).   
SNPs3D aims at integrating all of the available data relevant for assessing the 
likely role of particular genes and SNPs in a disease. The emphasis is on providing 
the users access to as much of the underlying information as possible, so that they 
may make informed judgments. To this end, in addition to SNP impact analysis, links 
are provided to relevant abstracts, the GAD (The Genetic Association Database) 
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(Becker et al. 2004) (http://geneticassociationdb.nih.gov/), OMIM (Hamosh et al. 
2005) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM) and HGMD 
(Stenson et al. 2003) (http://www.hgmd.org/) disease databases, GO annotation 
(Harris et al. 2004) (http://www.geneontology.org/), expression profile data (Su et al. 
2002), and mouse knockout results 
(http://www.bioscience.org/knockout/knochome.htm). Data are updated regularly. 
Exploration of gene networks and access is to all information is facilitated by a Java 
based graphical interface.   
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Results
Analysis of SNPs in each Human Gene 
A primary function of the SNPs3D resource is to provide a way of identifying 
those non-synonymous SNPs that are likely to have a deleterious impact on molecular 
function in vivo, so these may be included in association studies. An analysis of the 
likely functional impact of all human non-synonymous single base variants in the 
HGMD (as of 02/09/2002 , 9,625 variants in 696 genes) (Stenson et al. 2003) and 
dbSNP (Build 124,  29,485 SNPs in 11,303 genes) databases (Sherry et al. 2001) 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) is provided, using the previously 
developed methods (Yue et al. 2005; Yue 2005). Links to another available analysis 
(Dantzer et al. 2005) (http://mutdb.org/) are also included. The analysis is organized 
by gene. The structure/stability method (Wang and Moult 2001; (Yue et al. 2005)) 
requires knowledge of structure. Availability of experimental structures or 
sufficiently accurate structure models limits coverage to about 37% of monogenic 
disease variants in HGMD and 10% of variants in dbSNP. Greater availability of 
sequence information compared to structure allows a much higher fraction of variants 
to be analyzed (92% and 57% HGMD and dpSNP respectively) with the sequence 
profile method.  
Both methods make use of a machine learning technique, the support vector 
machine (SVM), to assign each SNP as deleterious or non-deleterious to protein 
function. The SVM is trained on monogenic disease data, so that the definition of 
deleterious is ‘sufficiently damaging to protein function in vivo as to be consistent 
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with a monogenic disease outcome’. Benchmarking has yielded false positive and 
false negative rates of 15% and 26% for the stability method and 10% and 20% for 
the sequence profile method. The higher false negative rate for the stability method 
reflects the fact that only stability effects on in vivo function are included. 
Approximately 30% of the non-synonymous SNPs in dbSNP are assigned as 
deleterious. Very few of the dbSNP cases are known to be associated with monogenic 
disease, and so most the deleterious ones are candidates for contributing to complex 
disease traits. As illustrated later, in many cases, low impact on the phenotype is 
likely the result of network level buffering against loss of function for individual 
proteins.  
Details of the analysis of each SNP are provided on additional pages.  For the 
profile model, a user can inspect the multiple protein sequence alignment from which 
the result is derived.  For the structure/stability model, feature values (for example, 
surface accessibility, electrostatic interactions and hydrophobicity) are provided, as 
well as an interactive molecular graphics interface (powered by Jmol, 
http://jmol.sourceforge.net/) displaying the affected residue in its three dimensional 
structural context. 
An example of Deleterious SNP Analysis 
To illustrate the SNP analysis process, we consider SNPs in the selectins, 
proteins involved in the early inflammatory response, playing a role in the 
accumulation of blood leukocytes at sites of inflammation.  SNP analysis for relevant 
genes may be accessed by typing a disease or process name into the corresponding 
search window. Entering ‘inflammation’ returns a ranked list of genes with abstracts 
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containing that term, hyperlinked to their SNP analysis pages. Entering a more 
specific search term, such as ‘selectin’ returns a list of relevant genes, including the 
members of the selectin family SELE, SELP and SELL, as well as proteins they 
interact with. Entering a specific gene name, such as SELE, takes the user directly to 
the analysis of SNPs in that protein. Table 4-1 shows a composite of the screen 
information for some inflammation related SNPs in selectins E, P and L and VCAM1. 
Each of these SNPs is classified as deleterious by the sequence profile method 
(indicated by the negative SVM scores). The SNPs in SELE (C130W) and SELP 
(G179R) are also analyzed by the structure/stability model, and are found to be 
deleterious by this criterion as well (a disulfide bridge is broken in SELE, there is 
overpacking and backbone strain in SELP). As discussed below, further insight into 
the relationship between these SNPs and the inflammatory response is provided by 
consideration of the inter-gene relationships.  
Gene-Gene Relationships 
Concept profile overlaps were used to score the relationship between all pairs 
of human genes in the current NCBI Entrez Gene database. Table 4-2 shows part of 
the resulting gene-gene relationship matrix, involving hypertension genes.  
Angiotensin-converting enzyme (ACE) and angiotensinogen (AGT) share 96 specific 
keyterms, such as ‘sodium intake’, ‘renin-angiotensin-system’ and ‘blood pressure’; 
generating a very strong (43.8) link between them. Many of the shared keywords also 
have relatively high weights. (That is, the frequency is high in abstracts for these 
genes, compared with all abstracts).  In contrast, the link between ACE and arginine 
vasopressin (AVP) is much weaker, with a score of 0.8, (still above the average for 
97 
 
Gene 
symbol 
refseq 
accession  snp  snp_id  
svm 
profile 
svm 
structure 
molecular 
effect  model frequency 
SELE NP_000441 C130W 5360 -1.89 -1.06 
OverPacking 
Breakage of a 
disulfide bond; 
0.02 
SELP NP_002996 G179R 3917718 -0.81 -1.46 
OverPacking 
Backbone 
Strain;  
0.02 
SELL NP_000646 P213S  4987310 -0.36 0.21 
VCAM1 NP_001069 S318F  3783611 -1.31 0.03 
VCAM1 NP_001069 G413A 3783613 -0.96 0.08 
VCAM1 NP_542413 I624L  3783615 -0.68 0.06 
Table 4-1.   Example interface page of candidate SNPs for inflammation related 
disease.   
Two support vector machine (SVM) models, based on sequence profiles (Yue 2005) 
and structural stability (Yue et al. 2005) are used to analyze SNPs in candidate genes 
for inflammation. SNPs are classified as deleterious (negative SVM score) or not to 
protein function in vivo. SNP population frequency information is extracted from the 
NCBI dbSNP database.  
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Table 4-2.  Subsection of the KnowledgeNet gene-gene linkage matrix.  
All three genes are associated with blood pressure regulation. ACE and AGT are 
strongly linked, other links are near the average value of 0.5.  
 ACE AGT AVP … 
ACE   43.8 0.8 … 
AGT 43.8   0.4 … 
AVP 0.8 0.4   … 
..  …  … …   
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non-zero relationships in the matrix, which is 0.5). There are only two shared 
keyterms between these genes: 'polydipsia’ and ‘hypotension’. ‘Hypotension’ 
represents a true concept overlap between these two genes, since both are involved in 
the regulation of blood pressure. ‘Polydipsia’ is a symptom found in more than one 
disease.  One of these is Autosomal dominant familial neurohypophyseal diabetes 
insipidus (ADNDI), some times caused by a  missense mutation in AVP (Smith et al. 
2002).  Mutations in ACE have also been shown to be a risk factor in a different 
disease, schizophrenia, for which polydipsia is also a symptom (Shinkai et al. 2003).  
Thus linkage of ACE and AVP through this term is a not a consequence of their joint 
role in blood pressure regulation. These indirect linkages are a source of noise in the 
matrix, but are generally rare.  
Figure 4-1 shows that the distribution of scores between gene pairs has an 
approximately power law distribution, with many scores near the minimum of 0.001, 
and a few high scores of up to 300.  Pairs of genes which are in the same KEGG 
pathway (Kanehisa et al. 2004) tend to have a stronger link than others, with median 
and mean scores of 0.5 and 2.5, while for all genes the corresponding values of 0.2 
and 0.5 respectively.  When only those pairs of genes involved in physical 
interactions included in the BIND database (Alfarano et al. 2005) are considered, the 
median and mean are dramatically higher, at 3.2 and 9.0 respectively.  Note that it is 
not our aim to reproduce either of these known gene-gene relationships, but to 
introduce a more general, literature based measure.  
Figure 4-2 shows the distributions of the number of gene links, for monogenic 
disease (defined by inclusion in the HGMD database (Stenson et al. 2003) and all 
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Figure 4-1.  Log- log plot of linkage scores in the gene-gene KnowledgeNet.  
Scores follow an approximately power law distribution, with a  few very high scoring 
relationships (up to a value of 300), and many relatively weak ones. 
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Figure 4-2.  Distribution of the number of links to each gene in the gene-gene 
 KnowledgeNet. Blue bars show the distribution for all genes with at least one link 
(15,799) and red, the distribution for 1669 linked HGMD monogenic disease genes. 
The tail is truncated – the highest linkage is 493, for TP53. Genes with no interactions 
above the threshold score of 0.5 are not included.  
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genes. Disease genes tend to be linked to more genes than non-disease genes, 
reflecting the fact that they are usually well studied, and have been placed in a 
network context.  
Using the Gene-Gene KnowledgeNet to Investigate SNP-Phenotype 
Relationships 
The SNPs in table 4-1 are classified as significantly deleterious to protein 
function, and are in genes involved in the inflammatory response. However, none of 
these SNPs is known to produce a disease phenotype. We next illustrate how the 
KnowledgeNet can be used to investigate the complex relationships between the 
effect of these SNPs on protein function and the disease phenotype, through network 
level buffering against defective protein components. For simplicity, we consider one 
pair of genes with deleterious SNPs, selectin E and selectin P.  The sidebar on the 
SNP analysis page provides direct access to a wide range of information relevant to 
this question, including OMIM, pathways, GO annotation, mouse knockout results, 
and tissue specific expression data, and relevant abstracts. Clicking ‘Gene Graph’ in 
the left sidebar creates a Java window displaying the gene-gene relationships centered 
on SELE. 
A large amount of information is accessible through the Java interface. At the 
moment, we are specifically interested in possible buffering mechanisms that shield 
the phenotype from these deleterious SNPs. One such buffering mechanism is 
overlapping protein function, and many proteins with overlapping function are 
homologous (Kafri et al. 2005) . Right clicking on the E-selectin node triggers a 
popup menu, including an option for highlighting all sequence homologs of that node 
103 
 
in the graph. L-selectin and P-selectin are seen to be homologous to E-selectin, 
suggesting possible functional redundancy. The redundancy of selectins E and P is 
supported by the information obtained from the mouse knockout link in the same 
menu, which reveals that single mouse knockouts of each gene produce a mild 
phenotype, while the double knockout is severe (Frenette et al. 1996).  Further 
support is provided by inspection of the expression profiles for the selectins, which 
shows a similar tissue specific pattern for Selectin E and selection P, with significant 
expression in multiple tissues, while selectin L is found in only a few tissues. Thus, 
an individual homozygous in either one of the deleterious SNPs will likely have a 
subclinically affected inflammatory response, because of redundancy of function. But 
an individual with both may have an epistatic interaction between them, and be 
seriously sick. Both are candidates for inflammation related disease association 
studies. 
Candidate Gene Lists for Diseases 
As discussed in the Introduction, the candidate gene approach is still widely 
used in association studies. Since knowledge of complex diseases is limited, a 
comprehensive list of candidate genes and a method of ranking those genes by their 
disease-relevance is important in designing a good association study.  The ‘Disease 
Candidate Genes’  module is used to list and rank candidate genes by building a 
concept profile for the disease and comparing it with the profiles for each human 
gene. The resulting ranked list of candidate genes can be edited by the user, before 
further analysis. The Java graphical interface provides access to the resulting gene 
network, helping a user navigate through the relationships and associated data. 
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We have pre-complied candidate genes lists for a set 76 diseases, taken from 
the NCBI on-line book, ‘Genes and Disease’ (http://www.ncbi.nlm.nih.gov/books 
/bv.fcgi?rid=gnd). A list for any additional disease may be generated by entering the 
disease name in the web interface. 
Table 4-3 lists the 16 diseases associated with the most genes, using an 
association threshold of 0.05. (Disease-gene profile overlaps have scores ranging 
from 0 to 24.5 with a mean of 0.04). Figure 4-3 shows the distribution of the number 
of genes using this threshold. Cancers tend to have the largest number of candidate 
genes, with the highest value of 197 genes for lung cancer. Next ranking are well 
studied common diseases such as asthma, hypertension, inflammation, obesity, 
Alzheimer’s disease, epilepsy, atherosclerosis and deafness. The number of genes 
associated with a particular disease primarily reflects the complexity of phenotype, 
but may also partly reflect the current state of knowledge. Not surprisingly, nominally 
monogenic diseases tend to have the least number of candidate genes. However, these 
are often not monogenic in this analysis. For example, Phenylketonuria (PKU) has 14 
associated genes.  As expected, in this case the primary disease gene (PAH - 
phenylalanine hydroxylase) has a very high linkage to the disease, with a score of 23, 
while all other genes have scores less than 0.5. The web resource provides a ranked 
list of candidate genes for each disease. 
In all, 2,582 genes are associated with one or more of the 76 pre-complied 
diseases, using a threshold score of 0.05. TP53 is associated with the most diseases 
(23).  The number of diseases a gene is associated with increases with the number 
articles associated with that gene. 
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Disease 
Score 
>0.05 
Lung Cancer 197 
Prostate cancer 190 
Gastric Cancer 142 
Pancreatic Cancer 134 
Breast Cancer 133 
Diabetes Mellitus 130 
Asthma 124 
Retinoblastoma 116 
hypertension 113 
Bladder Cancer 109 
Epilepsy 107 
Inflammation Related 107 
Atherosclerosis 99 
Alzheimer Disease 99 
Deafness 94 
Cervical Cancer 93 
Table 4-3.  Diseases with the largest number of significantly associated candidate 
genes.  
Cancers tend to have the largest number of candidates, followed by common complex 
trait diseases.  
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Figure 4-3.  Distribution of the number of candidate genes for a set of 76 diseases.  
The curve shows the distribution using a disease-gene linkage threshold of 0.05. 
Cancers and common human diseases tend to have many candidate genes, but 
monogenic diseases typically have more than one candidate as well.  
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KnowledgeNet Analysis of Candidate Genes and SNPs 
Once a candidate gene list is available, it is useful to be able to efficiently 
access the underlying literature, and to generate a list of deleterious SNPs in the genes 
of most interest. As an example of this process, we consider one of the pre-built 
disease candidate lists, for hypertension. Clicking on the disease returns a list of the 
candidate genes, ranked by confidence of disease relevance, based on profile overlap 
with the disease. Table 4-4 shows the top part of the list. Highest ranked are well 
known hypertension-related genes, for example, angiotensinogen (AGT) and 
angiotensin I converting enzyme (ACE).   Each gene in the list is linked directly to 
local copies of the relevant abstracts, with color highlighting of appropriate words, so 
that a user may very rapidly assess the evidence for candidate status. There are also 
links to OMIM (Hamosh et al. 2005) and the NIA genetic association database 
information (Becker et al. 2004), providing sources of expert information on disease 
relevance. 
Since hypertension is a complex trait, with susceptibility related to SNPs in 
multiple genes as well as the interactions between them, the ability to navigate the 
network of candidate genes is an important facility of the resource.  Viewing the set 
of candidate genes in the Java graphical interface provides the mechanism for this. 
Figure 4-4 shows a screen snapshot of the graphical interface for the hypertension 
candidate gene network. Strongly associated genes cluster in the display. In 
particular, in this case, the four primary blood pressure regulation pathways form 
distinct groups, indicated by the black ovals. Among these, the renin-angiotensin 
pathway (A), controlling absorption of sodium, is the most studied, and most of its 
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Gene Symbol Candidate SNPs OMIM GAD 
AGT 1 Y N3/Y19 
ACE 6   N6/Y24 
AGTR1 2 Y Y11 
GNB3 2 Y N1/Y6 
HSD11B2 1   Y1 
CYP11B2 2   N1/Y2 
BMPR2 0     
ADD1 1 Y N5/Y4 
REN 3   Y3 
EDN1 0     
Table 4-4.   Top ranking candidate genes for hypertension.  
The list was complied on the basis of the overlap of the disease concept profile with 
those of the individual genes. ‘Candidate SNPs’ shows the number SNPs classified as 
deleterious in each gene. The ’OMIM’ column indicates which genes are associated 
with essential hypertension in that database. The ‘GAD’ column shows the number of 
votes for or against a role for each gene in hypertension in the Genetic Association 
Database (Becker et al. 2004). 
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A
D
C
B
Figure 4-4.  Graphical Interface for the KnowledgeNet of candidate genes for 
hypertension.  
The four larger ovals circle the clusters of genes in each of the primary blood pressure 
regulation pathways. Oval symbols are used for genes involved in monogenic disease, 
rectangular symbols for the rest. Red indicates that one or more population SNPs are 
classified as harmful at the molecular level.  Italic red text indicates that one or more 
population SNPs with population frequency information are predicted to be 
deleterious.   
The length and color of the edges represent the strength of the link between pairs of 
genes.  Red edges link genes sharing the same abstracts.  Short edges link genes 
sharing a large number of biological keywords.  
Subsets of nodes can be highlighted by a number of criteria, such as membership of 
the same KEGG pathway, or homology, or SNP frequency.   
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genes have been implicated in monogenic types of hypertension (indicated by the 
oval gene symbols). The other pathways all influence blood pressure through vascular 
constriction via: (B), regulation by endothelin (EDN1); (C), regulation of natruretic 
peptide (NPPA, NPPB, NPPC); and (D), the bradykinin-killikrien pathway. Figure 4-
5 shows a simplified version of the pathways and their inter-relationships, derived 
from browsing the interface, reviews (Lifton et al. 2001) (Turner and Boerwinkle 
2003), and on-line data (http://www.cvphysiology.com/Blood%20Pressure 
/BP001.htm). The pathways are highly interconnected. For example, both natruretic 
peptide and bradykinin also act as antagonists of the rennin-angiotensin pathway, and 
are able to relax vascular contraction and down-regulate blood pressure. Conversely, 
ACE, which activates AGT in the renin-angiotensin pathway, can inactivate 
bradykinin.   
This gene/disease network for hypertension provides a number of deleterious 
SNPs for association studies. A sample of these is shown in table 4-5. All are 
classified as deleterious to protein function by the sequence profile method and the 
structure/stability method. The first is R333W in rennin, which results in the loss of 
salt bridge and thus is likely to cause loss of function.  Given rennin’s role an up-
regulator of blood pressure, this SNP is a candidate for involvement in hypotension. 
The second SNP, I444T, occurs in the hydrophobic core of angiotensin-converting 
enzyme (ACE) and causes a large loss of buried hydrophobic area. ACE is in the 
same pathway as rennin, and has an established role in blood pressure related disease. 
Mutants of ACE have been associated with monogenic-type hypertension (O'Donnell 
et al. 1998), and ACE knockout mice show ‘subnormal blood pressure, kidney 
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Figure 4-5.  Simplified view of the four primary candidate pathways involved in 
hypertension.  
A: renin-angiotensin pathway; B: regulation by endothelin (EDN1); C: regulation by 
natruretic peptide (NPPA, NPPB, NPPC); D: the bradykinin-killikrien pathway. 
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RefSNP ID 
Gene 
Name 
Refseq 
Protein SNP 
SVM 
profile 
SVM 
structure 
Structure and 
Sequence 
Properties 
dbSNP ID and 
Population 
Frequency 
rs11571098 REN NP_000528 R33W -1.63 -0.21 Salt Bridge lost 
ss20420843:4% 
(African 
American)  
rs4976 ACE NP_690044 I444T -1.26 -1.15 
Hydrophobic 
Interaction loss 
ss6413:5% 
(Multination) 
(Halushka et al. 
1999) 
rs5247 CMA1 NP_001827 H66R -2.51 -1.49 
Salt Bridge lost; 
key catalytic 
residue, very 
conserved 
ss6694:10% 
(Multination) 
(Halushka et al. 
1999) 
rs5518 KLK1 NP_002248 V193E -1.62 -0.70 
Buried Charge, 
hydrophobic 
interaction 
decreased 
ss6984:5% 
(Multination) 
(Halushka et al. 
1999) 
Table 4-5.   Example candidate SNPs for hypertension 
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obstruction and widening and thickening of infrarenal arterial vessels’ (Krege et al. 
1995). The third SNP, H66R, is in chymase (CMA1), and changes a key catalytic 
residue, as well a breaking a salt bridge. The physiological function of chymase is 
still controversial (Ju et al. 2001) (Takai and Miyazaki 2003). A SNP upstream of the 
transcription initiation site of CMA1 has been reported to be associated with 
hypertensive complications such as HDL cholesterol (possibly related to its lipid 
metabolism function), but not with blood pressure (Fukuda et al. 2002). The fourth 
SNP, V193E, in kallikrein (KLK1) results in a buried charge and loss of hydrophobic 
burial, affecting bradykinin processing. 
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Discussion
There are three unique features of the SNPs3D resource. First, it is designed 
specifically for the analysis of the relationship between SNPs and disease. Second, it 
constructs gene networks based on conceptual relationships derived from the 
literature, rather than experimental data. Third, it integrates access to all available and 
relevant information sources, wherever possible giving the user easy access to the 
underlying data and literature, so that informed judgments can be made.  
We have chosen to construct a network of connections between genes based 
on how strongly they are coupled in the literature, rather than whether there is 
extractable information supporting a physical interaction between them. There are 
two advantages to this approach.  First, relevant connections between proteins may be 
non-physical.  For example, genes that are involved in the same complex disease may 
not directly interact, or even be in the same local pathway, but may nevertheless 
interact in terms of affecting disease susceptibility. Second, the text mining procedure 
will capture considerably more information than is currently in any database, or that 
can be easily formalized in a simple cause and effect pathway description. In this 
sense, the KnowledgeNet expands on existing pathways descriptions by linking genes 
with conceptual relationships.  
The case studies illustrate how all this works in practice. Analysis of non-
synonymous SNPs in the selectins leads to the finding of several that appear to be  
deleterious to protein function, but which do not directly lead to a disease phenotype. 
Inspection of homologs in the KnowledgeNet graphical interface suggests a role for 
functional redundancy in conferring network level robustness, and consulting mouse 
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knockout and expression profile data supports that conclusion. The result also 
strongly suggests an epistatic relationship between the deleterious SNPs in selectin E 
and selectin P: An individual homozygous in either one will likely not display clinical 
symptoms, but an individual homozygous in both will probably have a significantly 
compromised inflammatory response. In the hypertension example, a list of possible 
candidate genes is generated. The KnowledgeNet interface allows a user to browse 
the relationships between those genes, clustering the main pathways, and providing 
access to analysis of the relevant non-synonymous SNPs. As is often the case, the 
roles of the some of the genes in disease susceptibility are complicated, and the 
available information is some times contradictory. For example, for chymase, there is 
considerable uncertainty of function. Instant access to the relevant literature allows 
the user to quickly appreciate the subtleties of the current state of knowledge. 
We now consider the strengths and weaknesses of the approach in more detail. 
Concept profiles for genes are built from the relative frequency of words and 
terms in PubMed abstracts. In turn, overlap of the profiles are used to identify gene-
gene relationships. In practice, the procedure provides intuitively reasonably results, 
but there is no way of rigorously benchmarking such knowledge generated networks.  
The method occasionally makes errors on the side of over-inclusiveness. For 
example, it is not able to distinguish between statements such as ‘protein A is 
associated with disease B’ versus ‘protein A is not associated with disease B’. As 
illustrated in the Results, it is also possible for a disease and gene to be linked by 
irrelevant factors, such as symptoms common to more than one syndrome. Similarly, 
gene-gene relationships may sometimes be based on non-pathway related factors. For 
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example the 13 members of the human kallikrein family are tightly coupled, because 
of many articles that discuss them as a group. In fact, most of the family members 
operate in quite different pathways. In future, more sophisticated natural language 
processing technology may be applied to reduce these effects. At present, a concept 
overlap weighting scheme that emphasizes relationships to ‘hub’ proteins is used, and 
ensures that proteins weakly linked to these are included. A weighting scheme that 
takes into account the number of papers published on a gene may further improve 
inclusion of relevant weak links. The analysis is limited to abstracts already annotated 
as relevant to a particular gene. Extension to all pubmed abstracts (currently about 8.5 
million) is desirable. In practice, the resource is very effective at narrowing down the 
amount of literature a user must consult in arriving at an informed position, our main 
goal. 
Concept profile overlaps are also used to provide lists of candidate genes for 
involvement in susceptibility to particular diseases. There is no gold standard for 
candidate genes for a disease, with different compilations using different criteria. 
Comparison of our hypertension list with a hand compiled list for essential 
hypertension (Halushka et al. 1999), shows informative similarities and differences. 
That list contains 75 candidate genes rated as ‘strong’, 57 of which are also in the 
SNPs3D hypertension set. Nine of the top ten ranking SNPs3D genes are in the hand 
complied hypertension list. The exception is BMPR2, which is involved in pulmonary 
hypertension, rather than essential hypertension. The 12th ranking gene in the 
SNPs3D list, ADRB2, is also not in the hand complied list, but is clearly associated 
with hypertension in PubMed abstracts. Conversely, some of the additional genes in 
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the hand complied list, such as GALR1, are not linked in any way to hypertension in 
PubMed, even with a more sophisticated profile based search, and including all 
abstracts. Their selection may reflect specialized insights on the part of the compliers. 
Others, such APOC2 and APOC4, are also not associated with hypertension in 
PubMed, but have a chromosome location covered by a known hypertension marker.  
SNPs3D candidate lists can be generated on demand, with little delay, and so 
have the advantage of taking into account all the current literature. On the other hand, 
there is a great deal of relevant specialized knowledge in the scientific community 
that is either not in the literature, or very difficult to extract in a useful way. The 
Genetic Association Database (GAD) is an archive of human genetic association 
studies of complex diseases and disorders (Becker et al. 2004) that provides an 
alternative approach to compiling the relevant information. Any user may submit 
information about an association between a disease and a gene, creating a mechanism 
of capturing community knowledge. We expect that in the long run, the most 
effective candidate lists will be complied by a hybrid of the two approaches. 
SNPs3D analysis is only provided for non-synonymous SNPs. Other sorts of 
SNPs, particularly those affecting transcription, splicing and perhaps RNA message 
structure will also play a role in susceptibility to complex trait disease. Little data on 
is available on the relative importance of the different SNP types, although for 
monogenic disease, the role is relatively small. For example, single base variant 
effects operating through transcription are quite rare, accounting for 0.5% of cases 
(Stenson et al. 2003). Whatever the case, it is clearly desirable to include other classes 
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of SNP. It should shortly be possible to extend coverage in this way, using DNA 
sequence profiles based on the complete genome sequences of higher eukaryotes.  
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Methods
Query Interface 
Each of the three modules (SNP analysis, gene-gene network, and disease 
candidate gene lists and networks) is accessed via a separate simple search window, 
on the site front page.  
The candidate gene search window will accept any word or phrase as an entry, 
and compiles a concept profile, as described below. For SNP analysis and gene-gene 
networks requests, a hierarchal query string processing procedure is used, providing a 
wide choice of input name types, including dbSNP IDs, Entrez Gene IDs, RefSEQ 
IDs, NBCI Gene Symbols, and common protein names, using the following 
procedure: 
1. A query string is first inspected to determine if its composition is consistent 
with a dbSNP ID, Entrez Gene ID or Refseq ID. If one of these name types is 
identified, the query is searched against the corresponding list of possibilities, and if a 
match is found, appropriate results are returned.  
2. If the type of ID cannot be identified, the query string is first treated as a 
NCBI gene symbol, and searched against that set. If an exact match is found, results 
are returned.  
3. If no exact match to a gene symbol is found, the string is searched against 
all words in the NCBI Gene summaries of each gene. Any hit adds to a list of high 
ranked possible genes.  
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4. This hit list is supplemented by a search of the query string against all the 
PubMed abstracts associated with each gene in the NCBI Gene Database. The 
number of times the query string is found in the abstracts for a gene provides a 
ranking weight. Finally, the user is invited to choose the appropriate gene from the 
ranked list of possibilities.  
5. If a search completely fails, the user is offered an alternative search 
window, with explicit query string categories.   
Literature Dataset 
The abstracts of all the medline entries associated with each gene in the NCBI 
Gene database (Pruitt et al. 2000) are the source of words and terms. In the current 
version, there are, 80,249 Medline references linked to 19,228 human genes. Word 
types are identified using SVMtagger (http://www.lsi.upc.es/~nlp/SVMTool/). 
Keyterms are constructed from single nouns and adjectives, adjective/noun pairs, and 
continuous strings of words classified as adjectives or nouns. For example, the phrase 
‘blood pressure’ occurring in an abstract would result in three keyterms: ‘blood’, 
‘pressure’, and ‘blood pressure’. Terms occurring only once are removed. There are 
currently a total of 266,337 keyterms. 
The number of occurrences of each keyterm ‘KW’ in all the abstracts 
(‘Total_count(KW)’ is retained, as well as the number of occurrences of each 
keyterm in the abstracts associated with each gene ‘G’, ‘Count(G,KW)’, and the 
fraction of all occurrences of each keyterm that are associated with each gene is 
calculated as: 
F1(G,KW) = Count(G,KW)/Total_Count(KW) 
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Construction of the Gene-Gene Relationship Matrix 
The interaction strength L(i,j) between every pair of genes i and j is calculated 
as: 
L(i,j) = ^KW F1(Gi,KW) + ^KW F1(Gj,KW) 
where the sum is over all keyterms common to the two genes, excluding any 
found in more than 300 genes. More studied genes have more associated abstracts in 
the NCBI Gene database, so that this expression upweights interactions involving 
those. Comparison with a more egalitarian gene-gene weighting, based on a dot 
product sum similar to that used for the disease/gene linkage, suggests that an 
emphasis on the hub-like genes is useful for including links to relevant but more 
weakly coupled genes.  
Because of memory constraints, the interactions are stored as a sparse matrix, 
retaining a maximum of 200 interacting genes per gene. A few well studied genes, 
such as P53, have more than 200 genes linked with significant scores (greater than the 
mean element value of the sparse matrix).  However, in almost all cases, these 
elements will be included in the list of associations for other genes.  
Generation of a Candidate Gene List for a Disease 
Given a disease name, a list of candidate genes is generated as follows: 
A. The subset of abstracts relevant to the disease is identified: 
1. Any abstract containing the full disease name, for example, ‘breast cancer’ 
is selected.  
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2. If this procedure results in less than 20 abstracts, and the disease name 
consists of more than one word, a further search of abstracts is made for the 
combination of words, for example ‘breast’ AND ‘cancer’.  
3. If less than a total of ten abstracts are selected, the process is aborted, 
returning a message of ‘Not enough abstracts to build a profile’. 
B: A keyterm profile is generated for the disease, using the selected abstracts. 
All Keyterms are ranked by the fraction of disease abstracts that contain them: 
 Rank(KW)= Count_abstracts(D,KW)/[Total_abstracts(KW) +50] 
where ‘Count_abstracts(D,KW)’ is the number of abstracts for disease ‘D’ 
containing the keyterm ‘KW’, and ‘Total_abstracts(KW)’ is the total number of 
abstracts containing the keyterm.  A pseudo count of 50 is added to reduce noise. The 
top ranking 40 keyterms are selected, providing Rank(KW) is at least 0.1.  
C: The overlap of the disease keyterms with those of each gene is calculated: 
1. The number of times each selected keyterm ‘KW’ occurs in the abstracts 
associated with the disease ‘D’, ‘Count(D,KW)’, is determined, and the relative 
frequency is calculated as : 
F2(D,KW) = Count(D,KW)/Total_Count(KW) 
2. The strength of association of the disease ‘D’ with a gene ‘G’ is calculated 
as the dot product of the relative frequencies of the disease keyterms with the relative 
frequencies of those same keyterms in that gene:  
SD(D,G) = ^KW F1(G,KW).F2(D,KW) 
where the sum is only over the up to 40 keywords selected as the keyterm set 
of disease ‘D’. The association strength is deliberately biased towards the keyterms 
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most strongly associated with the disease, as opposed to be associated with particular 
genes.  
D: Finally, all genes with a non-zero score are returned as candidates.  
Database Setup 
The database is implemented in MySQL. As shown in figure 4-6, the central 
table is ‘Gene’, an up-to-date list of human genes from the NCBI Entrez Gene 
database.  The Gene table is linked to other master tables: The SNP model table 
contains our stability and profile analysis of SNPs. There is a table of keyterms for 
each gene, and a table of PubMed abstract IDs for each gene. The KnowledgeNet 
matrix table contains the pairwise gene-gene interaction strengths, and there is also a 
disease/candidate gene matrix. Some other tables linked to the Gene table are: the 
Transcript table (RefSeq mRNAs); the Protein table (RefSeq proteins); the phenotype 
and disease-tables (NCBI OMIM and human gene mutation database (HGMD)); 
Mouse knockout table (Bioscience mouse knockout); pathway (KEGG), protein-
protein interactions (BIND); and protein function (GO).  
Web Interface 
SNPs3D is served using Apache software running on a Linux PC and with 
web pages derived from an early open source version of PHP-NUKE 
(http://www.phpnuke.org/).    
KnowledgeNet Graphical Interface 
The interactive graphical interface for displaying gene-gene relationships is 
based on open source Java code (http://www.touchgraph.com). Genes form nodes in a  
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Figure 4-6.  Database Schema.  
The Blue blocks represent individual modules, which may be single or multiple 
MySql tables. 
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graph and gene-gene relationships are edges. Clicking links and symbols leads to 
more detailed information. Symbol shape; font style; symbol, edge and font color as 
well as hover-over windows are used to provide as much information as possible. 
Gene symbol shape conveys whether or not that gene is involved in disease, gene 
symbol text color indicates whether there are deleterious SNPs. Subsets of genes 
containing one or more SNPs with population frequencies above some threshold may 
be highlighted (identifying those most likely to be involved in complex traits). A 
maximum of 300 genes are displayed in the graphical interface. These are genes most 
strongly associated with a query gene or a query disease. The threshold for displaying 
links between genes is adjustable to show only those most strongly linked, or all 
possible connections. Links may also be based on KEGG pathway connections or 
direct protein-protein interaction information, extracted from BIND (Bader et al. 
2003). Left clicking on a gene provides immediate access to all the gene specific 
information, including SNP analysis using the stability (Yue et al. 2005) and profile 
methods (Yue 2005) and the NCBI Gene summary, as well as pathways, dbSNP 
entries and homologs. 
Content for the graphical display can be generated using the list of genes 
associated with a reference gene or a disease (the candidate genes, with the strongest 
linked gene as initial center), or a specified list of genes.  All gene lists may be edited. 
One important feature is the ability to redraw the graph, using a selected node as the 
new center, allowing the user to smoothly navigate through adjacent regions of the 
knowledgeNet matrix. A pull down menu provides a list of all displayed genes, and 
any gene may be highlighted in the network via this list. Right clicking on a node 
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provides facilities for highlighting genes which share certain properties with the 
reference gene, such as KEGG pathway, associated papers, or sequence homology. 
Left clicking in a gene brings up its SNP analysis. 
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Chapter 5: Discussion and Conclusion 
Progress in Understanding Monogenic Disease
Role of Protein Destabilization in Monogenic Disease 
This thesis describes an investigation into the mechanisms by which mis-sense 
variants (the most abundant known disease variants) cause human disease. Since in 
vitro mutagenesis data show that many single residue variations decrease protein 
stability, we hypothesized that loss of stability plays a major role in causing human 
monogenic diseases.  In order to test this hypothesis, we developed a structure based 
model to evaluate the effect of mis-sense variants on protein stability by looking at 15 
structure features, such as electrostatic interactions, and overpacking.  The model 
successfully identifies 74% of mis-sense variants known to cause human monogenic 
disease with a 15% false positive rate.  We therefore conclude that the majority of 
monogenic disease variants act by destabilization of protein structure.  
Size of the Destabilization Effect 
The stability model was applied to a set of destabilizing mutations for which 
the in vitro change in stability has been experimentally measured.   We found that 
only a small fraction of mutants that stabilize or weakly destabilize a structure are 
assigned a disease-causing outcome, consistent with the overall false positive rate of 
the model, while 90% of mutants that destabilize a structure by 3 Kcal/mol or more 
are classified as disease causing. In addition to supporting the role of destabilization, 
this analysis provides an approximate free energy scale for disease-causing mutants – 
typically 2 to 3 Kcal/mol. 
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Significance of a Small Destabilization Effect in vivo  
The free energy difference between the folded and unfolded state of a globular 
protein typically ranges from 5-15 Kcal/mol (Privalov 1979), corresponding to an 
equilibrium constant between 10-4 and 10-13. A typical disease causing mutant 
destabilizes the folded state by 2 Kcal/mol and so increases the concentration of the 
unfolded state by about two orders of magnitude.  However, the fraction of unfolded 
molecules is still very small, so such a mutant will usually not have a detectable effect 
in vitro. In vivo, the 100 fold increase in the concentration of the unfolded state will 
result in a proportional increase of scavenging by chaperones (Hohfeld et al. 2001).  
We propose that this mechanism may play a role in dramatically lowering the 
concentration of a disease mutant protein in vivo. However, further experiments are 
required to test this hypothesis. 
Structure and Sequence Based Models: Pros and Cons 
The structure based model allows us to investigate how an amino acid variant 
affects protein function.  However, its application is limited by its requirement for 
protein three-dimensional (3D) structure.  Experimentally determining human protein 
3D structure is very challenging, and only a small fraction is so far available.  
Comparative modeling expands the useful structure coverage of human proteins, but 
still only 10% of human proteins can be analyzed by the stability model.  The 
sequence model does not require protein structure information and thus has a broader 
application, and also detects a wider range of functional effects.  It relies on analysis 
of evolutionary constraints which can be inferred from multiple alignments between 
human protein sequences and their homologs.  The drawback of the sequence model, 
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however, is that it can not provide direct insight on the mechanism by which an 
amino acid variant affects function.  The primary errors in the two models are caused 
by different factors: an incorrect protein structure for the stability method and too few 
sequences in an alignment for the sequence method.  The classification of a given 
variant can be further validated by comparing the results by these two models.   
Analysis of Human Population SNPs
One-Fourth of Human Mis-sense SNPs are Deleterious 
Both models were applied to known human population SNPs.  One major 
conclusion of this thesis is that about one quarter of the known missense SNPs in the 
human population are significantly deleterious to protein function in vivo. Two 
factors have been carefully considered in reaching that conclusion.  The first factor is 
related to the errors caused by the models and the second factor is related to the errors 
in the dataset.  The rate of deleterious SNPs in the population is overestimated due to 
the false positives and underestimated because of the false negatives.  We took both 
types of errors into account in estimation of deleterious SNPs.  False positive and 
false negative rates were obtained from benchmarking the methods against 
monogenic disease and a fitting procedure was then used to find the true deleterious 
rate.  The effect of errors in the dataset is controlled by comparing the results between 
all available SNPs and the SNPs validated by the HapMap project (2003) and 
Perlegen Inc (Hinds et al. 2005).   
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Discussion of Deleterious SNPs 
Most of the newly identified deleterious SNPS are not in human monogenic 
disease genes, and do not have any known role in complex disease.  There are three 
broad categories of explanation for this:   
1. These SNPs are not deleterious to protein function as our models suggest.  
While this explanation can not be entirely ruled out, we have carefully taken into 
account the effect of errors in the models and in the data.   
2. The monogenic disease proteins are somehow especially vulnerable to the 
effect of deleterious mis-sense mutants.  For example, the mechanism of removing 
unfolded proteins by chaperone-dependent processes may be only applicable to 
monogenic disease genes.  Little is known to prove or reject this possibility.  A 
comparison of protein types between disease genes and non-disease genes, based on 
their GO classification of molecular function, does not reveal any significant 
difference. 
3. The phenotype is somehow buffered against deleterious SNPs in most 
genes.  That is, the decrease or loss of function of a single gene caused by a 
deleterious variant does not show any significant impact at the phenotype level.  Such 
a hypothesis is supported by the results of knockout experiments.  Gene suppression 
in C.elegans (Kamath et al. 2003) and Saccharomyces (Cliften et al. 2003) (Rubin et 
al. 2000) as well as limited mouse knockout data  show that loss of function of many 
individual genes does not cause any detectable phenotype change.  One possible 
buffering mechanism is redundant function between genes, especially among 
sequence paralogs (Kafri et al. 2005).  Most human genes have paralogs within the 
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genome, but we found no difference between monogenic disease genes and non-
disease genes.  Therefore, functional redundancy between paralogous genes may not 
be the primary mechanism to buffer effects of damaging mutations in vivo. The 
second possible mechanism lies in the network properties of human gene-gene 
interactions.  Many known pathways contain feedback loops and alternative routes 
that provide system level robustness against damaging mutations.  Inspection of 
individual cases suggests that this type of buffering is the major factor. 
The KnowledgeNet: a knowledge based gene-gene network
In order to understand the impact of a deleterious SNP on the phenotype, it is 
necessary to consider its network environment.  We have constructed a knowledge-
based gene-gene network using a simple text mining method.  In the network, gene 
pairs are linked according to the overlap between their concept profiles.  A concept 
profile is a simple means of capturing the concept associated with each gene in the 
literature.  Each concept profile is a list of words and phrases found in abstracts 
related to a gene.  The advantage of such a network lies in its inclusiveness, because it 
reflects not only the known physical interactions between different genes, but also 
more abstract relationships between them.  For example, two genes may be linked 
because they are both involved in the same disease even though they may not directly 
interact.  The disadvantage of this network is also apparent: precise definitions of the 
relationship between gene pairs are not available.   
Concept profiles are not limited to genes, but can also be compiled for 
diseases or biological processes.  Overlap of disease and gene profiles can be used to 
compile a list of candidate genes involved in a given disease.  The case study of 
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hypertension shows that such an automatically-generated candidate list does include 
most genes in known blood pressure regulation related pathways.  It also suggests 
some new genes that are missing from the available expert curated gene list 
(Halushka et al. 1999). 
Relevance to Public Health
Up to now, most attempts to link SNPs and susceptibility to complex disease 
have relied on statistical association of a SNP with a disease.  While there have been 
some noticeable successes, for example the role of APOE SNPs in Alzhemer’s 
disease, in general it has proven difficult to relate mutations to disease.  There are 
several possible explanations for this, including the role of epistasis effects (non-
linear interactions between SNPs), the small contribution of most SNPs to disease 
susceptibility, and not including the relevant regions of the genome.  Whole genome 
association studies are now being proposed to address the third of these possibilities.  
It is not yet known how effective the studies will be, and new problems of statistical 
significance are raised.   
Understanding the mechanisms by which SNPs are related to disease offers a 
different and complementary approach to identifying disease mutations.  The work 
described in this thesis covers one aspect of mechanism, and has several direct 
applications: 1) potentially deleterious human population SNPs are identified and thus 
provides a list of SNPs for association studies. 2) An automatically generated 
candidate gene list for a given disease can help an investigator in designing a 
candidate gene based association study 3) The gene-gene interaction network can 
help users investigate possible epistasis effects between candidate genes.  More 
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importantly, this work can contribute to understanding of mechanism of common 
human diseases by helping to address the following questions: How does a mutation 
affect protein function? How is the effect on protein function transformed into an 
effect at a phenotypic level?  How do the network properties of gene-gene 
interactions buffer the effect of damage to a single gene? 
Summary of Conclusions and Contributions
The major conclusions and contributions of this thesis can be summarized as 
follows:  
We conclude that the loss of stability plays a major role in the development of 
monogenic human diseases. 
We conclude that approximately 25% of mis-sense SNPs in the human 
population significantly damage protein function.  These mis-sense SNPs provide a 
list of candidates for association with common human diseases. 
A simple gene-gene relationship network is set up to facilitate identification of 
network properties.  The network allows investigation of the impact of mis-sense 
SNPs on phenotypes and identification of sets of mis-sense SNPs for incorporating 
epitasis effect into general association studies. 
Concept profiles provide a means to identify links between gene and disease, 
allowing candidate genes to be compiled. 
A website has been developed to allow free access to the data for the scientific 
community.  
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Limitations and Suggestions for Future Work
Other Mutations Affecting Disease Susceptibility:  
There are many ways in which a SNP may affect a human phenotype. This 
work focuses only on the study of mis-sense SNPs because they are the most 
abundant genetic mutations causing human monogenic diseases.  However, SNPs in 
gene regulatory regions have long been suspected to play a major role in common 
human disease.  In addition, there are many non-gene related regions of DNA that 
display a high level of conservation between species of higher Eukaryotes, suggesting 
unknown but important functions (Loots et al. 2000).  
The sequences of a number of higher Eukaryote genomes, including human, 
mouse, rat and chimpanzee, have been completed and more sequencing efforts are 
ongoing.  With these data available, the principle of the amino acid sequence 
conservation model can be applied to analysis of genome conservation at the DNA 
level, identifying other classes of deleterious SNPs.  Moreover, systematic 
experimental projects, such as ENCODE (2004), will also expand our knowledge of 
the function of these non-coding regions.   
Beside SNPs, genomic structure variations, such as insertion, deletion and 
chromosomal duplication, have been observed in many cases of monogenic disease.  
As to common human diseases, the role of chromosome duplication in cancer has 
been broadly investigated, but so far only seldom studied in other diseases.  
Compared to SNPs, genomic structure variants are not easily detected.  In future, new 
technologies may provide the necessary data and thus allow investigation into the 
wide genomic structure of human disease. 
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Gene-Gene Network Construction 
The current gene-gene network is based on the over eighty thousand gene-
related Medline abstracts in the NCBI Gene database.   A general method of 
automatically identifying papers related to particular genes will broaden the coverage 
of the network.  The current simple literature mining method also has its limitations.  
For example, a paper may state that protein A is not associated with disease C.  The 
KnowledgeNet will ignore the ‘not’ and simply extract disease C as one of the 
keywords associated with protein A and thus erroneously link A to those proteins that 
are truly related to disease C.  In future, natural language processing technology 
should be able to reduce these problems.   
Experimental genetic approaches have been used in model organisms to 
systematically identify gene-gene interaction properties inside biological networks.  A 
recent paper describes a system-level study on epistasis by single and double 
knockout of 890 metabolic genes in yeast (Segre et al. 2005).  Incorporating these 
types of new data into the KnowledgeNet will further increase its usefulness. 
 
136 
 
References 
 
2003. The International HapMap Project. Nature 426: 789-796. 
2004. The ENCODE (ENCyclopedia Of DNA Elements) Project. Science 306: 636-
640. 
Alfarano, C., C.E. Andrade, K. Anthony, N. Bahroos, M. Bajec, K. Bantoft, D. Betel, 
B. Bobechko, K. Boutilier, E. Burgess, K. Buzadzija, R. Cavero, C. D'Abreo, 
I. Donaldson, D. Dorairajoo, M.J. Dumontier, M.R. Dumontier, V. Earles, R. 
Farrall, H. Feldman, E. Garderman, Y. Gong, R. Gonzaga, V. Grytsan, E. 
Gryz, V. Gu, E. Haldorsen, A. Halupa, R. Haw, A. Hrvojic, L. Hurrell, R. 
Isserlin, F. Jack, F. Juma, A. Khan, T. Kon, S. Konopinsky, V. Le, E. Lee, S. 
Ling, M. Magidin, J. Moniakis, J. Montojo, S. Moore, B. Muskat, I. Ng, J.P. 
Paraiso, B. Parker, G. Pintilie, R. Pirone, J.J. Salama, S. Sgro, T. Shan, Y. 
Shu, J. Siew, D. Skinner, K. Snyder, R. Stasiuk, D. Strumpf, B. Tuekam, S. 
Tao, Z. Wang, M. White, R. Willis, C. Wolting, S. Wong, A. Wrong, C. Xin, 
R. Yao, B. Yates, S. Zhang, K. Zheng, T. Pawson, B.F. Ouellette, and C.W. 
Hogue. 2005. The Biomolecular Interaction Network Database and related 
tools 2005 update. Nucleic Acids Res 33: D418-424. 
Altschul, S.F., T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D.J. 
Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein 
database search programs. Nucleic Acids Res 25: 3389-3402. 
Altshuler, D., J.N. Hirschhorn, M. Klannemark, C.M. Lindgren, M.C. Vohl, J. 
Nemesh, C.R. Lane, S.F. Schaffner, S. Bolk, C. Brewer, T. Tuomi, D. Gaudet, 
T.J. Hudson, M. Daly, L. Groop, and E.S. Lander. 2000. The common 
PPARgamma Pro12Ala polymorphism is associated with decreased risk of 
type 2 diabetes. Nat Genet 26: 76-80. 
Andreeva, A., D. Howorth, S.E. Brenner, T.J. Hubbard, C. Chothia, and A.G. Murzin. 
2004. SCOP database in 2004: refinements integrate structure and sequence 
family data. Nucleic Acids Res 32: D226-229. 
Bader, G.D., D. Betel, and C.W. Hogue. 2003. BIND: the Biomolecular Interaction 
Network Database. Nucleic Acids Res 31: 248-250. 
Baker, D. and A. Sali. 2001. Protein structure prediction and structural genomics. 
Science 294: 93-96. 
137 
 
Bava, K.A., M.M. Gromiha, H. Uedaira, K. Kitajima, and A. Sarai. 2004. ProTherm, 
version 4.0: thermodynamic database for proteins and mutants. Nucleic Acids 
Res 32: D120-121. 
Becker, K.G., K.C. Barnes, T.J. Bright, and S.A. Wang. 2004. The genetic association 
database. Nat Genet 36: 431-432. 
Beveridge, D.L. and F.M. DiCapua. 1989. Free energy via molecular simulation: 
applications to chemical and biomolecular systems. Annu Rev Biophys 
Biophys Chem 18: 431-492. 
Bhasin, M., H. Zhang, E.L. Reinherz, and P.A. Reche. 2005. Prediction of methylated 
CpGs in DNA sequences using a support vector machine. FEBS Lett 579:
4302-4308. 
Bidiwala, S. and T. Pittman. 2004. Neural network classification of pediatric posterior 
fossa tumors using clinical and imaging data. Pediatr Neurosurg 40: 8-15. 
Boeckmann, B., A. Bairoch, R. Apweiler, M.C. Blatter, A. Estreicher, E. Gasteiger, 
M.J. Martin, K. Michoud, C. O'Donovan, I. Phan, S. Pilbout, and M. 
Schneider. 2003. The SWISS-PROT protein knowledgebase and its 
supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370. 
Botstein, D. and N. Risch. 2003. Discovering genotypes underlying human 
phenotypes: past successes for mendelian disease, future approaches for 
complex disease. Nat Genet 33 Suppl: 228-237. 
Byrne, M.P., R.L. Manuel, L.G. Lowe, and W.E. Stites. 1995. Energetic contribution 
of side chain hydrogen bonding to the stability of staphylococcal nuclease. 
Biochemistry 34: 13949-13960. 
Canutescu, A.A., A.A. Shelenkov, and R.L. Dunbrack, Jr. 2003. A graph-theory 
algorithm for rapid protein side-chain prediction. Protein Sci 12: 2001-2014. 
Cargill, M., D. Altshuler, J. Ireland, P. Sklar, K. Ardlie, N. Patil, N. Shaw, C.R. Lane, 
E.P. Lim, N. Kalyanaraman, J. Nemesh, L. Ziaugra, L. Friedland, A. Rolfe, J. 
Warrington, R. Lipshutz, G.Q. Daley, and E.S. Lander. 1999. Characterization 
of single-nucleotide polymorphisms in coding regions of human genes. Nat 
Genet 22: 231-238. 
138 
 
Carlson, C.S., M.A. Eberle, L. Kruglyak, and D.A. Nickerson. 2004. Mapping 
complex disease loci in whole-genome association studies. Nature 429: 446-
452. 
Cavallo, A. and A.C. Martin. 2005. Mapping SNPs to protein sequence and structure 
data. Bioinformatics 21: 1443-1450. 
Chasman, D. and R.M. Adams. 2001. Predicting the functional consequences of non-
synonymous single nucleotide polymorphisms: structure-based assessment of 
amino acid variation. J Mol Biol 307: 683-706. 
Cliften, P., P. Sudarsanam, A. Desikan, L. Fulton, B. Fulton, J. Majors, R. Waterston, 
B.A. Cohen, and M. Johnston. 2003. Finding functional features in 
Saccharomyces genomes by phylogenetic footprinting. Science 301: 71-76. 
Corder, E.H., A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. 
Small, A.D. Roses, J.L. Haines, and M.A. Pericak-Vance. 1993. Gene dose of 
apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset 
families. Science 261: 921-923. 
Cozzetto, D. and A. Tramontano. 2005. Relationship between multiple sequence 
alignments and quality of protein comparative models. Proteins 58: 151-157. 
Dantzer, J., C. Moad, R. Heiland, and S. Mooney. 2005. MutDB services: interactive 
structural analysis of mutation data. Nucleic Acids Res 33: W311-314. 
Daraselia, N., A. Yuryev, S. Egorov, S. Novichkova, A. Nikitin, and I. Mazo. 2004. 
Extracting human protein interactions from MEDLINE using a full-sentence 
parser. Bioinformatics 20: 604-611. 
Deshpande, N., K.J. Addess, W.F. Bluhm, J.C. Merino-Ott, W. Townsend-Merino, Q. 
Zhang, C. Knezevich, L. Xie, L. Chen, Z. Feng, R.K. Green, J.L. Flippen-
Anderson, J. Westbrook, H.M. Berman, and P.E. Bourne. 2005. The RCSB 
Protein Data Bank: a redesigned query system and relational database based 
on the mmCIF schema. Nucleic Acids Res 33 Database Issue: D233-237. 
Dodge, C., R. Schneider, and C. Sander. 1998. The HSSP database of protein 
structure-sequence alignments and family profiles. Nucleic Acids Res 26: 313-
315. 
139 
 
Emahazion, T., L. Feuk, M. Jobs, S.L. Sawyer, D. Fredman, D. St Clair, J.A. Prince, 
and A.J. Brookes. 2001. SNP association studies in Alzheimer's disease 
highlight problems for complex disease analysis. Trends Genet 17: 407-413. 
Ferrer-Costa, C., M. Orozco, and X. de la Cruz. 2002. Characterization of disease-
associated single amino acid polymorphisms in terms of sequence and 
structure properties. J Mol Biol 315: 771-786. 
Fields, S. and O. Song. 1989. A novel genetic system to detect protein-protein 
interactions. Nature 340: 245-246. 
Frenette, P.S., T.N. Mayadas, H. Rayburn, R.O. Hynes, and D.D. Wagner. 1996. 
Susceptibility to infection and altered hematopoiesis in mice deficient in both 
P- and E-selectins. Cell 84: 563-574. 
Fukuda, M., T. Ohkubo, T. Katsuya, A. Hozawa, T. Asai, M. Matsubara, H. Kitaoka, 
I. Tsuji, T. Araki, H. Satoh, J. Higaki, S. Hisamichi, Y. Imai, and T. Ogihara. 
2002. Association of a mast cell chymase gene variant with HDL cholesterol, 
but not with blood pressure in the Ohasama study. Hypertens Res 25: 179-
184. 
Fulton, K.F., E.R. Main, V. Daggett, and S.E. Jackson. 1999. Mapping the 
interactions present in the transition state for unfolding/folding of FKBP12. J
Mol Biol 291: 445-461. 
Gabriel, S.B., S.F. Schaffner, H. Nguyen, J.M. Moore, J. Roy, B. Blumenstiel, J. 
Higgins, M. DeFelice, A. Lochner, M. Faggart, S.N. Liu-Cordero, C. Rotimi, 
A. Adeyemo, R. Cooper, R. Ward, E.S. Lander, M.J. Daly, and D. Altshuler. 
2002. The structure of haplotype blocks in the human genome. Science 296: 
2225-2229. 
Giot, L., J.S. Bader, C. Brouwer, A. Chaudhuri, B. Kuang, Y. Li, Y.L. Hao, C.E. Ooi, 
B. Godwin, E. Vitols, G. Vijayadamodar, P. Pochart, H. Machineni, M. 
Welsh, Y. Kong, B. Zerhusen, R. Malcolm, Z. Varrone, A. Collis, M. Minto, 
S. Burgess, L. McDaniel, E. Stimpson, F. Spriggs, J. Williams, K. Neurath, N. 
Ioime, M. Agee, E. Voss, K. Furtak, R. Renzulli, N. Aanensen, S. Carrolla, E. 
Bickelhaupt, Y. Lazovatsky, A. DaSilva, J. Zhong, C.A. Stanyon, R.L. Finley, 
Jr., K.P. White, M. Braverman, T. Jarvie, S. Gold, M. Leach, J. Knight, R.A. 
Shimkets, M.P. McKenna, J. Chant, and J.M. Rothberg. 2003. A protein 
interaction map of Drosophila melanogaster. Science 302: 1727-1736. 
140 
 
Green, S.M., A.K. Meeker, and D. Shortle. 1992. Contributions of the polar, 
uncharged amino acids to the stability of staphylococcal nuclease: evidence 
for mutational effects on the free energy of the denatured state. Biochemistry 
31: 5717-5728. 
Green, S.M. and D. Shortle. 1993. Patterns of nonadditivity between pairs of stability 
mutations in staphylococcal nuclease. Biochemistry 32: 10131-10139. 
Gromiha, M.M., S. Ahmad, and M. Suwa. 2004. Neural network-based prediction of 
transmembrane beta-strand segments in outer membrane proteins. J Comput 
Chem 25: 762-767. 
Guerois, R., J.E. Nielsen, and L. Serrano. 2002. Predicting changes in the stability of 
proteins and protein complexes: a study of more than 1000 mutations. J Mol 
Biol 320: 369-387. 
Halushka, M.K., J.B. Fan, K. Bentley, L. Hsie, N. Shen, A. Weder, R. Cooper, R. 
Lipshutz, and A. Chakravarti. 1999. Patterns of single-nucleotide 
polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 
22: 239-247. 
Hamosh, A., A.F. Scott, J.S. Amberger, C.A. Bocchini, and V.A. McKusick. 2005. 
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human 
genes and genetic disorders. Nucleic Acids Res 33: D514-517. 
Harris, M.A., J. Clark, A. Ireland, J. Lomax, M. Ashburner, R. Foulger, K. Eilbeck, S. 
Lewis, B. Marshall, C. Mungall, J. Richter, G.M. Rubin, J.A. Blake, C. Bult, 
M. Dolan, H. Drabkin, J.T. Eppig, D.P. Hill, L. Ni, M. Ringwald, R. 
Balakrishnan, J.M. Cherry, K.R. Christie, M.C. Costanzo, S.S. Dwight, S. 
Engel, D.G. Fisk, J.E. Hirschman, E.L. Hong, R.S. Nash, A. Sethuraman, C.L. 
Theesfeld, D. Botstein, K. Dolinski, B. Feierbach, T. Berardini, S. Mundodi, 
S.Y. Rhee, R. Apweiler, D. Barrell, E. Camon, E. Dimmer, V. Lee, R. 
Chisholm, P. Gaudet, W. Kibbe, R. Kishore, E.M. Schwarz, P. Sternberg, M. 
Gwinn, L. Hannick, J. Wortman, M. Berriman, V. Wood, N. de la Cruz, P. 
Tonellato, P. Jaiswal, T. Seigfried, and R. White. 2004. The Gene Ontology 
(GO) database and informatics resource. Nucleic Acids Res 32 Database 
issue: D258-261. 
Henikoff, S. and J.G. Henikoff. 1993. Performance evaluation of amino acid 
substitution matrices. Proteins 17: 49-61. 
141 
 
Henrick, K. and J.M. Thornton. 1998. PQS: a protein quaternary structure file server. 
Trends Biochem Sci 23: 358-361. 
Hinds, D.A., L.L. Stuve, G.B. Nilsen, E. Halperin, E. Eskin, D.G. Ballinger, K.A. 
Frazer, and D.R. Cox. 2005. Whole-genome patterns of common DNA 
variation in three human populations. Science 307: 1072-1079. 
Hirschhorn, J.N. and M.J. Daly. 2005. Genome-wide association studies for common 
diseases and complex traits. Nat Rev Genet 6: 95-108. 
Hohfeld, J., D.M. Cyr, and C. Patterson. 2001. From the cradle to the grave: 
molecular chaperones that may choose between folding and degradation. 
EMBO Rep 2: 885-890. 
Holder, J.B., A.F. Bennett, J. Chen, D.S. Spencer, M.P. Byrne, and W.E. Stites. 2001. 
Energetics of side chain packing in staphylococcal nuclease assessed by 
exchange of valines, isoleucines, and leucines. Biochemistry 40: 13998-
14003. 
Hua, S. and Z. Sun. 2001. A novel method of protein secondary structure prediction 
with high segment overlap measure: support vector machine approach. J Mol 
Biol 308: 397-407. 
Huang, H., E.E. Winter, H. Wang, K.G. Weinstock, H. Xing, L. Goodstadt, P.D. 
Stenson, D.N. Cooper, D. Smith, M.M. Alba, C.P. Ponting, and K. Fechtel. 
2004. Evolutionary conservation and selection of human disease gene 
orthologs in the rat and mouse genomes. Genome Biol 5: R47. 
Jansen, R., H. Yu, D. Greenbaum, Y. Kluger, N.J. Krogan, S. Chung, A. Emili, M. 
Snyder, J.F. Greenblatt, and M. Gerstein. 2003. A Bayesian networks 
approach for predicting protein-protein interactions from genomic data. 
Science 302: 449-453. 
Ju, H., R. Gros, X. You, S. Tsang, M. Husain, and M. Rabinovitch. 2001. Conditional 
and targeted overexpression of vascular chymase causes hypertension in 
transgenic mice. Proc Natl Acad Sci U S A 98: 7469-7474. 
Kafri, R., A. Bar-Even, and Y. Pilpel. 2005. Transcription control reprogramming in 
genetic backup circuits. Nat Genet 37: 295-299. 
142 
 
Kamath, R.S., A.G. Fraser, Y. Dong, G. Poulin, R. Durbin, M. Gotta, A. Kanapin, N. 
Le Bot, S. Moreno, M. Sohrmann, D.P. Welchman, P. Zipperlen, and J. 
Ahringer. 2003. Systematic functional analysis of the Caenorhabditis elegans 
genome using RNAi. Nature 421: 231-237. 
Kanehisa, M., S. Goto, S. Kawashima, Y. Okuno, and M. Hattori. 2004. The KEGG 
resource for deciphering the genome. Nucleic Acids Res 32: D277-280. 
Kragelund, B.B., P. Osmark, T.B. Neergaard, J. Schiodt, K. Kristiansen, J. Knudsen, 
and F.M. Poulsen. 1999. The formation of a native-like structure containing 
eight conserved hydrophobic residues is rate limiting in two-state protein 
folding of ACBP. Nat Struct Biol 6: 594-601. 
Krege, J.H., S.W. John, L.L. Langenbach, J.B. Hodgin, J.R. Hagaman, E.S. Bachman, 
J.C. Jennette, D.A. O'Brien, and O. Smithies. 1995. Male-female differences 
in fertility and blood pressure in ACE-deficient mice. Nature 375: 146-148. 
Krishnan, V.G. and D.R. Westhead. 2003. A comparative study of machine-learning 
methods to predict the effects of single nucleotide polymorphisms on protein 
function. Bioinformatics 19: 2199-2209. 
Kruglyak, L. and D.A. Nickerson. 2001. Variation is the spice of life. Nat Genet 27:
234-236. 
Lander, E.S. L.M. Linton B. Birren C. Nusbaum M.C. Zody J. Baldwin K. Devon K. 
Dewar M. Doyle W. FitzHugh R. Funke D. Gage K. Harris A. Heaford J. 
Howland L. Kann J. Lehoczky R. LeVine P. McEwan K. McKernan J. 
Meldrim J.P. Mesirov C. Miranda W. Morris J. Naylor C. Raymond M. 
Rosetti R. Santos A. Sheridan C. Sougnez N. Stange-Thomann N. Stojanovic 
A. Subramanian D. Wyman J. Rogers J. Sulston R. Ainscough S. Beck D. 
Bentley J. Burton C. Clee N. Carter A. Coulson R. Deadman P. Deloukas A. 
Dunham I. Dunham R. Durbin L. French D. Grafham S. Gregory T. Hubbard 
S. Humphray A. Hunt M. Jones C. Lloyd A. McMurray L. Matthews S. 
Mercer S. Milne J.C. Mullikin A. Mungall R. Plumb M. Ross R. Shownkeen 
S. Sims R.H. Waterston R.K. Wilson L.W. Hillier J.D. McPherson M.A. 
Marra E.R. Mardis L.A. Fulton A.T. Chinwalla K.H. Pepin W.R. Gish S.L. 
Chissoe M.C. Wendl K.D. Delehaunty T.L. Miner A. Delehaunty J.B. Kramer 
L.L. Cook R.S. Fulton D.L. Johnson P.J. Minx S.W. Clifton T. Hawkins E. 
Branscomb P. Predki P. Richardson S. Wenning T. Slezak N. Doggett J.F. 
Cheng A. Olsen S. Lucas C. Elkin E. Uberbacher M. Frazier R.A. Gibbs D.M. 
Muzny S.E. Scherer J.B. Bouck E.J. Sodergren K.C. Worley C.M. Rives J.H. 
Gorrell M.L. Metzker S.L. Naylor R.S. Kucherlapati D.L. Nelson G.M. 
143 
 
Weinstock Y. Sakaki A. Fujiyama M. Hattori T. Yada A. Toyoda T. Itoh C. 
Kawagoe H. Watanabe Y. Totoki T. Taylor J. Weissenbach R. Heilig W. 
Saurin F. Artiguenave P. Brottier T. Bruls E. Pelletier C. Robert P. Wincker 
D.R. Smith L. Doucette-Stamm M. Rubenfield K. Weinstock H.M. Lee J. 
Dubois A. Rosenthal M. Platzer G. Nyakatura S. Taudien A. Rump H. Yang J. 
Yu J. Wang G. Huang J. Gu L. Hood L. Rowen A. Madan S. Qin R.W. Davis 
N.A. Federspiel A.P. Abola M.J. Proctor R.M. Myers J. Schmutz M. Dickson 
J. Grimwood D.R. Cox M.V. Olson R. Kaul N. Shimizu K. Kawasaki S. 
Minoshima G.A. Evans M. Athanasiou R. Schultz B.A. Roe F. Chen H. Pan J. 
Ramser H. Lehrach R. Reinhardt W.R. McCombie M. de la Bastide N. Dedhia 
H. Blocker K. Hornischer G. Nordsiek R. Agarwala L. Aravind J.A. Bailey A. 
Bateman S. Batzoglou E. Birney P. Bork D.G. Brown C.B. Burge L. Cerutti 
H.C. Chen D. Church M. Clamp R.R. Copley T. Doerks S.R. Eddy E.E. 
Eichler T.S. Furey J. Galagan J.G. Gilbert C. Harmon Y. Hayashizaki D. 
Haussler H. Hermjakob K. Hokamp W. Jang L.S. Johnson T.A. Jones S. Kasif 
A. Kaspryzk S. Kennedy W.J. Kent P. Kitts E.V. Koonin I. Korf D. Kulp D. 
Lancet T.M. Lowe A. McLysaght T. Mikkelsen J.V. Moran N. Mulder V.J. 
Pollara C.P. Ponting G. Schuler J. Schultz G. Slater A.F. Smit E. Stupka J. 
Szustakowski D. Thierry-Mieg J. Thierry-Mieg L. Wagner J. Wallis R. 
Wheeler A. Williams Y.I. Wolf K.H. Wolfe S.P. Yang R.F. Yeh F. Collins 
M.S. Guyer J. Peterson A. Felsenfeld K.A. Wetterstrand A. Patrinos M.J. 
Morgan P. de Jong J.J. Catanese K. Osoegawa H. Shizuya S. Choi and Y.J. 
Chen. 2001. Initial sequencing and analysis of the human genome. Nature 
409: 860-921. 
Laskowski RA, M.M., Moss DS, Thornton JM. 1993. PROCHECK: A program to 
check the stereochemical quality of protein structures. J. Appl. Cryst. 26: 283-
291. 
Lau, A.Y. and D.I. Chasman. 2004. Functional classification of proteins and protein 
variants. Proc Natl Acad Sci U S A 101: 6576-6581. 
Lee, B. and F.M. Richards. 1971. The interpretation of protein structures: estimation 
of static accessibility. J Mol Biol 55: 379-400. 
Lee, I., S.V. Date, A.T. Adai, and E.M. Marcotte. 2004. A probabilistic functional 
network of yeast genes. Science 306: 1555-1558. 
Li, S., C.M. Armstrong, N. Bertin, H. Ge, S. Milstein, M. Boxem, P.O. Vidalain, J.D. 
Han, A. Chesneau, T. Hao, D.S. Goldberg, N. Li, M. Martinez, J.F. Rual, P. 
Lamesch, L. Xu, M. Tewari, S.L. Wong, L.V. Zhang, G.F. Berriz, L. Jacotot, 
P. Vaglio, J. Reboul, T. Hirozane-Kishikawa, Q. Li, H.W. Gabel, A. Elewa, B. 
Baumgartner, D.J. Rose, H. Yu, S. Bosak, R. Sequerra, A. Fraser, S.E. 
144 
 
Mango, W.M. Saxton, S. Strome, S. Van Den Heuvel, F. Piano, J. 
Vandenhaute, C. Sardet, M. Gerstein, L. Doucette-Stamm, K.C. Gunsalus, 
J.W. Harper, M.E. Cusick, F.P. Roth, D.E. Hill, and M. Vidal. 2004. A map of 
the interactome network of the metazoan C. elegans. Science 303: 540-543. 
Li, Z. and C. Chan. 2004. Inferring pathways and networks with a Bayesian 
framework. Faseb J.
Lifton, R.P., A.G. Gharavi, and D.S. Geller. 2001. Molecular mechanisms of human 
hypertension. Cell 104: 545-556. 
Loots, G.G., R.M. Locksley, C.M. Blankespoor, Z.E. Wang, W. Miller, E.M. Rubin, 
and K.A. Frazer. 2000. Identification of a coordinate regulator of interleukins 
4, 13, and 5 by cross-species sequence comparisons. Science 288: 136-140. 
Main, E.R., K.F. Fulton, and S.E. Jackson. 1998. Context-dependent nature of 
destabilizing mutations on the stability of FKBP12. Biochemistry 37: 6145-
6153. 
Mark, A.E. and W.F. van Gunsteren. 1994. Decomposition of the free energy of a 
system in terms of specific interactions. Implications for theoretical and 
experimental studies. J Mol Biol 240: 167-176. 
Markey, M.K., G.D. Tourassi, and C.E. Floyd, Jr. 2003. Decision tree classification 
of proteins identified by mass spectrometry of blood serum samples from 
people with and without lung cancer. Proteomics 3: 1678-1679. 
Markiewicz, P., L.G. Kleina, C. Cruz, S. Ehret, and J.H. Miller. 1994. Genetic studies 
of the lac repressor. XIV. Analysis of 4000 altered Escherichia coli lac 
repressors reveals essential and non-essential residues, as well as "spacers" 
which do not require a specific sequence. J Mol Biol 240: 421-433. 
Meeker, A.K., B. Garcia-Moreno, and D. Shortle. 1996. Contributions of the 
ionizable amino acids to the stability of staphylococcal nuclease. Biochemistry 
35: 6443-6449. 
Mitsumori, T., S. Fation, M. Murata, K. Doi, and H. Doi. 2005. Gene/protein name 
recognition based on support vector machine using dictionary as features. 
BMC Bioinformatics 6 Suppl 1: S8. 
145 
 
Molchanova, T.P., D.D. Pobedimskaya, and V. Postnikov Yu. 1994. A simplified 
procedure for sequencing amplified DNA containing the alpha 2- or alpha 1-
globin gene. Hemoglobin 18: 251-255. 
Mooney, S.D. and R.B. Altman. 2003. MutDB: annotating human variation with 
functionally relevant data. Bioinformatics 19: 1858-1860. 
Mori, Y., K. Takeda, M. Charbonneau, and S. Refetoff. 1990. Replacement of 
Leu227 by Pro in thyroxine-binding globulin (TBG) is associated with 
complete TBG deficiency in three of eight families with this inherited defect. 
J Clin Endocrinol Metab 70: 804-809. 
Nariai, N., S. Kim, S. Imoto, and S. Miyano. 2004. Using protein-protein interactions 
for refining gene networks estimated from microarray data by Bayesian 
networks. Pac Symp Biocomput: 336-347. 
Ng, P.C., J.G. Henikoff, and S. Henikoff. 2000. PHAT: a transmembrane-specific 
substitution matrix. Predicted hydrophobic and transmembrane. 
Bioinformatics 16: 760-766. 
Ng, P.C. and S. Henikoff. 2003. SIFT: Predicting amino acid changes that affect 
protein function. Nucleic Acids Res 31: 3812-3814. 
O'Donnell, C.J., K. Lindpaintner, M.G. Larson, V.S. Rao, J.M. Ordovas, E.J. 
Schaefer, R.H. Myers, and D. Levy. 1998. Evidence for association and 
genetic linkage of the angiotensin-converting enzyme locus with hypertension 
and blood pressure in men but not women in the Framingham Heart Study. 
Circulation 97: 1766-1772. 
Oliva, M.T. and J. Moult. 1999. Local electrostatic optimization in proteins. Protein 
Eng 12: 727-735. 
Pan, Y. and V. Daggett. 2001. Direct comparison of experimental and calculated 
folding free energies for hydrophobic deletion mutants of chymotrypsin 
inhibitor 2: free energy perturbation calculations using transition and 
denatured states from molecular dynamics simulations of unfolding. 
Biochemistry 40: 2723-2731. 
Pedersen, J.T. and J. Moult. 1997. Protein folding simulations with genetic algorithms 
and a detailed molecular description. J Mol Biol 269: 240-259. 
146 
 
Pelletier, J. and N. Sonenberg. 1987. The involvement of mRNA secondary structure 
in protein synthesis. Biochem Cell Biol 65: 576-581. 
Peri, S., J.D. Navarro, T.Z. Kristiansen, R. Amanchy, V. Surendranath, B. 
Muthusamy, T.K. Gandhi, K.N. Chandrika, N. Deshpande, S. Suresh, B.P. 
Rashmi, K. Shanker, N. Padma, V. Niranjan, H.C. Harsha, N. Talreja, B.M. 
Vrushabendra, M.A. Ramya, A.J. Yatish, M. Joy, H.N. Shivashankar, M.P. 
Kavitha, M. Menezes, D.R. Choudhury, N. Ghosh, R. Saravana, S. Chandran, 
S. Mohan, C.K. Jonnalagadda, C.K. Prasad, C. Kumar-Sinha, K.S. 
Deshpande, and A. Pandey. 2004. Human protein reference database as a 
discovery resource for proteomics. Nucleic Acids Res 32: D497-501. 
Phizicky, E., P.I. Bastiaens, H. Zhu, M. Snyder, and S. Fields. 2003. Protein analysis 
on a proteomic scale. Nature 422: 208-215. 
Plemper, R.K. and D.H. Wolf. 1999. Retrograde protein translocation: ERADication 
of secretory proteins in health and disease. Trends Biochem Sci 24: 266-270. 
Prince, J.A., L. Feuk, S.L. Sawyer, J. Gottfries, A. Ricksten, K. Nagga, N. 
Bogdanovic, K. Blennow, and A.J. Brookes. 2001. Lack of replication of 
association findings in complex disease: an analysis of 15 polymorphisms in 
prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet 9: 
437-444. 
Pritchard, J.K. and N.J. Cox. 2002. The allelic architecture of human disease genes: 
common disease-common variant...or not? Hum Mol Genet 11: 2417-2423. 
Pritchard, J.K. and M. Przeworski. 2001. Linkage disequilibrium in humans: models 
and data. Am J Hum Genet 69: 1-14. 
Privalov, P.L. 1979. Stability of proteins: small globular proteins. Adv Protein Chem 
33: 167-241. 
Pruitt, K.D., K.S. Katz, H. Sicotte, and D.R. Maglott. 2000. Introducing RefSeq and 
LocusLink: curated human genome resources at the NCBI. Trends Genet 16:
44-47. 
Przybylski, D. and B. Rost. 2002. Alignments grow, secondary structure prediction 
improves. Proteins 46: 197-205. 
147 
 
Ramensky, V., P. Bork, and S. Sunyaev. 2002. Human non-synonymous SNPs: server 
and survey. Nucleic Acids Res 30: 3894-3900. 
Reich, D.E. and E.S. Lander. 2001. On the allelic spectrum of human disease. Trends 
Genet 17: 502-510. 
Rennell, D., S.E. Bouvier, L.W. Hardy, and A.R. Poteete. 1991. Systematic mutation 
of bacteriophage T4 lysozyme. J Mol Biol 222: 67-88. 
Reumers, J., J. Schymkowitz, J. Ferkinghoff-Borg, F. Stricher, L. Serrano, and F. 
Rousseau. 2005. SNPeffect: a database mapping molecular phenotypic effects 
of human non-synonymous coding SNPs. Nucleic Acids Res 33: D527-532. 
Risch, N. and K. Merikangas. 1996. The future of genetic studies of complex human 
diseases. Science 273: 1516-1517. 
Rost, B. and V.A. Eyrich. 2001. EVA: large-scale analysis of secondary structure 
prediction. Proteins Suppl 5: 192-199. 
Rubin, G.M., M.D. Yandell, J.R. Wortman, G.L. Gabor Miklos, C.R. Nelson, I.K. 
Hariharan, M.E. Fortini, P.W. Li, R. Apweiler, W. Fleischmann, J.M. Cherry, 
S. Henikoff, M.P. Skupski, S. Misra, M. Ashburner, E. Birney, M.S. Boguski, 
T. Brody, P. Brokstein, S.E. Celniker, S.A. Chervitz, D. Coates, A. Cravchik, 
A. Gabrielian, R.F. Galle, W.M. Gelbart, R.A. George, L.S. Goldstein, F. 
Gong, P. Guan, N.L. Harris, B.A. Hay, R.A. Hoskins, J. Li, Z. Li, R.O. Hynes, 
S.J. Jones, P.M. Kuehl, B. Lemaitre, J.T. Littleton, D.K. Morrison, C. 
Mungall, P.H. O'Farrell, O.K. Pickeral, C. Shue, L.B. Vosshall, J. Zhang, Q. 
Zhao, X.H. Zheng, and S. Lewis. 2000. Comparative genomics of the 
eukaryotes. Science 287: 2204-2215. 
Sachs, G.S. 2003. Decision tree for the treatment of bipolar disorder. J Clin 
Psychiatry 64 Suppl 8: 35-40. 
Samudrala, R. and J. Moult. 1997. Handling context-sensitivity in protein structures 
using graph theory: bona fide prediction. Proteins Suppl 1: 43-49. 
Schwehm, J.M., E.S. Kristyanne, C.C. Biggers, and W.E. Stites. 1998. Stability 
effects of increasing the hydrophobicity of solvent-exposed side chains in 
staphylococcal nuclease. Biochemistry 37: 6939-6948. 
148 
 
Scriver, C.R., M. Hurtubise, D. Konecki, M. Phommarinh, L. Prevost, H. Erlandsen, 
R. Stevens, P.J. Waters, S. Ryan, D. McDonald, and C. Sarkissian. 2003. 
PAHdb 2003: what a locus-specific knowledgebase can do. Hum Mutat 21:
333-344. 
Segre, D., A. Deluna, G.M. Church, and R. Kishony. 2005. Modular epistasis in yeast 
metabolism. Nat Genet 37: 77-83. 
Serrano, L., J.T. Kellis, Jr., P. Cann, A. Matouschek, and A.R. Fersht. 1992a. The 
folding of an enzyme. II. Substructure of barnase and the contribution of 
different interactions to protein stability. J Mol Biol 224: 783-804. 
Serrano, L., A. Matouschek, and A.R. Fersht. 1992b. The folding of an enzyme. III. 
Structure of the transition state for unfolding of barnase analysed by a protein 
engineering procedure. J Mol Biol 224: 805-818. 
Serrano, L., A. Matouschek, and A.R. Fersht. 1992c. The folding of an enzyme. VI. 
The folding pathway of barnase: comparison with theoretical models. J Mol 
Biol 224: 847-859. 
Serrano, L., J. Sancho, M. Hirshberg, and A.R. Fersht. 1992d. Alpha-helix stability in 
proteins. I. Empirical correlations concerning substitution of side-chains at the 
N and C-caps and the replacement of alanine by glycine or serine at solvent-
exposed surfaces. J Mol Biol 227: 544-559. 
Service, R. 2005. Structural biology. Structural genomics, round 2. Science 307:
1554-1558. 
Shen, L.X., J.P. Basilion, and V.P. Stanton, Jr. 1999. Single-nucleotide 
polymorphisms can cause different structural folds of mRNA. Proc Natl Acad 
Sci U S A 96: 7871-7876. 
Sherry, S.T., M.H. Ward, M. Kholodov, J. Baker, L. Phan, E.M. Smigielski, and K. 
Sirotkin. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids 
Res 29: 308-311. 
Shinkai, T., O. Ohmori, H. Hori, and J. Nakamura. 2003. Genetic approaches to 
polydipsia in schizophrenia: a preliminary report of a family study and an 
association study of an angiotensin-converting enzyme gene polymorphism. 
Am J Med Genet B Neuropsychiatr Genet 119: 7-12. 
149 
 
Shortle, D., W.E. Stites, and A.K. Meeker. 1990. Contributions of the large 
hydrophobic amino acids to the stability of staphylococcal nuclease. 
Biochemistry 29: 8033-8041. 
Shrake, A. and J.A. Rupley. 1973. Environment and exposure to solvent of protein 
atoms. Lysozyme and insulin. J Mol Biol 79: 351-371. 
Smith, D., K. McKenna, K. Moore, W. Tormey, J. Finucane, J. Phillips, P. Baylis, 
and C.J. Thompson. 2002. Baroregulation of vasopressin release in adipsic 
diabetes insipidus. J Clin Endocrinol Metab 87: 4564-4568. 
Smith, D.J. and A.J. Lusis. 2002. The allelic structure of common disease. Hum Mol 
Genet 11: 2455-2461. 
Smith, N.G. and A. Eyre-Walker. 2003. Human disease genes: patterns and 
predictions. Gene 318: 169-175. 
Stapley, B.J. and G. Benoit. 2000. Biobibliometrics: information retrieval and 
visualization from co-occurrences of gene names in Medline abstracts. Pac 
Symp Biocomput: 529-540. 
Stenson, P.D., E.V. Ball, M. Mort, A.D. Phillips, J.A. Shiel, N.S. Thomas, S. 
Abeysinghe, M. Krawczak, and D.N. Cooper. 2003. Human Gene Mutation 
Database (HGMD): 2003 update. Hum Mutat 21: 577-581. 
Stites, W.E., A.K. Meeker, and D. Shortle. 1994. Evidence for strained interactions 
between side-chains and the polypeptide backbone. J Mol Biol 235: 27-32. 
Stitziel, N.O., T.A. Binkowski, Y.Y. Tseng, S. Kasif, and J. Liang. 2004. topoSNP: a 
topographic database of non-synonymous single nucleotide polymorphisms 
with and without known disease association. Nucleic Acids Res 32: D520-522. 
Stitziel, N.O., Y.Y. Tseng, D. Pervouchine, D. Goddeau, S. Kasif, and J. Liang. 2003. 
Structural location of disease-associated single-nucleotide polymorphisms. J
Mol Biol 327: 1021-1030. 
Su, A.I., M.P. Cooke, K.A. Ching, Y. Hakak, J.R. Walker, T. Wiltshire, A.P. Orth, 
R.G. Vega, L.M. Sapinoso, A. Moqrich, A. Patapoutian, G.M. Hampton, P.G. 
150 
 
Schultz, and J.B. Hogenesch. 2002. Large-scale analysis of the human and 
mouse transcriptomes. Proc Natl Acad Sci U S A 99: 4465-4470. 
Sunyaev, S., V. Ramensky, I. Koch, W. Lathe, 3rd, A.S. Kondrashov, and P. Bork. 
2001. Prediction of deleterious human alleles. Hum Mol Genet 10: 591-597. 
Takai, S. and M. Miyazaki. 2003. Application of a chymase inhibitor, NK3201, for 
prevention of vascular proliferation. Cardiovasc Drug Rev 21: 185-198. 
Tishkoff, S.A. and B.C. Verrelli. 2003. Role of evolutionary history on haplotype 
block structure in the human genome: implications for disease mapping. Curr 
Opin Genet Dev 13: 569-575. 
Tong, A.H., G. Lesage, G.D. Bader, H. Ding, H. Xu, X. Xin, J. Young, G.F. Berriz, 
R.L. Brost, M. Chang, Y. Chen, X. Cheng, G. Chua, H. Friesen, D.S. 
Goldberg, J. Haynes, C. Humphries, G. He, S. Hussein, L. Ke, N. Krogan, Z. 
Li, J.N. Levinson, H. Lu, P. Menard, C. Munyana, A.B. Parsons, O. Ryan, R. 
Tonikian, T. Roberts, A.M. Sdicu, J. Shapiro, B. Sheikh, B. Suter, S.L. Wong, 
L.V. Zhang, H. Zhu, C.G. Burd, S. Munro, C. Sander, J. Rine, J. Greenblatt, 
M. Peter, A. Bretscher, G. Bell, F.P. Roth, G.W. Brown, B. Andrews, H. 
Bussey, and C. Boone. 2004. Global mapping of the yeast genetic interaction 
network. Science 303: 808-813. 
Tramontano, A. and V. Morea. 2003. Assessment of homology-based predictions in 
CASP5. Proteins 53 Suppl 6: 352-368. 
Tsirigos, A. and I. Rigoutsos. 2005. A sensitive, support-vector-machine method for 
the detection of horizontal gene transfers in viral, archaeal and bacterial 
genomes. Nucleic Acids Res 33: 3699-3707. 
Turner, S.T. and E. Boerwinkle. 2003. Genetics of blood pressure, hypertensive 
complications, and antihypertensive drug responses. Pharmacogenomics 4: 
53-65. 
Valdar, W.S. and J.M. Thornton. 2001. Conservation helps to identify biologically 
relevant crystal contacts. J Mol Biol 313: 399-416. 
Vapnik, V.N. 1995. The Nature of Statistical Learning Theory. Springer-Verlag, New 
York. 
151 
 
Venter, J.C. M.D. Adams E.W. Myers P.W. Li R.J. Mural G.G. Sutton H.O. Smith M. 
Yandell C.A. Evans R.A. Holt J.D. Gocayne P. Amanatides R.M. Ballew D.H. 
Huson J.R. Wortman Q. Zhang C.D. Kodira X.H. Zheng L. Chen M. Skupski 
G. Subramanian P.D. Thomas J. Zhang G.L. Gabor Miklos C. Nelson S. 
Broder A.G. Clark J. Nadeau V.A. McKusick N. Zinder A.J. Levine R.J. 
Roberts M. Simon C. Slayman M. Hunkapiller R. Bolanos A. Delcher I. Dew 
D. Fasulo M. Flanigan L. Florea A. Halpern S. Hannenhalli S. Kravitz S. Levy 
C. Mobarry K. Reinert K. Remington J. Abu-Threideh E. Beasley K. Biddick 
V. Bonazzi R. Brandon M. Cargill I. Chandramouliswaran R. Charlab K. 
Chaturvedi Z. Deng V. Di Francesco P. Dunn K. Eilbeck C. Evangelista A.E. 
Gabrielian W. Gan W. Ge F. Gong Z. Gu P. Guan T.J. Heiman M.E. Higgins 
R.R. Ji Z. Ke K.A. Ketchum Z. Lai Y. Lei Z. Li J. Li Y. Liang X. Lin F. Lu 
G.V. Merkulov N. Milshina H.M. Moore A.K. Naik V.A. Narayan B. Neelam 
D. Nusskern D.B. Rusch S. Salzberg W. Shao B. Shue J. Sun Z. Wang A. 
Wang X. Wang J. Wang M. Wei R. Wides C. Xiao C. Yan A. Yao J. Ye M. 
Zhan W. Zhang H. Zhang Q. Zhao L. Zheng F. Zhong W. Zhong S. Zhu S. 
Zhao D. Gilbert S. Baumhueter G. Spier C. Carter A. Cravchik T. Woodage F. 
Ali H. An A. Awe D. Baldwin H. Baden M. Barnstead I. Barrow K. Beeson 
D. Busam A. Carver A. Center M.L. Cheng L. Curry S. Danaher L. Davenport 
R. Desilets S. Dietz K. Dodson L. Doup S. Ferriera N. Garg A. Gluecksmann 
B. Hart J. Haynes C. Haynes C. Heiner S. Hladun D. Hostin J. Houck T. 
Howland C. Ibegwam J. Johnson F. Kalush L. Kline S. Koduru A. Love F. 
Mann D. May S. McCawley T. McIntosh I. McMullen M. Moy L. Moy B. 
Murphy K. Nelson C. Pfannkoch E. Pratts V. Puri H. Qureshi M. Reardon R. 
Rodriguez Y.H. Rogers D. Romblad B. Ruhfel R. Scott C. Sitter M. 
Smallwood E. Stewart R. Strong E. Suh R. Thomas N.N. Tint S. Tse C. Vech 
G. Wang J. Wetter S. Williams M. Williams S. Windsor E. Winn-Deen K. 
Wolfe J. Zaveri K. Zaveri J.F. Abril R. Guigo M.J. Campbell K.V. Sjolander 
B. Karlak A. Kejariwal H. Mi B. Lazareva T. Hatton A. Narechania K. 
Diemer A. Muruganujan N. Guo S. Sato V. Bafna S. Istrail R. Lippert R. 
Schwartz B. Walenz S. Yooseph D. Allen A. Basu J. Baxendale L. Blick M. 
Caminha J. Carnes-Stine P. Caulk Y.H. Chiang M. Coyne C. Dahlke A. Mays 
M. Dombroski M. Donnelly D. Ely S. Esparham C. Fosler H. Gire S. 
Glanowski K. Glasser A. Glodek M. Gorokhov K. Graham B. Gropman M. 
Harris J. Heil S. Henderson J. Hoover D. Jennings C. Jordan J. Jordan J. 
Kasha L. Kagan C. Kraft A. Levitsky M. Lewis X. Liu J. Lopez D. Ma W. 
Majoros J. McDaniel S. Murphy M. Newman T. Nguyen N. Nguyen M. 
Nodell S. Pan J. Peck M. Peterson W. Rowe R. Sanders J. Scott M. Simpson 
T. Smith A. Sprague T. Stockwell R. Turner E. Venter M. Wang M. Wen D. 
Wu M. Wu A. Xia A. Zandieh and X. Zhu. 2001. The sequence of the human 
genome. Science 291: 1304-1351. 
Waltz, M.R., T.N. Pullman, K. Takeda, P. Sobieszczyk, and S. Refetoff. 1990. 
Molecular basis for the properties of the thyroxine-binding globulin-slow 
variant in American blacks. J Endocrinol Invest 13: 343-349. 
152 
 
Wang, Z. and J. Moult. 2001. SNPs, protein structure, and disease. Hum Mutat 17:
263-270. 
Wang, Z. and J. Moult. 2003. Three-dimensional structural location and molecular 
functional effects of missense SNPs in the T cell receptor Vbeta domain. 
Proteins 53: 748-757. 
Wheeler, D.L., T. Barrett, D.A. Benson, S.H. Bryant, K. Canese, D.M. Church, M. 
DiCuccio, R. Edgar, S. Federhen, W. Helmberg, D.L. Kenton, O. Khovayko, 
D.J. Lipman, T.L. Madden, D.R. Maglott, J. Ostell, J.U. Pontius, K.D. Pruitt, 
G.D. Schuler, L.M. Schriml, E. Sequeira, S.T. Sherry, K. Sirotkin, G. 
Starchenko, T.O. Suzek, R. Tatusov, T.A. Tatusova, L. Wagner, and E. 
Yaschenko. 2005. Database resources of the National Center for 
Biotechnology Information. Nucleic Acids Res 33: D39-45. 
Wheeler, D.L., D.M. Church, R. Edgar, S. Federhen, W. Helmberg, T.L. Madden, 
J.U. Pontius, G.D. Schuler, L.M. Schriml, E. Sequeira, T.O. Suzek, T.A. 
Tatusova, and L. Wagner. 2004. Database resources of the National Center for 
Biotechnology Information: update. Nucleic Acids Res 32: D35-40. 
Yue, P., Z. Li, and J. Moult. 2005. Loss of protein structure stability as a major 
causative factor in monogenic disease. J Mol Biol 353: 459-473. 
Yue, P., Moult, J. 2005. Identification and Analysis of Deleterious Human SNPs. 
Submitted.
Zhao, C.Y., H.X. Zhang, X.Y. Zhang, M.C. Liu, Z.D. Hu, and B.T. Fan. 2005. 
Application of support vector machine (SVM) for prediction toxic activity of 
different data sets. Toxicology.
153 
 
Glossary 
 
ANOVA: 
Analysis of variance (ANOVA) is a test of the statistical significance of the 
differences among the mean scores of two or more groups. 
 
Backbone Strain:  
An unfavorable contribution to energy of the folded configuration arising from close 
atomic contact.  Backbone strain can be caused in three different ways: replacement 
of a glycine residue with d/e angles in a non-allowed region for other residues, 
replacement of cis-proline with another residue, and replacement of another residue 
by proline where the d value is inappropriate.  Mutagenesis data show that backbone 
strain may result in up to 2 Kcal/mol loss of free energy of stabilization. 
 
B factor: 
See Crystallographic B-factor. 
 
BIND: 
The Biomolecular Interaction Network Database (BIND) is a database of 
biomolecular interactions.  
 
BLAST:
BLAST (Basic Local Alignment Search Tool) is a computational method for rapid 
searching of nucleotide and protein databases for sequences similar to a query 
sequence. An amino-acid substitution matrix is used by BLAST to calculate the 
sequence similarity score between sequences.  The default matrix of BLAST is 
BLOSUM62. 
 
BLOSUM 
BLOSUM (Blocks Substitution Matrix) is a type of amino-acid substitution matrix.  It 
is derived from sequence alignments within conserved protein families.  The 
frequency of each amino acid substitution is calculated from the alignments.  
Different levels of the BLOSUM matrix can be created from different levels of 
sequence similarity.  For example, the BLOSUM62 matrix is calculated from protein 
blocks where no two sequences are more than 62% identity.  
 
Breakage of a disulfide bond:  
In a protein, a disulfide bond is the bond between a pair of Cysteine residues.  
Breakage of a disulfide bond by mutating one Cysteine to a different residue usually 
has a large effect on protein stability.  
 
Buried charge:  
An unpaired charged residue introduced into the hydrophobic core of a protein by 
mutation.  Buried charged residues are known to destabilize proteins by 3-5 Kcal/mol. 
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Buried Polar:  
An unpaired polar residue introduced into the hydrophobic core of a protein by 
mutation.  A buried polar residue is known to be destabilizing.  
 
CASP: 
CASP (Critical Assessment of Techniques for Protein Structure Prediction) is a 
community-wide experiment to make blind predictions on the structures of a set of 
proteins whose solved structures are temporally hidden from participants. The goal is 
to establish the current state of the art in protein structure prediction. 
 
C@
The backbone aliphatic carbon atom of an amino acid is called CV, and is bonded to 
an amino group, a carboxyl group, the side chain and one hydrogen atom.  
 
Cavity:  
A cavity is an interior empty space in a protein structure.  A cavity can be created by 
mutating a residue to one with a smaller side chain in the core of a protein, and is 
known to be destabilizing to a protein structure.    
 
CD/CV 
The common disease-common variant model.  It assumes that common diseases are 
affected by common disease-susceptibility alleles at a small number of loci that exist 
at a high frequency across populations. 
 
CLUSTALW: 
CLUSTALW is a multiple sequence alignment program for DNA or proteins. 
 
Comparative Modeling: 
Comparative Modeling, also termed homology modeling, is a method which is used 
to  model a three-dimensional structure from the structures of homologous proteins.  
 
Concept Profile: 
A concept profile refers to an ordered list of terms that are most closely associated 
with the concept of interest in the literature. 
 
Crystallographic B-factor: (also referred as B factor)  
Atomic B factors are obtained from the crystallographic refinement of protein 
structures, and are a measure of the diffuseness of the electron density distribution 
around atoms.  A high B factor indicates the relatively high mobility of the 
corresponding atom.  It has been suggested that regions with high B factors tend to be 
more tolerant of mutations.    
 
dbSNP: 
dbSNP is a central, public, repository for SNP data. 
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DIP: 
The DIPTM (database of interacting proteins) catalogs experimentally determined 
interactions between proteins. 
 
EcoCyc: 
EcoCyc is a database for the Escherichia coli K-12 MG1655 bacterium.  The 
database contains a range of curated biological information, such as transcriptional 
regulation and metabolic pathways.  
 
Electrostatic interaction:  
Protein structures are organized such that almost all polar and charged groups are in 
locally favorable electrostatic environments.  We divide electrostatic interactions into 
three types: hydrogen-bond between polar-polar groups (PP), hydrogen-bond between 
polar-charge groups (PC), and saltbridge between charge-charge groups (CC).  In 
vitro mutagenesis data show that removing a hydrogen-bond or salt-bridge will 
destabilize protein structure. 
 
Electrostatic repulsion: 
Electrostatic repulsion is the repulsion between two same charges.  Electrostatic 
repulsion is known to destabilize a protein structure. 
 
Epistasis:  
Epistasis is non-linear interaction between genes affecting a single phenotype. 
 
Entropy: 
Entropy is a quantity used to measure the degree of disorder in a system. The higher 
the entropy, the greater the disorder.   
 
E-score: 
Expect value, also termed E-value.  The E-score is a parameter that is used by 
BLAST and PSIBLAST to describe the chance by which a sequence similarity hit can 
be seen when searching a sequence database.  The lower the E-score is, the lower the 
chance. 
 
FN: 
FN is the number of false negatives in a test. 
 
FOLD-X: 
FOLD-X is a program for calculating the effect of a single residue mutations on the 
stability of a protein. 
 
FP: 
FP is the number of false positives in a test. 
 
GAD: 
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The Genetic Association Database (GAD) is an archive of human genetic association 
studies of complex diseases and disorders. 
 
GO: 
The Gene Ontology (GO) is a database that provides a controlled vocabulary to 
describe gene and gene product attributes in any organism. 
 
HGMD: 
The Human Gene Mutation Database (HGMD) is a database of published gene 
lesions responsible for human inherited disease (mostly monogenic disease).  
 
Homolog: 
Homologs are genes that are descendent from the same ancestor.  Paralogs and 
orthologs are two forms of homologs.  
 
HomoloGene: 
HomoloGene is a NCBI database that collects homologs among the annotated genes 
of several completely sequenced eukaryotic genomes. 
 
HSSP: 
The HSSP is a database of homology-derived secondary structure of proteins.  
 
Hydrophobic burial:
The hydrophobic effect is considered to be the major driving force for the folding of 
globular proteins.  It causes nonpolar side-chains to cluster in proteins.  The non-polar 
area buried in a folded protein is used to quantify hydrophobic burial.  
 
Jmol: 
Jmol is a free software package that is used to view three-dimensional structures. 
 
KEGG 
KEGG (Kyoto Encyclopedia of Genes and Genomes) is a suite of databases and 
associated software which facilitate integration of the current knowledge on 
biological information.   
 
LD 
Linkage Disequilibrium (LD) is the non-random association between genetic markers 
in a population. 
 
Machine learning: 
Machine learning refers to a system that is capable of autonomous acquisition and 
integration of knowledge.  It usually requires training an algorithm on a given data set 
and testing it on other data set. 
 
Mis-sense SNPs: 
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Mis-sense SNPs, also termed non-synonymous SNPs, are SNPs that are located in 
coding regions and result in amino acid variation in the protein products of genes. 
 
MySQL: 
MySQL is a database management system.  
 
Natural language processing (NLP): 
Natural Language Processing (NLP) technology is software for analyzing, 
understanding and generating natural human language. 
 
Non-synonymous SNPs: 
See mis-sense SNPs.  
 
NR: 
NR is the NCBI non-redundant protein sequence database. 
 
OMIM  
Online (Mendelian Inheritance in Man) is a database of human genes and genetic 
disorders. 
Ortholog: 
Orthologs are genes in different species that evolved from a common ancestral gene 
by speciation. 
 
Overpacking 
Introducing a residue with a large side chain into the core of a protein may cause 
steric clashes between this residue and the surrounding residues.  This phenomenon is 
called overpacking and destabilizing protein structure.    
 
Paralog: 
Paralogs are genes related by duplication within a genome. 
 
PDB: 
PDB (Protein Data Bank) is the database of the 3-D structures of proteins and nucleic 
acids. 
PHD: 
PHD is a program for predicting protein secondary structure and per residue solvent 
accessibility from multiple sequence alignments.  
 
Phenylketonuria (PKU): 
Phenylketonuria (PKU) is a genetic disorder that is characterized by an impaired 
ability to process phenylalanine into other compounds. 
 
PHP: 
PHP is a scripting language that has been widely used for web development.  
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PHP-NUKE: 
PHP-NUKE is an open source template for web development.  It is written in PHP. 
 
PQS: 
Protein Quaternary Structure (PQS) is a database of probable protein quaternary 
structures based on structures in the PDB database. 
 
Principal component analysis 
Principal component analysis (PCA) is a mathematical procedure that transforms a 
number of (possibly) correlated variables into a (smaller) number of uncorrelated 
variables called principal components. 
 
PROCHECK: 
PROCHECK is a program for assessing the stereochemical quality of a given protein 
structure. 
 
Protein Stability: 
The stability of a protein is the difference in Gibbs free energy (aG) between the 
folded and the unfolded states of a protein.  
 
ProTherm: 
ProTherm(Protein Thermodynamic Database) is a database that collects numerical 
data of thermodynamic parameters (such as Gibbs free energy change and enthalpy 
change on folding) for wild type and mutant proteins. 
 
PSIBLAST 
PSIBLAST (Altschul et al. 1997) is a program that iteratively searches protein 
databases for sequences similar to the query sequence.  PSIBLAST and BLAST are 
similar except that the former uses position-specific scoring matrices (PSSMs) 
generated in the searching process while the later uses pre-defined substitution 
matrices such as BLOSUM62.  
 
PSIBLAST can be used to repeatedly search target databases.  It uses a multiple 
alignment of high scoring sequences found in each search round to generate a new 
PSSM for use in the next round of searching. PSIBLAST will iterate until no new 
sequences are found, or the user may specify a maximum number of iterations.  A 
maximum of three iterations is used in the profile model.  
 
PSSM 
PSSM is a position-specific scoring matrix.  It is generated by PSIBLAST during the 
process of searching for the sequences related to a query sequence. 
 
RefSeq: 
RefSeq is the NCBI database of reference sequences.  It contains a curated and non-
redundant set of nucleotide and protein sequences. 
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RefSNP: 
RefSNP is a non-redundant set of variations in dbSNP. 
 
Relative Surface accessibility: 
See surface accessibility. 
 
Root mean square (RMS) error: 
In this work, the root mean square (RMS) error is used to measure the distance 
between two 3-dimensional structures.  The RMS error is defined as the root mean 
square distance between sets of related atoms.   
 
SCOP: 
Structural Classification of Proteins (SCOP) is a database of protein structure 
classification.  
 
ScoreCons: 
A program for scoring residue conservation in a multiple sequence alignment.  
 
SCWRL:
SCWRL is a program for adding sidechains to a protein backbone based on a 
backbone-dependent rotamer library.  The library provides lists of n1-n2-n3-n4 values 
and their related probabilities for residues with given d-e values.  The library is 
generated from a selected list of solved protein structures.  
 
Sensitivity: 
Sensitivity = TP/TP+FN, where TP is the number of true positives and FN is the 
number of false negatives. 
 
Sequence Profile: 
A Sequence Profile in this dissertation is defined as a multiple sequence alignment 
between a human sequence and its homologs.  
 
SNPSubSNPLink: 
SNPSubSNPLink is a mapping table of RefSNP IDs and the corresponding Submitted 
SNP IDs. 
 
Specificity: 
Specificity = TN/TN+FP, where TN is the number of true negatives and FP is the 
number of false positives. 
 
(Relative) Surface accessibility (or solvent accessibility): 
Solvent surface area describes the area of a protein that is accessible to solvent.  In 
order to calculate the solvent surface area of a protein or residue, a probe sphere 
representing the solvent molecule is rolled over the protein surface.  The contact 
surface between the protein molecule (solute) and the solvent molecule is defined as 
160 
 
the solvent surface area.  The surface accessibility of a residue is represented by the 
ratio between the solvent surface area of the residue in a folded protein and that in an 
unfolded protein.  A residue is classified as on the protein surface if its surface 
accessibility is more than 20%.   
 
SVM 
SVM is a computational method of data classification. 
 
Swiss-Prot: 
Swiss-Prot is a curated protein sequence database. 
 
Temperature factor: 
See Crystallographic B-factor.  
 
Z-score:  
Z-score is a statistical measure that quantifies the difference (measured in standard 
deviations) between a sample and the mean of a data set. 
 
